Development of in vitro 3D model systems for screening non-viral neurotrophic factor gene therapies for the retina by Chen, Ding-Wen
 
 
Development of in vitro 3D model systems for screening non-viral 


















A thesis  
presented to the University of Waterloo  
in fulfillment of the thesis requirement  
for the degree of  














Ding-Wen Chen 2018 
ii 
 
Examining Committee Membership 
 
The following served on the Examining Committee for this thesis. The decision of the 
Examining Committee is by majority vote. 
 
 
External Examiner Dr. Heather Sheardown 
Professor (Chemical Engineering, McMaster University) 
Canada Research Chair in Ophthalmic Biomaterials and Drug 
Discovery 
 
Supervisor Dr. Marianna Foldvari 
Professor (Pharmacy, University of Waterloo) 
 
Internal Member Dr. Michael Beazely 
Associate Professor (Pharmacy, University of Waterloo) 
 
Internal Member Dr. John G. Flanagan 
Dean and Professor (Optometry and Vision Science, University 
of California, Berkeley)   
Adjunct Professor (Pharmacy, University of Waterloo) 
 
Internal Member Dr. Jonathan Blay 
Professor (Pharmacy, University of Waterloo) 
 
Internal-External Member  Dr. Vivian Choh 











I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including 
any required revisions, as accepted by my examiners.  
 



































Glaucoma is a neurodegenerative disease that can lead to a complete loss of vision due to 
retinal ganglion cell (RGC) death. Therapies that have the capacity to protect and rescue stressed 
RGCs remain a critical unmet need in glaucoma management. Neurotrophic factor (NF) gene 
therapy is a promising therapeutic approach that can address this current clinical deficiency by 
providing damaged RGCs with extrinsic neurotrophic support as a means of protection and repair. 
Moreover, a non-viral approach to the delivery of NF-encoding plasmid DNA (pDNA) confers 
many advantages over a viral approach for its improved immunogenicity and mutagenesis risks, 
patient compliance and large-scale manufacturing cost and feasibility. In this research, the main 
objective was to address the challenges facing non-viral NF gene therapy field for the retina, 
through development of three in vitro model systems that aim to facilitate the preclinical screening 
and identification of promising NF gene delivery systems. The first model system developed was 
a versatile co-culture model that simulates cellular interactions between “healthy” and “stressed” 
cells in the retina. Furthermore, through incorporation of techniques including enzyme-linked 
immunosorbent assay (ELISA), immunofluorescent imaging, and neurite tracing into the co-
culture setup, the model system enables a systematic evaluation of the therapeutic potential of gene 
delivery systems through assessment of bioavailability and bioactivity of therapeutic proteins 
produced from transfected cells. The second model system was a new potential RGC cell line, 
termed XFC series of cells, that express key RGC characteristics and suitable for the evaluation of 
RGC-aimed gene therapies. Derived from multipotent retinal stem cells (RSCs), XFC cells express 
multiple RGC markers including Map-2, Rbpms, and Tubb3, and exhibit RGC-like neurite 
extension capacity in response to brain-derived neurotrophic factor (BDNF), ciliary neurotrophic 
factor (CNTF), and rho-kinase inhibitor (RKI) Y-27632 activation. The feasibility of the cell 
model was further validated in the described co-culture setup as XFC cells were able to validate 
v 
the bioactivity of the BDNF proteins released by transfected cells. The third model system 
developed was a stem cell-derived 3D “mini-retina” culture model (termed MiEye series of retinal 
neurospheres) that contains multiple retinal cell types and enables in vivo-like gene delivery 
assessment. Derived from differentiating multipotent RSCs in 3D culture, MiEye retinal 
neurospheres with different retinal biomarker expressions can be generated using different 
protocols. Moreover, by harnessing the tissue-like arrangement of retinal cells in MiEye retinal 
neurospheres, it enables the assessment of infiltration and transfection capacity of gene delivery 
systems in tissue-like structure, towards the establishment of a more representative in vitro-in vivo 
correlation and prediction of in vivo gene delivery feasibility. 
Concurrent to model system development, aspects that focus on the development of non-
viral gene delivery systems for the retina were also explored. The first aspect involved the 
optimization of gemini surfactant (GS) lipid nanoparticle systems (GL-NPs) physicochemical 
properties by evaluating the roles of minicircle plasmid (MC), sonication processing, and total NP 
component concentration (TNPC). Through dynamic light scattering and fluorescent correlation 
spectroscopy physicochemical characterizations, it was found that the size, particle size 
distribution, and zeta potential could be effectively optimized through sonication processing and 
TNPC. Moreover, the number of pDNA per particle homogeneity can be improved by formulating 
GL-NPs with MCs. The second aspect involved an investigation on the application of carbon 
nanotubes (CNTs) as a gene delivery vehicle to retinal cell types. More specifically, GS-
functionalized SWNT gene delivery system (ƒ-ptSWNT) was developed and demonstrated the 
ability to deliver pDNA to a retinal astrocyte cell line. The results demonstrate the feasibility of 
utilizing ƒ-ptSWNT to deliver pDNA to retinal cells and serves as a starting point for future ƒ-
ptSWNT retinal gene delivery system development.   
vi 
The development of the three in vitro model systems in this thesis collectively aims to 
facilitate the preclinical screening and development of non-viral NF gene therapies in a synergistic 
manner, covering key areas of assessments that are critical to in vivo therapeutic success. 
Furthermore, concurrent developments in non-viral gene delivery systems through GL-NP 
optimization and CNT exploration also advance the knowledge towards the development of better 
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PALS Phase analysis light scattering 
PBS Phosphate buffered solution 
PCG Primary congenital glaucoma 
pDNA Plasmid DNA 
PEG Polyethylene glycol 




PNS Peripheral nervous system 
POAG Primary open-angle glaucoma 
ptSWNT Puretubes™ carbon nanotube 
RGC Retinal ganglion cell 
ROS Reactive oxygen species 
RP Regular plasmid 
RPE Retinal pigmented epithelium 
RSC Retinal stem cell 
RSCDM-1 Retinal stem cell differentiation medium 1 
RSCDM-2 Retinal stem cell differentiation medium 2 
SC Schlemm’s canal  
ScN Sciatic nerve 
SMI-32 Anti-neurofilament H 
TE Transfection efficiency 
TIMP1 Metallopeptidase inhibitor 1 
TIMP2 Metallopeptidase inhibitor 2 
TIMP4 Metallopeptidase inhibitor 4 
TNPC Total nanoparticle component concentration 
TM Trabecular meshwork 
trA7 Transfected A7 cells 
trXFC-3 Transfected XFC-3 cells 
TrkB Tropomyosin receptor kinase B 
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Chapter 1 Introduction 
1.1 Gene therapy: status to date 
Gene therapy is a novel form of therapeutic approach that utilizes genetic materials as the 
therapeutic agent, providing the possibility of addressing diseases and conditions at the molecular 
level through various methods of genetic augmentation, inhibition or deletion. As of July 2018, 
there are seven human gene therapy products that are approved worldwide (Table 1.1), 
demonstrating the feasibility of three main types of gene-based therapeutic approaches directed 
for seven different disease interventions.  
Gendicine and Oncorine were the first two gene therapies that entered the market 
globally, through their approval in China by the Chinese State Food and Drug Administration 
(CSFDA) in 2003 and 2005, respectively [1, 2]. Both therapies are viral-based gene therapies 
indicated for the treatment of head and neck squamous cell carcinoma through genetic 
augmentation of a tumor suppressor gene. More specifically, these therapies are designed for 
intratumoral injection of adenoviruses carrying the p53 gene, a pro-apoptotic tumor suppressor 
gene, aimed to induce apoptosis in cancer cells through the p53-mediated pathway which is 
otherwise suppressed [3]. The p53 gene is a well-studied anti-tumor gene for its role in the 
induction of pro-apoptotic cascades, which have been shown to play a promising role in tumor 
suppression. Development of Gendicine and Oncorine carries two major significances: 1) it 
enables a novel treatment option for patients with head and neck squamous cell carcinoma beyond 
existing pharmacological, radiological, and surgical interventions; and 2) it demonstrates the 
clinical feasibility of a human gene therapy intervention at the bedside for the first time.  
One of the most unique advantages of a genetic-based therapy, otherwise inconceivable 
through traditional pharmacological or surgical interventions, is the ability to treat genetic-based 
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disease conditions by replacing the mutated dysfunctional gene(s) responsible. Currently, 
treatment options available for patients suffering from acquired or hereditary genetic diseases 
focus on either symptom reduction or delay disease progression as there are no effective means of 
treating the root genetic causative factor. Recently, new hope emerged for patients suffering from 
hereditary lipoprotein lipase deficiency (LPLD) and Leber Congenital Amaurosis (LCA) with the 
approval of Glybera and Luxturna, two first of its class of therapeutic offerings to treat these 
two hereditary monogenic diseases by replacing the causative mutated gene with a functional 
version. Glybera is the first gene therapy approved by the European Medicines Agency (EMA) 
for the treatment of a rare monogenic disease known as LPLD, which is a hereditary disease caused 
by a mutation of the lipoprotein lipase (LPL) gene that results in the inability to breakdown 
triglycerides and leads to excessive accumulation of chylomicrons throughout the body. High 
levels of chylomicrons accumulation lead to elevated risk of developing acute pancreatitis and 
other complications. Glybera treatment regimen aims to restore triglyceride metabolism function 
through intramuscular injection of the AAV1 virus carrying functional LPLs447x gene, which would 
be taken up by monocytes and subsequently facilitate the production of LPL [4, 5]. On the other 
hand, Luxturna is the first direct-administered gene therapy product approved by the United 
States Food and Drug Administration (FDA), indicated for the replacement of an inherited 
defected gene that causes vision loss. More specifically, the approved gene therapy is a RPE65 
replacement gene therapy, designed for the treatment of a rare form of inherited vision loss known 
as the biallelic RPE65 mutation-associated retinal dystrophy or LCA. Patients who suffer from 
such inherited retinal dystrophy have a mutated RPE65 gene that consequently leads to progressive 
loss of vision and eventual blindness [6, 7]. Luxturna™ is formulated using AAV-based viral vector 
carrying a functional RPE65 gene, which is administered through subretinal injection to replace 
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the defective RPE65 gene in retinal pigment epithelial cells in the retina. The approval of the two 
gene therapy products, Glybera and Luxturna, is significant in multiple aspects. From gene 
therapeutic development perspective, it marks a major breakthrough in demonstrating the 
feasibility of gene therapy for the treatment of monogenic diseases through replacement of a 
defective gene. From a monogenic disease management perspective, the two products 
demonstrated the clinical feasibility to treat hereditary diseases using gene therapy.  
Another novel genetic-based therapeutic approach involves the integration of cell therapy 
and gene therapy, where genetic manipulation of somatic cells is performed ex vivo for subsequent 
reintroduction into the patient body. While involving numerous sophisticated steps from 
harvesting patient cells to ex vivo genetic manipulation and cellular expansion, the series of ex vivo 
steps allow for high degree of controlled genetic manipulation, maximizing synergistic therapeutic 
potential between the two therapeutic principles. Strimvelis, an ex vivo hematopoietic stem cell 
gene therapy approved by EMA in 2016 was the first approved human gene therapy product of its 
kind, developed for the treatment of a rare disease known as adenosine deaminase deficiency 
severe combined immunodeficiency (ADA-SCID) [8]. ADA-SCID is a monogenic 
immunodeficiency disease caused by the mutation of the adenosine deaminase (ADA) gene. 
Mutation of ADA results in dysfunctional deoxyadenosine clearance, which incurs toxicity 
primarily towards monocytes that leads to the development of severe immunodeficiency. 
Strimvelis is composed of retroviruses carrying functional ADA genes designed to treat ADA 
deficiency through the integration of functional ADA genes into CD34+ hematopoietic stem cells 
harvested from the patient, which are then intravenously infused back to the patient upon 
successful ADA augmentation of the stem cells for engraftment and restoration of ADA expression 
[9]. Successful treatment through this therapy provides a possibility for sustained long-term 
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engraftment of ADA-expressing CD34+ hematopoietic stem cells, restoring immune system 
development through lymphocyte generating capacity. The combination cell and gene therapy 
approach was also shown to be a promising therapeutic approach in cancer therapy with the 
approval of Kymriah and Yescarta by the FDA in 2017. Both Kymriah and Yescarta are 
human gene therapy products indicated for cancer therapy through the mechanism of chimeric 
antigen receptor T-cells (CAR-T), which is a novel therapeutic approach that utilizes and combines 
the patient’s own immune system and gene therapy for the treatment of lymphocytic leukemia. 
More specifically, Kymriah not only was the first approved CAR-T gene therapy, but also the 
first gene therapy approved for two indications by the FDA. The first approved indication of 
Kymriah was for the treatment of a B-cell precursor acute lymphoblastic leukemia (ALL), an 
aggressive type of leukemia most commonly found in children that stemmed from B-cell 
malignancy. More recently in May 2018, a second indication of Kymriah was approved by the 
FDA, for the treatment of relapsing or refractory large B-cell lymphoma including diffuse large 
B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular 
lymphoma. DLBCL is one of the most common form of non-Hodgkin’s lymphoma that is also a 
result of B-cell malignancy [10]. Approval of Kymriah for the second indication is in direct 
competition with Yescarta, another CAR-T gene therapy approved by the FDA to treat DLBCL. 
Majority of the B-cell malignancies are associated with elevated level of CD19 expression, thus it 
is the major receptor target in CAR-T therapy. CAR-T genetically modifies patient’s own T-cells 
to express anti-CD19 antigen receptors, which act as targeting molecules assisting T-cells in 
recognizing CD19 expressing cancerous B-cells and terminating the growth of the cancerous B-
cells in B-cell ALL and DLBCL. Approval of the two CAR-T based gene therapies further 
demonstrates the potential of gene therapy as the new therapeutic paradigm for utilizing patient’s 
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own immune system as scavengers for cancer cells, offering alternative means of effective cancer 
management.  
The approval of the seven gene therapy products to date demonstrates the feasibility of 
bringing gene therapy products to the bedside despite the hurdles and challenges. Moreover, it 
opens new dimensions to disease management that are not possible through traditional 

















Table 1.1 Human gene therapy products approved worldwide as of July 2018 
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1.1 Non-viral gene therapy nanomedicine: key component of gene therapy maturation 
Approval of multiple human gene therapy products in recent years marked significant 
milestones in genetic-based therapeutic development across the globe. Despite the recent 
momentum, many important questions still need to be investigated and properly addressed in order 
to bring forth the full therapeutic potential of gene therapy. In addition to the approved treatments, 
the majority of gene therapies undergoing pre-clinical and clinical investigations are currently 
dominated by viral-based gene therapies. With the intrinsic ability designed by nature to 
specifically carry out the task of gene transfer through dedicated transduction machinery on human 
host, viral-based gene delivery vectors derived from various types of viruses such as adeno-
associated virus (AAV) [11], adenovirus (AD) [12], and lentivirus (LV) [13] are indisputably 
prime candidates for gene delivery applications. While advantageous for gene delivery 
applications, viruses are naturally an impediment to the human immune system owing to the 
intrinsic host immune response that actively responds to the presence of viral particles in human 
body [14-16]. Innate immune response may eliminate viral vectors before they arrive at target sites 
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or cells, thereby eliminating the viral particles before therapeutic activity could take place [17], or 
limiting therapeutic efficacy at low viral titre [18]. However, using elevated levels of viral vector 
titre may subsequently increase the risks of systemic immune response and mutagenesis. To 
address these concerns, immunomodulators, corticosteroids or antihistamines, such as 
methylprednisolone, cyclosporin, mycophenolate mofetil, busulfan, and prednisone are 
recommended as part of the prescribing guidelines for pre-treatment and post-treatment 
conditioning of the immune system. Of note on CAR-T therapy, tocilizumab is recommended for 
managing cytokine release syndrome (CRS) [19], a major risk associated with excessive T-cell 
based therapy [20]. Aside from immune response-related risk factors, other factors such as viral 
mobility and cost of manufacturing are also important factors to be considered. Viral mobility is a 
major concern when administered viral vectors travel beyond the intended target due to the risk of 
initiating undesirable immunogenicity or introducing genetic interventions beyond the intended 
therapeutic region. As shown in a comparative study between nanoparticles (NPs) and AAVs, 
subretinally injected AAVs were found to have exited the eye and travelled to parts of the brain, 
while NPs remained within the subretinally injected eye [21]. Another reflective point revolves 
around the pricing associated with these novel gene therapy products. Currently approved gene 
therapies such as Glybera (€990,000 EUR), Strimvelis (€594,000 EUR), Yescarta 
($373,000 USD), Kymriah ($475,000 USD), and Luxturna ($850,000 USD) all are associated 
with a hefty treatment cost. New models of payment have been proposed to reduce the financial 
burdens of the treatments such as the incorporation of risk-sharing approaches and long-term 
payment plans [22]. On the other hand, better pricing models have also been called upon to better 
assign the value and pricing of gene therapy through finding a common ground between R&D 
investment, drug manufacturing cost, company profitability, patient accessibility and affordability 
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[23]. From the perspective of gene therapy development, one of the key cost contributors in viral-
based gene therapy lies in the high cost of large-scale manufacturing of viral vectors. Since vectors 
are a substitutable component in a gene therapy system, utilization of non-viral vector is a 
promising approach for providing gene therapy treatments with higher safety profile and at a more 
affordable cost. Collectively, the risks of virus associated immunogenicity, mutagenicity, mobility, 
and manufacturing costs are all reasonable grounds to consider alternatives to deliver the full 
potential of gene therapy. 
Non-viral gene therapy is an alternative approach to viral-based gene therapy that utilizes 
nanomaterials for the construction of gene-carrying vectors instead of packaging therapeutic genes 
within a viral capsid [24, 25]. Using synthetic and naturally derived nanomaterials as the basic 
building blocks of gene delivery vectors, they offer a better safety profile with lower cost of 
production. However, the advancement of non-viral vectors to the bedside is hindered primarily 
by low gene delivery efficiencies. In contrast to viral vectors, non-viral vectors are not equipped 
with the biological machinery designed to initiate gene delivery through transduction mechanisms. 
As a result, non-viral gene delivery systems need to overcome several major barriers to achieve 
successful transfection. Currently, there are at least 40 liposomal and polymeric gene delivery 






Table 1.2 Lipid- and polymer- based non-viral gene therapies as of July 2018 
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Indication Gene Therapy Drug 
Phases 
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1.2 Gemini Surfactant NP System: A Promising Nanomedicine Solution to Gene Therapy 
 GL-NPs are a novel class of gene delivery system that could play a significant role in the 
development of non-viral gene delivery systems. GS is an amphiphilic surfactant molecule first 
described by Menger and Littau consists of a dimeric structure composed of two amphiphilic 
moieties linked by a modifiable hydrocarbon spacer in a m-s-m configuration [26]. The structure 
offers a diverse possibility of GS variations, which can be achieved through hydrocarbon length 
modifications of the spacer and alkyl chains. Further functionalization of GS can be achieved 
through conjugation of various functional moieties to either the spacer or the alkyl chain [27]. In 
addition to the self-assembling amphiphilic properties, another hallmark of GS is the two polar 
head groups. In particular, the family of GS that contains two positively-charged quaternary 
nitrogen head groups provide an important electrostatic-based physicochemical property that 
enables the compaction of nucleic acids and initiation of cellular membrane interactions, properties 
that are essential in gene delivery applications [28-30]. In the past 18 years of research in this 
laboratory, several advancement of GS were made through generation of novel GS compounds 
[31-34], and their therapeutic applications have also been explored heavily in transdermal delivery 
[31, 35-38]. In some of the more recent work, developments of GS in the areas of pulmonary [39] 
and ocular delivery have shown promise [40, 41]. Previous work by Alqawlaq and colleagues 
demonstrated GL-NPs are thermodynamically stable in the posterior segment of the eye, capable 
of evenly distributing across the nerve fiber layer of the retina upon intravitreal injection 
administration. On the other hand, GL-NPs have also shown to localize in the anterior segments 
of the eye upon topical eye drop administration [42].   
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1.3 Gene therapy in ophthalmology 
The eye can greatly benefit from genetic-based therapeutic interventions as major 
degenerative diseases of the macula, retina, and choroid all have either acquired or inherited 
genetic basis. As of July 2018, there is one approved human gene therapy product and more than 
forty-five ocular gene therapies in clinical trials for ocular disease interventions (Table 1.3). Gene 
therapy of LCA is in the forefront of ocular gene therapy development, with the approval of 
Luxturna™ by the FDA as described in the previous section. In addition to LCA, Leber Hereditary 
Optic Neuropathy (LHON) is another disease in the forefront with three phase III clinical trials 
currently in progress.  LHON is a rare inherited retinal dystrophy that results in the degeneration 
of RGCs caused by mitochondrial gene mutation in NADH dehydrogenase-1 (ND1), NADH 
dehydrogenase-4 (ND4), or NADH dehydrogenase-6 (ND6) enzymes [43-45]. Previous studies 
have shown that a replacement of functional ND4 in a rat model of LHON containing G11778A 
mutated ND4 protected RGCs and prevented associated visual field loss [46, 47]. GS010, an AAV 
gene therapy system that carries functional ND4 gene is currently in phase III clinical trials for the 
treatment of LHON.  Concurrently, promising advancement in ocular gene therapy is also observed 
throughout a spectrum of other ocular diseases such as achromatopsia, age-related macular 
degeneration (AMD), choroideremia, giant axonal neuropathy, gyrate atrophy, retinitis 
pigmentosa, Stargardt disease, and x-linked retinoschisis, where active clinical trials are currently 
taking place for the treatment of these ocular diseases (Table 1.3). One of the ocular diseases that 
has not been mentioned but could greatly benefit from gene therapy is glaucoma. Glaucoma is a 
neurodegenerative disease and the second leading cause of blindness globally. While there is yet 
any gene therapy for glaucoma, substantial research and development efforts are in progress 
towards clinical trials.  
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1.4 Glaucoma  
1.4.1 Glaucoma pathophysiology & disease management 
From glaukos, to gutta serena, to glaucoma, the evolving nomenclature of the optic 
neuropathic disease reflects our progressive understanding from a disease described by the 
changing opacity and color of the pupils in the 8th century BC, to a multifactorial 
neurodegenerative disease of the optic nerve today [48]. Presently, glaucoma is considered the 
world’s second leading cause of blindness with an estimated 111.8 million people to be affected 
by the disease by 2040 [49].  
Glaucoma can be broadly categorized based on the clinical presentation of the iridocorneal 
angle, the passage between iris and lens that channels aqueous humour outflow from the ciliary 
body, into two main types: open-angle and angle-closure. A primary open-angle glaucoma 
(POAG) refers to a glaucomatous eye with an “open” iridocorneal angle, which consists of an open 
passage that enables aqueous humour outflow to subsequent drainages in the trabecular meshwork 
and Schlemm’s canal [50]. However, aqueous humour drainage resistance from the trabecular 
meshwork and Schlemm’s canal was shown to play an important role in IOP elevation, which is 
deemed as a major risk factor for POAG. Despite this correlation, the specific mechanism of IOP-
mediated optic nerve degeneration remains unclear as patients can still develop the 
pathophysiology of POAG even in the absence of elevated IOP such as normal tension glaucoma 
(NTG). On the other hand, primary angle-closure glaucoma (PACG) refers to glaucomatous eye 
with  a “closed” iridocorneal angle, obstructing the outflow of the aqueous humour that results in 
its rapid accumulation and subsequent elevation of IOP [51]. Primary congenital glaucoma (PCG) 
is the third major form of glaucoma that results from deficiencies in the development of drainage 
canals [52].  
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Major risk factors of glaucoma are found to have high associations with ethnicity, family 
history, and age [53]. POAG has the highest prevalence amongst African Americans, while PACG 
is most prevalent amongst Asians [49]. Individuals who are either over the age of 60, have a family 
history of glaucoma, or have diabetes are also at higher risk of glaucoma [53]. High IOP remains 
the most measurable and treatable risk factors amongst the risk factors [54]. Other possible risk 
factors that may contribute to glaucoma development are factors such as neurotrophin deprivation, 
glutamate excitotoxicity, oxidative stress, and hypoxia [55]. 
Early detection plays a key role in the success of glaucoma management as the onset of 
visual field loss symptom signifying a significant level of optic nerve damage has already been 
triggered and taken place. Several assessments are important in the diagnosis of glaucoma: 
tonometry, ophthalmoscopy, perimetry, gonioscopy and pachymetry. The diagnosis of glaucoma 
is mainly based on the combination of optic nerve fiber layer assessment of the cup-disc ratio and 
visual field test. Cup-disk ratio is a clinical feature that measures optic nerve health through the 
comparison of the ratio between the diameters of optic cup and optic disc [56, 57]. An enlarged 
cup-disc ratio, as a consequence of increased cupping, is the manifestation of optic nerve head 
widening and posterior movement towards the lamina cribosa [58]. Cupping and thickening of the 
prelaminar tissues suggests increasing degeneration of the nerve fiber layer and increases the 
likelihood of glaucoma development [58]. Corneal thickness has also been suggested to be an 
indicator of POAG development [59]. Current glaucoma management consists of IOP reduction-
focused therapeutic regimens, with topical eye drops that facilitate the drainage of the aqueous 
fluid such as prostaglandin, mitotics, epinephrine, beta-blocker, and carbonic anhydrase inhibitors. 
Surgically, laser trabeculoplasty and laser iridotomy are common surgical procedures for POAG 
and PACG, respectively.  
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Oxidative stress is implicated as one of the factors that contribute to glaucoma disease 
development and the death of the RGCs [60]. Oxidative stress is a state of intracellular imbalance 
where high levels of reactive oxygen species (ROS) are present due to insufficient intrinsic cellular 
ROS scavenging. Moderate levels of ROS are routinely generated and removed through redox 
modifications in essential metabolic processes from signal transduction to ATP production in the 
mitochondria [61]. However, excessively high ROS levels can result from mitochondrial 
dysfunction and insufficient ROS removal in stressed cellular states. Consequently, it can further 
inflict cellular damages such as lipid peroxidation, mitochondrial membrane damage, and protein 
oxidation that would subsequently trigger various pathways of cell death [60]. 
While current glaucoma management can effectively reduce IOP, many patients continue 
to experience progressive visual field loss. Furthermore, IOP reduction has limited therapeutic 
benefit to patients with normal-tension glaucoma [62]. More importantly, IOP reduction alone 
does not address the health of RGCs as damaged RGCs may continue to degenerate even after IOP 
reduction. RGCs are the main cell types of the retina responsible for the visual communication 
between the eye and the brain. Thus, a therapeutic approach that aims to improve the health of 
RGCs is an important unmet need in glaucoma management. 
1.4.2 Retinal ganglion cell death: role of neurotrophin deprivation theory 
Composed of more than 30 different subtypes that distribute across the ganglion cell layer 
of the retina, the axons of RGCs extend and converge to form the optic nerve [63]. The optic nerve 
extends from the retina to the brain, most of which innervates the lateral geniculate nucleus (LGN), 
with some that innervates superior colliculus [64]. The “neurotrophin deprivation” hypothesis is 
one of the main theories that attempts to explain the death of RGCs [65].The hypothesis suggests 
that axonal transport obstruction in glaucoma causes insufficient retrograded transport of collicular 
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derived neurotrophins to the ganglion cell body, resulting in cellular stress and triggering cell death 
mechanisms [65]. Neurotrophins, also known as neurotrophic factors, are a family of growth 
factors that are responsible for neuronal development, growth, maintenance, and survival [66]. 
Examples of NFs include nerve growth factor (NGF), BDNF, neurotrophin 3 (NT-3), and 
neurotrophin 4/5 (NT-4/5). Furthermore, NFs were shown to have anti-apoptotic effects in neurons 
[67, 68]. Evidently, NFs play an important role in the pathogenesis of glaucoma. In particular, 
BDNF has shown protective effect of RGCs in multiple studies. Direct BDNF protein injection 
into the retina have shown to enhance RGCs survival in various experimental glaucoma models 
such as optic nerve crush model in cat [69], spontaneous glaucoma model in DBA2/J mouse [70], 
acute ocular hypertension model in rat [71], and optic nerve crush and transection in Crl:CD1 
mouse model [72]. Combination injections of BDNF protein at sites of superior colliculus and 
retina resulted in further enhancement of RGC survival after optic nerve crush in cats compared to 
single site injection, which further demonstrated the therapeutic value that can be achieved with 
BDNF [73]. BDNF-mediated RGC rescue was achieved through various gene based therapeutic 
approaches using AAV vector [74, 75], AD vector [76, 77], and electroporation [78] in 
experimental rat glaucoma models. Furthermore, a study utilizing a transgenic mouse model Thy-
1-CreERT2::BDNFstop containing Cre-recombinase inducible system upstream of BDNF has shown 
that induced BDNF overexpression was able to provide protection to specific type of RGC after 
optic nerve crush in mouse [79]. Recent studies have also suggested that there is differential 
tolerance to glaucomatous stress and responsiveness to BDNF treatment between different RGC 
subtypes. For example, brn3a+ RGCs were more susceptible to acute hypertension-mediated cell 
death compared melanopsin+ RGCs in an acute hypertension rat model [71]. In addition, the 
survival of both RGC subtypes were improved with BDNF protein injection [71]. In a separate 
22 
study using transgenic mouse, it was shown that SMI-32+ RGCs were less susceptible to optic 
nerve crush and more responsive to BDNF overexpression mediated rescue compared to large-
soma RGCs [79]. Altogether, research to date shows that BDNF is an important therapeutic 
molecule in the overall objective of protection and rescue of RGCs and subtype-specific efficacy 
remains to be elucidated to harness its maximum therapeutic potential. 
 
Figure 1.1 NF gene therapy for the protection of RGCs in the retina. (A) Illustration of the two anatomical sites for 
gene therapy administration: retina and superior colliculus. (B) Superior colliculus, the site at which retinal ganglion 
cell axons innervate in the brain. (C) Schematic drawing describing the rationale of NF gene therapy and the role of 
retinal cells and superior collicular cells play in the cellular level. 
1.5 Three-dimensional cell culture: enriching the value of in vitro culture models 
 In vitro cell culture models have been an integral part of scientific research for decades, 
contributing to discoveries from basic cellular mechanism to drug development. Despite their 
pivotal roles, the lack of in vivo-relevant results derived from in vitro models remains a major 
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hindrance for efficient clinical translation of scientific discovery. A potential solution to this 
obstacle is to bypass in vitro screening and directly perform screening in vivo using animal models 
instead. While possible, direct animal model screening approach is an expensive and complex 
option for screening libraries of candidate compounds and elucidating complex molecular 
pathways. Evidently, a solution that bridges the gap between in vitro and in vivo is needed [80]. 
The lack of in vivo relevance is attributed to the inability for in vitro model to yield results that are 
representative and reproducible in an in vivo environment [81]. Cells found in vivo exhibit diverse 
cellular interactions with the extracellular matrices, as well with the neighboring cells from 
multiple directions. However, cells cultured in 2D plastic surfaces are forced to reside on a flat 
plane in monolayer, thus cellular contacts are only limited to cells to their sides. The issue of 
limited cellular interactions under 2D culture particularly restrains our level of understanding in 
disease models involving complex cellular crosstalk and extracellular matrix interactions in the 
microenvironment.  
Three-dimensional (3D) cell culture is a novel method that was designed to overcome the 
limitations present in traditional 2D culture methods by allowing cells to be cultured in vitro, yet 
still able to be grown in a microenvironment representative of in vivo conditions. Unlike traditional 
2D culture where cells are grown on flat plastic surface in monolayers, cells in 3D culture are 
grown in multilayers in multicellular spheroids or scaffold-dependent multilayer arrangements. 
The goal of 3D cell culture is to create in vitro microenvironment that are representative of in vivo 
cellular architecture and topology to facilitate cells to grow and differentiate in a more in vivo-
relevant condition. Functional differences in cellular structures [82], gene expression profiles [83], 
receptor presentation [84], growth factor secretion [85] and stimuli mediated responses [86] have 
all been reported to have closer resemblance to in vivo using 3D cultures.  
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1.5.1 Structural composition of three-dimensional culture system  
Rapid advancements in 3D culture system development have generated a diversity of three-
dimensional cell culture methods (Table 1.4). 3D culture systems can be broadly classified into 
two major types based on the presence of anchors available for cellular attachment into scaffoldless 
and scaffold-based systems.  
Scaffold-based systems are typically established using naturally derived proteins or 
synthetic materials for scaffold construction. The scaffold acts as an architecture that enables cells 
to adhere and grow either above, beneath, within or surrounding the scaffold. Naturally derived 
scaffolds are typically composed of ECM proteins such as collagen, laminin, and proteoglycans in 
the form of hydrogels [87, 88]. On the other hand, synthetic scaffolds are typically prefabricated 
using synthetic materials with defined shape and architecture. Both naturally derived and synthetic 
scaffold methods utilize similar principles as they both provide cells with a third dimension that 
resembles in vivo architecture. Naturally derived scaffold such as Matrigel™ is an example of 
complex ECM protein hydrogel system isolated from Engelbreth-Holm-Swarm mouse sarcoma 
cells consisting of mainly collagen IV and laminin [89]. Other naturally derived systems with a 
more defined protein content are also available such as purified collagen [90, 91] or fibrin extract 
[92-94]. Naturally derived proteins from plants such as alginate [95, 96], agarose [97], and chitosan 
[98, 99] are also compatible biomaterial candidates. Synthetic scaffolds are typically prefabricated 
porous structures of a set shape and size, in which cells could enter the matrices and establish 
multicellular arrangements with shape and size determined by the scaffold architecture, 
constructed using synthetic polymeric materials such as polystyrene [100], polyethylene glycol 
(PEG), and poly(lactic-co-glycolic acid) (PLGA) [101]. 
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Scaffoldless systems are the other main type of 3D culture systems that rely on cells’ 
intrinsic intercellular adhesion properties in the absence of ECM support. The two types of 
scaffoldless culture systems are forced-floating and hanging-drop methods. The forced-floating 
method enables the establishment of multicellular spheroidal architecture by prohibiting cellular 
attachment to the plastic surface functionalized with ultra-low adhesives or micropatterns. On the 
other hand, the hanging-drop method relies on the formation of multicellular architecture in a cell 
suspension droplet, where cells collects at the bottom of the droplet to form multicellular 

















Table 1.4 Commercially available 3D cell culture systems 
Method of 3D construction Material 3D Culture System Company 
Scaffoldless 
Hanging Drop  Cellular intrinsic adhesion 
Perfecta 3D (Discontinued) 3D Biomatrix 
Gravity Plus inSphero 
Forced-Floating 
Micropatterned Surface 
SCIVAX 3D Nanoculture Plate Infinite Bio 
CYTOOchips Cytoo 
Elplasia Kuraray 
3D Petri Dish Microtissue 
Low-Adhesion Surface 
Costar Ultra-Low Adhesion Plate Corning 
Prime Surface Sumitomo Bakelite 
Naturally-derived Scaffold 
Naturally-derived material 
Alginate Algimatrix Life Technologies 
Extracted from Engelbreth-
Holm-Swarm (EHS) Mouse 
Sacroma 




CD-Link (Polyethylene glycol 
and matrix metalloprotease -
cleavable peptides) 
3D Life Biomimetic Cellendes 
Extracted from Engelbreth-
Holm-Swarm (EHS) Mouse 
Sacroma 








PEG-based molecule QGel QGel BIo 
Arginine-Alanine-Aspartic Acid-





















Magnetic scaffold and magnetic 
ECM coupled with levitation 
Bio Levitator 
Hamilton Company 
(Global Cell Solutions) 
Gold, iron oxide, poly-l-lysine to 
magnetize cells; for levitation 
BioAssembler System Nano 3D Biosciences 
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Chapter 2 Research Focus 
2.1 Rationale and objective 
Current glaucoma management focuses on IOP-reduction using pharmacological and 
surgical therapeutic interventions. While effective in lowering IOP-mediated risk factors and 
delaying glaucoma disease progression, direct extrinsic support to RGCs to improve RGC health 
is lacking. Evidently, therapies that can provide extrinsic support to protect and repair damaged 
RGCs is an unmet clinical need in glaucoma disease management. NF gene therapy is a therapeutic 
approach that has the potential to address such clinical deficiency by providing RGCs with NF 
support. Moreover, using a non-viral approach of gene delivery improvements compared to viral 
systems may be achieved such as low risk of immunogenicity and mutagenesis, coupled with better 
patient compliance and production cost. In this research, the objective was to facilitate the 
preclinical screening and identification of promising NF gene delivery systems through 
developments of retinal 3D in vitro model methodologies and non-viral gene delivery systems for 
the retina.  
2.2 Hypothesis 
Main hypothesis:  
 A non-viral gene delivery approach can deliver BDNF-encoding pDNA to retinal cells for 
NF gene therapy in three-dimensional culture. 
Sub hypothesis: 
I. Sub-hypothesis #1: An in vitro co-culture modality utilizing BDNF-responsive neuronal 
cells can serve to evaluate bioactivity of BDNF protein secreted from NP-transfected 
retinal cells. 
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Corresponding findings: Developed a neurite outgrowth functional assay to assess the 
bioavailability and bioactivity of BDNF protein produced and secreted from retinal cells 
transfected by NPs carrying BDNF encoding pDNA. (Chapter 3) 
II. Sub-hypothesis #2: A multipotent stem cell-derived RGC-like cell can be isolated and 
characterized for future screening of non-viral gene delivery systems.  
Corresponding findings: Generated and characterized RGC-like cells derived from 
differentiated multipotent retinal stem cells. The newly isolated cells express RGC 
biomarkers and exhibit neurite extension and can serve as a model cell line for in vitro 
screening of non-viral gene delivery systems. (Chapter 4) 
III. Sub-hypothesis #3: A multipotent stem cell-derived 3D retinal neurosphere model can be 
used to improve the in vitro – in vivo correlations of gene delivery system evaluation. 
Corresponding findings: Developed a “mini-retina” 3D retinal neurosphere model that 
can be utilized as a tool for evaluating transfectability, targeting, and infiltration capacity 
of gene delivery systems. (Chapter 5) 
IV. Sub-hypothesis #4: GL-NP physicochemical properties can be improved through the 
replacement of regular plasmid vector with minicircle plasmid and manufacturing 
considerations. 
Corresponding findings: Minicircle plasmid, sonication and formulation concentration 
can result in generation of GL-NPs with smaller size and higher particle size 
homogeneity. (Chapter 6) 
V. Sub-hypothesis #5: SWNTs can complex pDNA and be utilized as gene delivery vehicle 
for ocular delivery application.  
Corresponding findings: SWNTs can complex with pDNA and be utilized as gene 
delivery carrier for the delivery of pDNA to A7 retinal astrocytes in vitro. (Chapter 7) 
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Chapter 3 Development of an in vitro bioassay to evaluate the effect of 
BDNF expressed and secreted by non-virally transfected retinal cells  
 
Majority of this chapter are reflective of an original manuscript published in the journal Drug 
Delivery and Translational Research and a book chapter published in Springer Protocols Retinal 
Gene Therapy Methods and Protocols. 
 
Chen, D.W. and Foldvari, M., 2016. In vitro bioassay model for screening non-viral neurotrophic 
factor gene delivery systems for glaucoma treatment. Drug Delivery and Translational 
Research, 6(6), pp.676-685. 
 
Author contributions: DWC and MF developed the concept and designed the experiments. DWC 
performed the experiments. DWC and MF analyzed the data and prepared the manuscript. 
 
Chen D.W., Pauloff K., and Foldvari M., 2018. Three-dimensional co-culture bioassay for 
screening of retinal gene delivery systems. Methods in Molecular Biology (MiMB) series; In: 
“Retinal Gene Therapy: Methods and Protocols” ed. Wijnholds J. (Springer) 1715:79-88. 
 
Author contributions: DWC, KP, and MF developed the concept and designed methodologies. 
DWC and MF prepared the manuscript.  
 
3.1 Rationale and objective 
 One of the preclinical hurdles in the development of BDNF gene therapy systems for RGC 
is the lack of representative model for efficient and effective in vitro screening. To address this 
issue, an in vitro 3D co-culture model that simulates the “stressed” and “medic” retinal cells 
interactions in vivo, which can be utilized using different combination of cellular candidates was 
developed. Furthermore, by incorporating ELISA, immunofluorescent imaging, and neurite 
tracing techniques into the methodology, the therapeutic potential of the “medic” cell secreted 
BDNF can be assessed based on its bioavailability and bioactivity. 
3.2 Background 
Gene therapy using NFs is a novel therapeutic approach that could revolutionize glaucoma 
therapy and provide a means of disease management that beyond risk factor reduction. NFs are a 
class of proteins that are known to play an important role in the development, maintenance and 
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survival of neurons in both the central nervous system (CNS) and the peripheral nervous system 
(PNS) [65, 104]. In particular, BDNF has shown to be a potent NF based on results from several 
in vivo studies, thus is a suitable candidate for gene therapy applications by supporting both 
protective and regenerative functions [70, 74, 105].  
Local support of RGCs within the retina with BDNF could provide neuroprotection if 
challenges such as maintenance of BDNF levels in the retina for a prolonged period and needle-
free administration of the therapeutic plasmid can be safely and effectively addressed. This could 
be achieved using NPs carrying BDNF-encoding plasmids to the retina, where the expressed 
BDNF protein could rescue RGCs that are damaged from glaucomatous stress. There are several 
candidate cells within the retina that could serve as BDNF producers, including non-damaged 
RGCs, astrocytes [106], Müller glial cells [76], or retinal pigment epithelial cells (RPE). Astroglial 
cells, located mostly in the innermost retinal layers, are prime candidates because of their close 
proximity to RGCs within the retina nerve fiber layer (NFL) and optic nerve head (ONH), and 
their role in structural, metabolic and neurotrophic support, and in sensing hypoxia, immunological 
damage and neurogenesis [107].  
Screening of non-viral gene delivery system carrying pDNA involves the assessment of 
nucleic acid delivery and protein production efficiency, however, the biological effect of the 
expressed protein is not typically evaluated. To develop an in vitro system that would allow the 
measurement of the bioactivity of the expressed protein, a co-culture model consisting of two cell 
populations was utilized. Cell layer 1 represents the cells to be transfected non-virally with NPs 
carrying the therapeutic gene of interest, while cell layer 2 represents the cells responding to the 
therapeutic protein. In the context of the retina, cell layer 1 represents the potential retinal target 
cell population (eg. healthy RGCs, astrocytes or Müller cells) and cell layer 2 represents the 
31 
neuronal-like test cells for neurite outgrowth measurement. As an initial model, an astrocyte cell 
line was selected to serve as “medic cells” after non-viral transfection producing and secreting 
BDNF and SH-SY5Y neuroblastoma cells, routinely used in high throughput neurite outgrowth 
assays, as BDNF-responsive cells and suitable for the evaluation of BDNF bioactivity [108]. 
Moreover, SH-SY5Y neuroblastoma cells, exposed to hydrogen peroxide, provide an in vitro 
oxidative stress disease model representing one of the major glaucomatous stresses that contributes 
to the disease pathogenesis.  
Using the described co-culture model, it was demonstrated that transfected astrocytes were 
able to secrete enough bioactive BDNF and induced neurite outgrowth and extension in both 
untreated and oxidatively stressed SH-SY5Y cells. The two-layer co-culture model could 
potentially be used as a versatile system to test the transfectability and protein production of several 
retinal target cell types. The modality described here shows the feasibility of the approach for rapid 
screening of non-viral gene delivery systems for retinal gene therapy and provide a proof-of-
concept that astrocytes can be genetically transformed into BDNF producing cells using a non-
viral transfection method and the level of BDNF produced is sufficient to stimulate neurite 
outgrowth in a standard SH-SY5Y neuroblastoma cell model.  
3.3 Materials and methods 
3.3.1 Plasmid construct and NP formulation 
The pDNA was prepared by cloning the BDNF (transcript variant 1) sequence (NCBI 
Reference Sequence: NM_170735) into pCMV6-Entry expression vector (Origene, Rockville, 
MD, USA) with 5’ Sgfl (GCGATCGC) and 3’ Mlul (ACGCGT). TAG stop codon was inserted 
downstream of the BDNF construct, upstream of the Myc-DDK, to prohibit the expression of 
BDNF-Myc-DDK fusion protein. De novo gene synthesis, construct cloning and DNA purification 
32 
was performed by Blue Heron Biotech (Bothell, WA, USA). NPs (NPs) were formulated by 
complexing either BDNF-encoding plasmid or gWiz™ GFP (green fluorescence protein) reporter 
plasmid (Aldevron, Fargo, ND, USA) with K2® transfection agent (Biontex Laboratories GmBH, 
München, Germany) at ratios of either 2 µL of K2® per 1 µg of pDNA (Formulation #1) or 4 µL 
of K2® transfection reagent per 1 µg of pDNA (Formulation #2). Size and zeta potential of K2-
NPs were characterized by DLS using Zetasizer Nano ZS (Malvern Instruments, Malvern, 
Worcestershire, United Kingdom). Two hours prior to NP transfection, 2.5 μL of K2® Multiplier 
were added into the culturing medium of A7 astrocytes followed by K2-NPs. 
3.3.2 Genetically modified BDNF-expressing astrocyte co-culture model  
Co-culture was established using a combination of 0.4 µm polyester (PET) membrane 
transwell 12-well inserts (Corning) and glass bottom 12-well plates (MatTek Corporation, 
Ashland, MA, USA). Each well of the glass-bottom plates were pre-coated using recombinant 
human laminin (EMD Millipore, Billerica, MA, USA) at 0.625 µg/cm2 overnight at 4°C, followed 
by seeding 100,000 A7 cells into each transwell insert and 200,000 SH-SY5Y cells into each well 
of the plates. Oxidative stress was induced in SH-SY5Y cells with 100 µM of hydrogen peroxide 
for 24 hours prior to co-culturing. A total of four conditions were evaluated, all in triplicates, with 
two conditions containing non-virally transfected astrocytes trA7/oxSH-SY5Y and trA7/SH-
SY5Y; along with two controls such as oxidatively stressed neuroblastoma only (oxSH-SY5Y), 
and non-transfected A7 astrocyte co-cultured with oxidatively-stressed neuroblastoma cells 
(A7/oxSH-SY5Y).  
3.3.3 Oxidative stress SH-SY5Y model  
SH-SY5Y neuroblastoma cells (CRL-2266, ATCC, Manassas, VA, USA) were cultured in 
in 1:1 ratio of Eagle’s Minimum Essential Medium (EMEM, ATCC, Manassas, VA, USA) and 
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F12 medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin antibiotics (Pen/Strep). Cells were cultured in a 37 
°C incubator with 95% air/5% carbon dioxide. To establish the oxidatively stressed SH-SY5Y 
modality, 20,000 SH-SY5Y cells were seeded into each well of black clear-bottom 96-well 
microplates (Corning, Corning, NY, USA) and hydrogen peroxide at concentrations of 50, 100, 
150 or 200 M was added for 24 hours, each in triplicates. The viability was measured using Presto 
Blue® viability assay (Thermo Fisher Scientific) at 24 hours with SpectraMax M5 microplate 
reader (Molecular Devices, Sunnyvale, CA, USA).  
3.3.4 Transfection of A7 astrocytes 
A7 rat astrocytes (a gift from Dr Jeremy Sivak, University of Toronto; [109, 110]) were 
cultured in DMEM/high glucose media (Hyclone, GE Healthcare Life Sciences, Logan, Utah, 
USA) supplemented with 10% FBS and 1% Pen/Strep at 37 °C in a 95% air/5% carbon dioxide. 
K2-NPs were first evaluated and optimized in monolayer cultures of A7 astrocytes. Cells at 25,000, 
50,000 and 100,000/well (n=3 each) were seeded into clear 24-well culture plates (Grenier Bio-
One, Monore, NC, USA) and transfected using K2-NPs carrying gWiz™ GFP. The transfection 
efficiency (TE) was assessed based on the percentage of cells expressing GFP and viability based 
on MitoTracker® Deep Red (Thermo Fisher Scientific) staining using Attune Flow Cytometer 
(Thermo Fisher Scientific).  
3.3.5 BDNF protein production and neurite outgrowth bioassay 
BDNF production in A7 astrocyte supernatants was assayed at 24, 48 and 72 hours using 
a human BDNF ELISA kit (R&D Systems, Minneapolis, MN, USA). Standards were prepared 
according to the manufacturer’s protocol and standard curve was constructed using the 4 Parameter 
Logistic (4PL) Non-Linear Regression Model with an r2 of 0.997. Neurite counts and length 
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measurements were performed by first fixing SH-SY5Y cells with 4% paraformaldehyde (PFA) 
in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4) containing 1 mM of CaCl2 and 0.5 mM MgCl2 for 20 minutes at room temperature. Cells 
were then blocked using PBS containing 10% FBS, 0.1% Triton X-100, and 1% bovine serum 
albumin at 37 °C for 40 minutes. Post-blocking, 1X NorthernLights™ 493 (NL493)-conjugated 
mouse monoclonal anti-neuron-specific β-III tubulin antibody (R&D Systems) in PBS was added 
and incubated for 4 hours at 37°C. After immunostaining, cells were counterstained with 1 µM 
SYTO™ 61 (Thermo Fisher) for 20 minutes at 37°C. Cells were imaged using Zeiss LSM710 
confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Baden-Wü, Germany) with 63x 
oil immersion objective. Ten fields of 2048x2048 images were captured from each replicate of 
each experimental condition with approximately 100 cells per field using Zen 2009 software (Carl 
Zeiss AG). Acquired images were evaluated for neurite counts and length by tracing the neurites 
using the Simple Neurite Tracer plug-in from Fiji software (ImageJ, National Institute of Health, 
Bethesda, MD, USA) [111]. Neurite length was determined by converting the number of pixels in 
each of the traced neurites to micrometer using a predetermined pixels/micron ratio. 
3.3.6 Statistical analysis 
The statistical analysis was performed using the Graph Pad Prism software (GraphPad 
Software, La Jolla, CA, USA). One-way ANOVA and two-way ANOVA in conjunctions Tukey 
post hoc test were used to analyze neurite distribution for single variable and multi-variable 
analysis, respectively. A p-value of less than 0.05 was considered as statistically significant. 
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3.4 Results 
3.4.1 Astrocyte-neuroblastoma three-dimensional co-culture model for neurite extension 
evaluation 
A simple contact-independent two-layer (three-dimensional) neuronal co-culture model was 
developed to test the effect of BDNF, produced by non-virally transfected A7 astrocytes, by 
evaluating the neurite growth stimulation of a second cell population representing oxidatively 
damaged retinal cells. The transfected A7 astrocytes were seeded into transwell inserts, while the 
SH-SY5Y neuroblastoma cells cultured as a monolayer in the bottom of the wells (Figure 3.1) 
 
 
Figure 3.1 Schematic drawing of the two-layer, contact-independent 3D astrocyte-SH-SY5Y co-culture model. SH-
SY5Y cells were cultured on laminin-coated glass bottom plates and astrocytes were cultured in transwell inserts that 
were positioned in the same well separated by the culture medium and membrane. NP-transfected astrocytes carrying 
BDNF-encoding plasmid express BDNF, stimulating SH-SY5Y cells. The bioactivity and therapeutic potential of the 
secreted BDNF are evaluated by comparing the neurite counts and the neurite lengths of BDNF-exposed SH-SY5Y 
versus the SH-SY5Y presented in BDNF-absent controls. 
 
To estimate the LD50, oxidative stress was titrated in separate SH-SY5Y cultures with 50, 
100, 150, and 200 µM hydrogen peroxide. The corresponding cell viabilities were 52.0±13.5%, 
54.1±5.1%, 12.3±0.9%, and 1.9±2.0% after 24 hours of exposure, respectively. The 100µM 
concentration was chosen for generating oxidative stress in the co-culture model (Figure 3.2), due 
to robustness and lower variability compared to 50 µM. 
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Figure 3.2 Viability of SH-SY5Y cells 24 hours after hydrogen peroxide exposure at concentrations of 50, 100, 150, 
and 200 µM. Viability was measured based on Presto Blue® assay. Values expressed as mean ± s.d., n=3. Statistical 
significance was compared to the untreated condition. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 
 
3.4.2 Efficient and safe non-viral gene delivery system for astrocyte delivery 
K2-NPs are highly cationic NPs with a mean hydrodynamic diameter of 97.0±1.1 and 
83.9±0.4 nm, with a polydispersity index (PDI) of 0.22±0.01 and 0.17±0.01, and an average zeta 
potential of +59.6±1.6 mV and +57.3±2.8 mV with DNA:K2 ratio of 1 g: 2 L (Formulation 1) 
and 1 g: 4 L (Formulation 2), respectively (Table 3.1). The TE of A7 astrocytes was optimized 
using two different compositions of K2-NPs and three different cell seeding densities. The TE was 
17.3±5.8%, 15.8±2.6%, and 14.3±5.2% (Formulation 1) and 39.5±4.6%, 31.3±1.6%, and 
29.9±1.8% (Formulation 2) after 48 hours with seeding densities of 25,000, 50,000 and 100,000 
cells/well, respectively (Figure 3.3). The viability of A7 cells after transfection were 
71.40±15.52%, 76.2±1.7%, 86.3±0.4% (Formulation 1), and 72.6±2.3%, 44.8±2.2%, and 
54.9±3.9% (Formulation 2) at the indicated cell densities, respectively (Figure 3.3).  
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Table 3.1 Size (hydrodynamic diameter), polydispersity index and zeta potential of the K2-NPs formulated with 
different DNA:K2 ratios. Values expressed as mean ± s.d., n=3 
NP Formulation Size (nm) PDI Zeta Potential (mV) 
DNA : K2 (1 µg : 2 µL) 
(Formulation #1) 
96.9±1.1 0.22±0.01 +59.6±1.6 
DNA : K2 (1 µg : 4 µL) 
(Formulation #2) 
83.9±0.3 0.17±0.01 +57.3±2.8 
 
 
A)  B)  
Figure 3.3 Optimization of K2-NPs for optimal transfection condition using two different formulations and three 
different seeding densities of 25,000, 50,000 and 100,000 A7 astrocytes cells: B) TE was measured based on GFP 
expression and the viability was evaluated by MitoTracker® Deep Red using flow cytometry. Values expressed as 
mean ± s.d., n=3  * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 
 
3.4.3 BDNF-transfected astrocytes can produce and secrete BDNF protein 
BDNF was detected in co-cultures containing non-virally transfected astrocytes in 
increasing concentrations with time. More specifically, 3,750.8±251.1 ng/mL, 9,052.6±1391.2 
ng/mL, and 10,367.1±390.8 ng/mL were detected in trA7/oxSH-SY5Y co-culture conditions at 
24, 48, and 72 hours, respectively (Figure 3.4). Similarly, BDNF was also detected in the culture 
medium of trA7/SH-SY5Y co-cultures at concentrations of 3,836.9±595.5 ng/mL, 8,816.8±911.6 
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detectable in control experimental conditions such as oxSH-SY5Y and A7/oxSH-SY5Y, where 
BDNF-transfected astrocytes were not present in the co-culture. 
 
Figure 3.4 Quantification of the secreted BDNF protein using ELISA in the four different experimental conditions at 
24, 48, and 72 hours. Values expressed as mean ± s.d., n=3; n.d.= not detectable. * p<0.05; ** p<0.01; *** p<0.001; 
**** p<0.0001 
 
3.4.4 BDNF secreted from non-virally transfected astrocyte are bioactive and sufficient to 
induce neurite extension in neuroblastoma 
The increased number of neurites with higher neurite lengths confirmed the bioactivity of 
BDNF secreted from the transfected A7 astrocytes over 72 hours (Figure 3.5). Neurite count 
comparison showed that both trA7/oxSH-SY5Y and trA7/SH-SY5Y consistently produced higher 
neurite counts compared to A7/oxSH-SY5Y and oxSH-SY5Y only experimental conditions 
(Figure 3.6). Statistical analysis using one-way ANOVA shows that trA7/oxSH-SY5Y 
consistently showed higher neurite count compared to oxSH-SY5Y and A7/oxSH-SY5Y at 24, 48, 
































































have consistently higher number of neurite counts compared to oxSH-SY5Y and A7/oxSH-SY5Y, 
the differences peaked at 48 and 72 hours with p-value of at least <0.001.  
 
Figure 3.5 Evaluation of BDNF-mediated effect on total neurite count at 24, 48, and 72 hours. * p<0.05; ** p<0.01; 
*** p<0.001; **** p<0.0001 
 
Neurite length distribution profile was generated to compare the number of neurites in 
different length categories: <10 μm, between 10 and 20 μm, or > 20μm. Based on the neurite 
distribution profile, it was shown that trA7/oxSH-SY5Y and trA7/SH-SY5Y consistently had 
higher number of neurites that were longer than 20 μm compared to oxSH-SY5Y and A7/oxSH-
SY5Y over 72 hours (Figure 3.7). The most significant increase in the number of neurites that was 
longer than 20 μm was observed at 24 and 72 hours. The trA7/oxSH-SY5Y was shown to have 8.2 
times and 7.5 times more neurites longer than 20 μm compared to the BDNF-absent controls of 






































Figure 3.6 SH-SY5Y cells neurite length distribution profile under various experimental conditions at 24 hours (A), 
48 hours (B) and 72 hours (C). Each condition was performed in triplicates, and 10 frames were measured for each 
replicate. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 
 
Furthermore, trA7/oxSH-SY5Y was also shown to have 10.8 times and 10.4 times the 
number of neurites with longer than 20 μm compared to the BDNF-absent controls of oxSH-SY5Y 
and A7/oxSH-SY5Y at 72 hours, respectively. Whereas, the extent of neurite extension longer 
than 20 μm in unstressed SH-SY5Y cells co-cultured with BDNF-transfected A7 (trA7/SH-SY5Y 




Figure 3.7 Total number of SH-SY5Y neurites in each length categories: less than 10 µm, between 10-20 µm, or 
greater than 20 µm over 24 hours (E), 48 hours (F), and 72 hours (G). Each condition was performed in triplicates, 






The specific modalities for non-viral gene therapy using NFs to support regenerative 
functions of the retina are currently under intensive investigations. Several specific aspects of a 
neuroprotective and neuroregenerative treatment, including the design of non-viral gene delivery 
systems, best candidate cell types to produce the NF and delivery methods require elucidation.  
In this study, the usefulness of a two-layer astrocyte-neuroblastoma co-culture system to 
test the BDNF production efficiency of non-virally transfected astrocytes and neurite outgrowth 
stimulation by the secreted BDNF protein was demonstrated. Additionally, the effect of astrocyte-
secreted BDNF on oxidatively damaged SH-SY5Y cells as a potential in vitro disease model 
system was also evaluated. This aspect of the co-culture system is useful since it can model 
oxidative stress in the gene therapy recipient cell line which was implicated to be one of the major 
contributors to RGC death in glaucoma [60].   
The results show that BDNF expressed by trA7 cells increased neurite outgrowth response 
in both SH-SY5Y and oxSH-SY5Y cells over 72 hours. BDNF-mediated neurite extension 
increase included both the neurite counts and the proportion of neurites that were longer than 20 
μm in neuroblastoma cells compared to cells that were not exposed to BDNF.  However, more 
detailed investigation on the dose-dependency of BDNF-mediated neurite extension will be 
needed. Furthermore, assessment of total neurite count alone is insufficient in determining the 
bioactivity and neurite outgrowth potential, and instead, the profiling and comparing of neurite 
lengths abundancy is a more accurate indicator.  
In case of a therapy that aims to rescue retinal ganglion cells in glaucoma, astrocytes appear 
to be one of the most promising candidates for neurotrophin supplementation gene therapy 
approach given their distribution in strategic areas of the eye such as in the matrices of lamina 
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cribrosa, which is strongly associated with the pathogenesis of glaucoma [112]. By targeting the 
astrocytes in the eye for gene delivery, transfected-astrocytes can be transformed into “medic 
cells” and become the protein production ‘factories’, particularly in the area close to the lamina 
cribrosa to provide the retinal ganglion cells with NFs for rescue and potential regeneration 
capacity.  
In terms of the selection of a NF for gene therapy, BDNF continues to be a molecule of 
interest for therapeutic applications in glaucoma. Findings within the past decade have revealed 
the increasing importance of BDNF on the health of RGCs. In glaucoma, although BDNF is 
expressed locally in the retina, it is only expressed at low levels while most of the BDNF is 
retrogradely transported from the SC, which is blocked in the event of elevated intraocular pressure 
[113]. BDNF appears to have multiple effects on RGCs as it directly corrects the problem 
associated with bidirectional transport of NFs, and at the same time indirectly influence other 
retinal cells in the guidance of damaged axons. For instance, neurotrophin deprivation due to 
bidirectional axonal transport obstruction within RGCs was shown to result in axonal damage 
[114]. Orthograde flow at the optic nerve head prevents proteins made by RGCs from reaching 
their axonal extensions and perturbed retrograde transport of NFs produced in the SC in the brain 
to reach the RGC soma [115]. BDNF also appears to support axonal path finding to the brain [116, 
117]. Given the results in this study showing that transfected astrocyte can produce bioactive 
BDNF, further research in the development of targeted astrocyte delivery would be advantageous. 
In this study, BDNF-mediated neurite extension resulted in increased neurite counts and the 
proportion of extended neurites (>20 μm) in neuroblastoma cells compared to cells that were not 
exposed to BDNF at 24 and 72 hours, suggesting that BDNF gene therapy is promising for optic 
nerve repair and regeneration. 
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Throughout the decades of glaucoma research, a significant obstacle was the lack of a true 
representative RGC line for in vitro research. The RGC-5 virally transformed and known at the 
time as a rat RGC cell line provided a much needed model for close to a decade [118]. However, 
recent investigations confirmed that RGC-5 is in fact a mouse photoreceptor cell line, rather than 
a rat RGC line as it was claimed to be [119]. There is currently no RGC line available, apart from 
primary RGCs. Indeed, primary RGCs would be the most ideal cells to use, however, RGCs are 
present in low abundance in vivo, which makes it costly to isolate high cell populations for rapid 
and large-scale drug screenings. Furthermore, primary RGCs undergo spontaneous degeneration 
upon isolation, which makes it difficult to recreate representative glaucomatous stress model in 
vitro given it is already undergoing degeneration as soon as it is isolated. As a result, an initial 
model was described in the study for rapid screening of non-viral BDNF gene therapy with 
astrocytes. The model presented in this study is flexible in terms of the two cell layers; depending 
on the target “medic cell” of interest, various gene delivery target cells could be selected for 
evaluation, such as Müller glial cells or healthy RGCs. 
3.6 Conclusion 
Overall, our results show that the neurite outgrowth quantitation of astrocyte-neuronal co-
culture model described in this study can be used to evaluate non-viral gene delivery systems for 
retinal gene therapy by determining the bioactivity of the secreted BDNF. A schematic describing 
the systematic flow of bioassay is illustrated in Figure 3.8. Furthermore, it also demonstrates that 
K2® NPs can efficiently deliver BDNF-encoding pDNA into A7 astrocytes to produce functional 
BDNF and initiate neurite extension in cell layer 2. Lastly, BDNF supplementation gene therapy 
using a non-viral gene delivery vector could be a promising approach for the rescue of 
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glaucomatous-stressed retinal ganglion cells using astrocytes as gene delivery targets with the 
added possibility of needle-free topical administration of NPs in the future.  
 
 
Figure 3.8 Schematic of the systemic bioassay protocol procedure for therapeutic protein bioavailability and 
bioactivity assessment [120] 
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Chapter 4 Characterization of RGC-like cells derived from retinal 
multipotent stem cells  
4.1 Rationale and objective 
Protection and rescue of RGCs is a pivotal aspect in glaucoma management. The lack of a 
representative RGC cell model to assess RGC-specific responses of candidate therapeutics is 
currently a major hindrance to therapeutic discovery of new candidate compounds and delivery 
systems for downstream development. To address this issue, multipotent retinal stem cell-derived 
RGCs was generated, termed XFC cells, which can be utilized for preclinical screening of RGC-
aimed therapeutics. Multiplexed gene expression profiling and stimuli-mediated neurite extension 
assessment showed that one of the isolated cell population, XFC-3 cells, express key RGC 
biomarkers Map-2, Rbpms, and Tubb3, and exhibit neurite extension upon activation by BDNF, 
CNTF, and Y-27632. The application of XFC-3 cells in therapeutic discovery was demonstrated 
in the co-culture bioassay model described in previous chapter for screening NF gene therapy 
systems. By using ELISA, immunofluorescent imaging and neurite tracing techniques, the 
bioavailability and bioactivity of BDNF secreted from XFC-3 cells transfected by various 
nanoparticles were evaluated. In summary, this study showed the generation of stem cell-derived 
XFC-3 cells that express key RGC characteristics that have potential as an RGC cell model for 
preclinical screening and therapeutic discovery applications. 
4.2 Background 
Degeneration of RGCs is a key aspect of glaucoma pathogenesis that ultimately results in 
continued loss of vision despite the current standard of treatment. Gene therapy with NF is a 
promising approach for neuroprotection of the retina by supporting the functions of damaged 
RGCs. In order to develop effective gene delivery systems, a reliable and representative RGC cell 
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model is needed. In light of the misidentification of the RGC-5 cell line [119], used extensively 
by many research groups for years, currently no cell model is available that can be utilized for in 
vitro preclinical screening of promising therapeutic candidates. While the utilization of primary 
RGCs as a source of RGCs is a possible option for in vitro investigations, their use is limited due 
to low abundancy in vivo, poor isolation efficiency, and spontaneous degeneration upon isolation.  
Stem cells are unique cell types characterized by their intrinsic ability to self-renew and to 
differentiate into multiple different cell types, providing opportunity for generating specific cell 
types of interest for broad biomedical and research applications. In particular, multipotent retinal 
stem cells (RSCs) are promising for generating most retinal cell types. Li and colleagues have 
described successful isolation of CD1-4 multipotent RSCs from CD-1 mouse retina that can 
differentiate into multiple retinal cell types including rod photoreceptor cells, cone photoreceptor 
cells, Müller glial cells, bipolar cells, amacrine cells, horizontal cells, and RGCs [121]. 
Furthermore, they showed that the photoreceptor cells isolated from differentiated retinal 
populations were able to restore the functionality of the photoreceptors in photoreceptor-deficient 
rd1 mutant mouse after transplantation [121].  
In this study, we show the isolation and characterization of RGC-like cells from the mixed 
retinal cell population differentiated from CD1-4 RSCs. Amongst the cells isolated, one of the 
isolate termed XFC-3 was determined to be RGC-like, expressing key RGC biomarkers Map-2, 
Rbpms, and Tubb3. Moreover, XFC-3 cells exhibit neuronal morphology with neurites that can be 
extended in response to stimuli such as BDNF, CNTF, Y-27632 RKI, and their combinations. 
Isolated XFC-3 cells were incorporated into the 3D co-culture bioassay model developed 
previously in our laboratory for screening retinal gene delivery systems [122]. This 3D co-culture 
model has two layers of cells where cell layer 1 represents the transfected cells and cell layer 2 
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represents the cells responding to the expressed therapeutic proteins such as NF. The choice of 
cells in each layer can reflect the particular research question asked. In the model the astrocyte-
neuroblastoma cell combination represented a healthy transfected cells (astrocytes) or “medic 
cells” producing and secreting BDNF and the recipient SH-SY5Y neuroblastoma cells (routinely 
used in high throughput neurite outgrowth assays) as BDNF-responsive cells and suitable for the 
evaluation of BDNF bioactivity. In the current study, the use of XFC-3 cells allow direct evaluation 
of the transfectability and gene expression by RGC-like cells, both healthy and stressed thereby 
providing an opportunity to develop it as a ‘disease’ model [122].  Overall, the results described 
in this paper demonstrate the generation and characterization of RGC-like cells that may serve as 
a cell model for the preclinical in vitro development and screening of candidate RGC therapeutics. 
4.3 Materials and methods 
4.3.1 CD1-4 RSC culture 
CD1-4 RSCs were kindly gifted by Dr. Ting Xie from the Stower Institute for Medical 
Research and University of Kansas. CD1-4 RSCs were isolated from the neuroretina, excluding 
retinal pigmented epithelium (RPE), ciliary body, and posterior tissue surrounding the optic nerve 
head, of 4-8 weeks old CD-1 mouse as described in published literature [121]. Purified CD1-4 
RSCs were cultured in 12-well plates coated with 0.2% gelatin for 3 hours at 37 °C and maintained 
in advanced DMEM/F12 media (1:1) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 
containing 1.0 g/L glucose (Sigma-Aldrich, St. Louis, MO, USA), 1.0 g/L lactose (Sigma-
Aldrich), 1.0 g/L BSA (Sigma-Aldrich), 0.045 g/L proline (Sigma-Aldrich), 2 mM nicotinamide 
(Sigma-Aldrich), 2 mM L-glutamate (Gibco), 1% penicillin/streptomycin (Hyclone, GE 
Healthcare Life Sciences, Logan, Utah, USA), 1% insulin-transferrin-supplement (Gibco), 5% 
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knockout serum replacement (Gibco), 20 ng/mL EGF (Gibco), and 20 ng/mL bFGF (Gibco). Cells 
were cultured in humidified incubator at 37°C with 5% CO2. 
4.3.2 Differentiation of CD1-4 RSCs into retinal cell types 
CD1-4 RSCs were differentiated in 24-well glass-bottom plates (MatTek Corporation, 
Ashland, MA, USA) coated with 0.015 mg/mL poly-L-ornithine (EMD Millipore, Billerica, MA, 
USA) overnight at room temperature, followed by subsequent coating of 2 µg/cm2 laminin (EMD 
Millipore) overnight at 4 °C. 100,000 cells per well were seeded for differentiation, with 
differentiation medium containing DMEM/F12 (1:1) (Gibco), B-27 supplement (1:50) (Gibco), 2 
mM L-glutamate (base differentiation medium) in addition to 10 ng/mL bFGF for the first 2 days. 
For the next 4 days, differentiation medium was replaced with advanced DMEM/F12 media 
(Gibco) containing, 2% B-27 supplement (Gibco), 1% N-2 supplement (Gibco), 2 mM L-
glutamate (Gibco), and 10 ng/mL bFGF (Gibco). Isolated XFC cells were cultured in laminin-
coated 6-well glass-bottom plates (MatTek Corporation) using advanced DMEM/F12 (Gibco) 
media containing 1.0 g/L glucose (Sigma-Aldrich), 1.0 g/L lactose (Sigma-Aldrich), 1.0 g/L BSA 
(Sigma-Aldrich), 0.045 g/L proline (Sigma-Aldrich), 2 mM nicotinamide (Sigma-Aldrich), 2 mM 
L-glutamate (Gibco), 1% penicillin/streptomycin (Hyclone), 1% insulin-transferrin-supplement 
(Gibco), and 10% FBS (Thermo Fisher Scientific). These cells were named XFC cells representing 
the new differentiated RGC-like cells, with five different cell line variants of XFC were isolated 
(XFC-2, XFC-3, XFCm-2, XFCm-4, and XFCfacs-1). 
4.3.3 NP gene delivery systems preparation 
Three different types of non-viral gene delivery systems were formulated. GL-NP system 
were prepared by complexation of 18-7NH-18 GS (synthesized in-house [123]) with gWiz™ GFP 
plasmid (Aldevron, Fargo, ND, USA) at desired charge ratios for 15 minutes at room temperature, 
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followed by addition of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) neutral lipid at 
desired GS/lipid ratios. SWNT system were prepared by first non-covalently functionalizing 
PureTube™ SWNT (ptSWNT) with GS as described earlier [124]. Briefly, ptSWNTs 
(NanoIntegris Inc., Boisbriand, QC, Canada) were dispersed in 1 mg/mL 12-3-12 GS solution at 
10 µg/mL, and sonicated using Branson bath sonicator at 40 kHz frequency (Branson Ultrasonics 
Corporation, Danbury, CT, USA) for 1h at temperature not exceeding 40°C. The functionalized 
ptSWNTs (ƒ-ptSWNT) were then complexed with gWiz™ GFP pDNA (Aldevron) at specified 
ratios for generation of ƒ-ptSWNT-pDNA complexes. The third transfection agent, the 
commercially available K2® lipopolyamine-based proprietary transfection reagent (Biontex 
Laboratories GmBH, München, Germany) was used. K2-NPs were formulated by the 
complexation of K2® transfection reagent with either gWiz™ GFP (Aldevron) or BDNF (Blue 
Heron) pDNA at desired ratios according to the manufacturer’s protocol. Either gWiz™ GFP or 
BDNF pDNA was used depending on the specific goal of the evaluation. A pDNA dose of 1 
µg/well was used in each transfection. 
4.3.4 Magnetic-activated magnetic cell separation 
Immunopanning separation was performed using an RGC isolation kit (Miltenyi Biotec, 
Auburn, CA, USA) with mouse anti-Thy1.2 microbeads instead of anti-Thy1.1 microbeads for 
mouse RGC isolation. Briefly, differentiated stem cells were dissociated using Accumax™ cell 
detachment solution (Innovative Cell Technologies, San Diego, CA, USA) and pelleted at 300 x g 
for 5 minutes. Cells were then resuspended with 500 µL of Thy-1.2 microbeads (1:10, Miltenyi 
Biotec) and biotinylated depletion antibody (1:50, Miltenyi Biotec) in 0.5% BSA-containing PBS 
(with calcium and magnesium) for 15 minutes at room temperature. Cells were then pelleted at 
130 x g for 5 minutes and stained with anti-biotinylated antibody (1:5, Miltenyi Biotec) diluted in 
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500 µL of 0.5% BSA-containing PBS (with calcium and magnesium) for 15 minutes. Endothelial 
and microglial cells were depleted using the MACSiMAG separator (Miltenyi Bitoec) and Thy-1 
positive cells were selected with MACs separator using MS column (Miltenyi Biotec).  
4.3.5 Fluorescent-activated cell sorting 
The differentiated retinal cell population was blocked with blocking media (10% serum 
and 1% in PBS) for 15 minutes at room temperature. Cells were then stained with anti-Thy1.2-
FITC antibody (1:250) (Miltenyi Biotec) for one hour on ice. Stained cells were sorted using BD 
FACSAria Fusion Cell Sorter with automated cell deposition unit (BD Biosciences, San Jose, CA, 
USA). Cells were sorted into advanced DMEM/F12 medium (Gibco) supplemented with 10% FBS 
(Thermo Fisher Scientific), 2% B-27 supplement (Gibco), 1% L-glutamine (Gibco), and 1% 
penicillin/streptomycin (Hyclone).  
4.3.6 Gene expression profiling analysis 
RNA samples were isolated using PicoPure® RNA Isolation Kit (Arcturus, Thermo Fisher 
Scientific, Waltham, MA, USA), based on the manufacturer’s protocol and subjected to retinal 
biomarker gene expression profiling using NanoString nCounter® Analysis System, through 
quantification of mRNA targets in the custom retinal biomarker codeset (NanoString, Seattle, 
Washington, USA). The panel of target genes included biomarkers representing major retinal cell 
types: ISL-1, Map-2, Nef-H, Pou4f1, Rbpms, Sncg, Thy-1.2, and Tubb3 as representative RGC 
biomarkers; Aqp4, Prdx6 and Slcla3 as representative astrocyte biomarkers; Abca8a, ald1a1, and 
Vim as representative Müller glia biomarkers; and Nrl and Rom1 as representative photoreceptor 
biomarkers. Rpe65, Calb2, Prkca, and Lim2 each individually represent RPE, amacrine, bipolar 
and horizontal cell biomarkers, respectively.  Each reaction was performed with 100 ng of RNA 
in a 5µL loading volume, mixed with capture and reporter probes. 
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4.3.7 BDNF, CNTF, and Y-27632 treatment 
Five thousand cells were seeded into each well of 24-well glass-bottom plates (MatTek 
Corporation) and allowed for incubation for 24 hours prior to the addition of the stimuli with a 
media volume of 500 µL. BDNF (PeproTech, Montreal, QC, Canada), CNTF (Peprotech), and Y-
27632 (Sigma-Aldrich) proteins were prepared by dissolving the lyophilized proteins in sterile 
water. Protein treatments were added directly into the appropriate wells at desired concentration.  
4.3.8 Immunofluorescent staining for flow cytometry analysis 
 Cells were fixed with 4% PFA (Alfa Aesar, Tewksbury, MA, USA) for 15 minutes at room 
temperature and blocked with 10%  bovine serum (Thermo Fisher Scientific) and 0.3% Triton X-
100 for 45 minutes at room temperature. Cells were then stained with one of the following 
antibodies: mouse anti-Nestin conjugated with Alexa Fluor® 488 (1:250, EMD Millipore), mouse 
anti-beta-III tubulin conjugated with Alexa Fluor® 488 (1:250, EMD Millipore), mouse anti-Map-
2 conjugated with Alexa Fluor® 488 (1:250, EMD Millipore), or mouse anti-Thy.1.2 conjugated 
to FITC (1:250, Miltenyi Biotec) for one hour at room temperature. Stained cells were then 
analyzed using Attune Flow Cytometer (Applied Biosystems, Thermo Fisher Scientific, Waltham, 
MA, USA).  
4.3.9 Immunofluorescent staining for confocal microscopy and neurite tracing 
 After 24 hours of incubation, equal volumes of 4% PFA (Alfa Aesar) were added directly 
into the media for 2 minutes at room temperature. After 2 minutes, media were removed and 200 
µL of 4% PFA (Alfa Aesar) were added into each well and incubated for 13 minutes at room 
temperature. After fixation, PFA was removed and each well was washed twice with 200 µL of 
Wash Buffer (0.1% BSA in PBS), and blocked with 200µL of Blocking Buffer (10% FBS + 0.03% 
Triton in PBS) for 45 minutes at room temperature. Beta Tubulin III conjugated with Alexa Fluor® 
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647 (BioLegend, San Diego, CA, USA) staining buffer was prepared in Dilution Buffer (1% FBS 
+ 1% BSA + 0.03% Triton + 0.01% sodium azide) at 1 µg/mL. After 45 minutes of blocking, 200 
µL of the antibody was added into each well and incubated overnight at 4°C. Cells were washed 
with cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and 
counterstained with fluorescent nucleic acid stain, Syto™ 16 (Thermo Fisher Scientific), at 500 
nM concentration prior to imaging. Each well was imaged using a Zeiss LSM710 laser scanning 
confocal microscope (Carl Zeiss AG, Oberkochen, Baden-Wu, Germany) with a 20x objective. 
For each well, nine images with a resolution of 1024x1024 were captured using the tile scan 
function in the Zen 2009 software (Carl Zeiss AG). Captured images were traced using Simple 
Neurite Tracer plugin in Fiji software (ImageJ). Neurite length changes were quantified and 
analyzed using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). 
4.4 Results 
4.4.1 Differentiated CD1-4 RSC population expresses biomarkers indicative of retinal 
ganglion cell 
Immunofluorescence results showed that the six-day differentiated CD1-4 RSC population 
consisted of cells that express β-tubulin III (15.86.9%), Map-2 (37.75.9%), and Thy-1 
(3.90.5%), suggesting the presence of RGCs within the differentiated cell population. Stem cell 
biomarker nestin was also evaluated, and it was found that 56.9% of the differentiated cell 




Table 4.1 Biomarker characterization of differentiated RSC after 6 days of differentiation. Values expressed as mean 
± s.d., n=3 
Biomarker Fluorophore % of Cells Expressing Biomarker 
Nestin Alexa Fluor® 488 56.9±8.3 
B-III Tubulin Alexa Fluor® 488 15.8±6.9 
Map-2 Alexa Fluor® 488 37.7±5.9 
Thy-1 FITC 3.9±0.5 
 
4.4.2 Isolation and cultivation of XFC cells in vitro  
Three types of stem cell-derived RGC-like cells (XFC, XFCm, and XFCfacs) were generated 
using different combinations of differentiation protocols and Thy-1 positive cell isolation methods. 
More specifically, XFC cell series (Figure 4.1) are stem cell-derived RGC-like cells isolated from 
6-day differentiated stem cell population using MACS isolation method. XFCm cell series are stem 
cell-derived RGC-like cells isolated from a 14-day differentiated stem cell population using 
MACS isolation method. XFCfacs cell series are stem cell-derived RGC-like cells isolated from a 
6-day differentiated stem cell population using FACS isolation method.  
 
 
Figure 4.1 Thy-1 positive cell isolated from differentiated RSC cultured on laminin-coated surface over time: A) 2 
days after isolation; B) 3 days after isolation; and C) 7 days after isolation. Images were captured with 10x objective 




4.4.3 XFC cells express multiple RGC biomarkers  
XFC, XFCm, and XFCfacs were characterized using multiplexed gene expression profiling 
technique, NanoString nCounter® technology, to characterize the cells based on their retinal cell 
biomarker mRNA expression profile. The nCounter® technology utilizes a mRNA multiplex 
platform, which can quantify the levels of mRNA expression of the desired gene targets. For this 
evaluation, we have designed a multiplex gene panel that includes biomarkers representing major 
cell types found in the retina including RGCs, astrocytes, Müller glia, photoreceptor, RPE, 
amacrine, bipolar, and horizontal cells. ISL-1, Map-2, Nef-H, Pou4f1, Rbpms, Sncg, Thy-1.2, and 
Tubb3 are representative RGC markers; Aqp4, Prdx6 and Slcla3 are representative astrocyte 
markers; Abca8a, ald1a1, and Vim are representative Müller glia markers; and Nrl and Rom1 are 
representative photoreceptor markers. Rpe65, Calb2, Prkca, and Lim2 each individually 
representative markers for RPE, amacrine, bipolar, and horizontal cells, respectively.  
The XFC series of cells consist of XFC-2 and XFC-3 cells, which were isolated from 
independent 6-day differentiated RSC cell populations using MACS. Similarly, the XFCm series 
cells consist of XFCm-2 and XFCm-4 cells, which were isolated from independent 14-day 
differentiated RSC cell populations using MACS. An alternative method of isolation using FACS 
was also evaluated on 6-day differentiated RSCs for comparison, which resulted in XFCfacs cells. 
Gene expression was profiled by quantifying target gene mRNA copies expressed from target 




Figure 4.2 Retinal biomarker mRNA expression profile of XFC-2 (A), XFC-3 (B), and XFCfacs-1 (C) cells. Horizontal 
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 Six-day differentiated and isolated XFC cells demonstrated multiple retinal biomarker gene 
expression, including RGC biomarkers (Figure 4.2). Amongst twenty different retinal biomarkers 
in this panel, XFC-2 cells were found to positively express eight biomarkers Map-2, Rbpms, 
Tubb3, Slc1a3, Aldh1al, Vim, Rom1, and Prkca, three of which are representative of RGCs. An 
additional five other biomarkers detected in low threshold copy number were Isl-1, Sncg, Prdx6, 
Abca8a, and Rpe65. XFC-3 cells were also found to have a highly similar expression profile, with 
minor differences in copy numbers compared to XFC-2 cells. XFCfacs cells yielded similar gene 
expression profile with a few differences compared to XFC cells. XFCfacs-1 cells were found to 
positively express six biomarkers from the panel including Rbpms, Tubb3, Slc1a3, Aldh1al, Vim, 
and Prkca. An additional seven biomarkers were detected but in low levels, and that did not meet 








Figure 4.3 Retinal biomarker mRNA gene expression profile of XFCm-2 (A) and XFCm-4 (B) cells. Horizontal dotted 
line represents threshold level where n>20 indicates positive gene expression 
 
RGC-like cells isolated from a 14-day differentiated stem cell population, XFCm-2 and 
XFCm-4 cells, also expressed RGC biomarkers (Figure 4.3).  Expression profile for XFCm-2 cells 
showed the expression of six retinal biomarkers Rbpms, Tubb3, Slc1a3, Aldh1al, Vim, and Prkca, 
two of which were representative of RGCs. Additional five biomarkers detected at low levels were 
Map-2, Prdx6, Abca8a, Rom1, and Rpe65. XFCm-4 was a biological replicate of XFCm-2 cells and 
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The XFC and XFCm cells had similar gene expression profiles with slight fluctuations in 
the copy number over three passages (Figure 4.4). For example, in the third passage of XFC-3 
cells, RGC biomarkers Map-2 showed a 4-fold increase in mRNA copy number, while Tubb3 
expression exhibited a slight decrease by 0.35-fold compared to the first passage. Additional retinal 
biomarkers such as Slc1a3 and Aldh1al exhibited an increase of 0.64-fold and 8.71-fold, while Vim 
and Prkca exhibited a decrease of 0.43-fold and 0.29-fold compared to the first passage, 
respectively. For XFCm-2 cells, RGC biomarker Map-2 was found to exhibit a 2.92-fold increase 
compared to the first passage, a biomarker that was not expressed at a high enough level in the 
first passage to be considered as a positive expression. Expression of the two other RGC 
biomarkers Rbpms and Tubb3 both exhibited an increase of 1.09-fold and 2.57-fold compared to 
the first passage, respectively. Additional retinal biomarkers such as Vim, and Prkca all exhibited 
a 0.26-fold and 0.25-fold increase compared to the first passage, respectively.  
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Figure 4.4 Comparative analysis of XFC-3 cells (A) and XFCm-2 cells (B) retinal biomarker mRNA gene expression 
profile at passage 1 and passage 3. Horizontal dotted line represents threshold level where n>20 indicates positive 
gene expression 
 
To gain a better understanding of the gene expression profile of cells in vivo and to serve 
as controls, the gene expression profile of retina and primary mouse RGCs isolated using MACS 
were analyzed (Figure 4.5). Primary mouse RGC expresses all the RGC biomarkers in the panel, 























































































XFC-3 P1 & P3
XFC-3 (P#1)
XFC-3 (P#3)
ISL$1 MAP2 Nef$H Pou4f1 Rbpms Sncg Thy$1.2 Tubb3 Aqp4 Prdx6 Slc1a3 Abca8a aldh1a1 Vim Nrl Rom1 Rpe65 Calb2 Prkca Lim2
P1 11 24 0 1 559 8 1 316 2 13 862 9 42 30422 4 29 14 3 288 0




















































































XFCm-2 P1 & P3
XFCm-2 (P#1)
XFCm-2 (P#3)
ISL$1 MAP2 Nef$H Pou4f1 Rbpms Sncg Thy$1.2 Tubb3 Aqp4 Prdx6 Slc1a3 Abca8a aldh1a1 Vim Nrl Rom1 Rpe65 Calb2 Prkca Lim2
P1 5 12 1 1 281 2 1 133 0 9 467 8 20 16004 1 11 6 0 142 1





Figure 4.5 Comparative analysis of retinal biomarker mRNA gene expression profile of mouse primary cells: CD-1 
retina (A) and isolated primary RGCs (B). Horizontal dotted line represents threshold level where n>20 indicates 
positive gene expression 
 
4.4.4 XFC-3 neurites can be extended upon stimuli activation 
From the various XFC, XFCm and XFCfacs cells generated, XFC-3 cells were selected for 
further validation for neuronal characteristics and RGC-like stimuli-dependent neurite extension 
responses using NF and RKI such as BDNF, CNTF, Y-27632, and their combinations, as follows: 
20 ng of BDNF protein alone; 20 ng of CNTF protein alone; 10 M of Y-27632 RKI alone; 
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combination of 20 ng of CNTF protein with 10 M of Y-27632 RKI (CNTF+Y27632); or 
combination of 20 ng of BDNF protein with 20 ng of CNTF protein and 10 M of Y-27632 RKI 
(BDNF+CNTF+Y-27632). 
 
Figure 4.6 XFC-3 cells after 24 hours of stimuli exposure. Cells were stained with Beta-Tubulin AF647 (purple) and 
Syto™16 nuclei stain (blue). Images were captured using a 20x objective with tile scan function (area 3x3). XFC-3 
cells treated with A) untreated; B) BDNF protein (20 ng); C) BDNF protein (20 ng) and Y-27632 (10 M); D) CNTF 
(20 ng); E) CNTF (20 ng) + Y-27632 (10 M; F) Y-27632 (10 M); and G) BDNF (20 ng) + CNTF (20 ng) + Y-
27632 (10 M) 
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 Analysis of XFC-3 cells treated with BDNF, CNTF, Y-27632, and their combinations 
showed that the cells have neurites that can be extended extend upon activation, evident by the 
elongated neurites seen in Figure 4.6. Further neurite length distribution profiling was carried out 
by neurite length tracing and quantitation (Figure 4.7), which showed increased number of neurites 
with longer neurite lengths in XFC-3 cells treated with stimuli compared to untreated XFC-3 cells.  
 
 
Figure 4.7 Total neurite length distribution profiling of XFC-3 cells in response to BDNF, CNTF, and Y-27632 
activation. Values expressed as mean ± s.d., n=3.  ** p<0.01; *** p<0.001; **** p<0.0001 
 
Further neurite length categorization (Figure 4.8) showed that XFC-3 cells treated with 
BDNF+Y-27632 and BDNF+CNTF+Y-27632 demonstrated the highest degree of neurite 
extensions (p<0.0001), followed by Y-27632 alone (p<0.001) and CNTF+Y-27632 (p<0.01). 
XFC-3 cells treated with BDNF+CNTF+Y-27632 and BDNF+Y-27632, where XFC-3 cells 
exhibit 38 and 43.7 times more neurites that were 100 m compared to untreated XFC-3 cells. 
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times more neurites with length greater than 100 m compared to untreated condition. XFC-3 cells 
treated with either BDNF or CNTF alone also demonstrated evidence of neurite extension as the 
number of neurites with length greater than 100 m were 4.7 and 4 times higher compared to the 
untreated control.  
 
 
Figure 4.8 Neurite length category analysis of XFC-3 cells in response to BDNF, CNTF, and Y-27632 activation. 
Values expressed as mean ± s.d., n=3.  * p<0.05; ** p<0.01; **** p<0.0001; n.s. = not significant 
 
4.4.5 Integration of XFC-3 cells into the 3D co-culture bioassay 
As XFC-3 cells have shown to exhibit neurite extension in response to activation, in 
particular BDNF protein, XFC-3 cells were integrated into the 3D co-culture bioassay for NF gene 
delivery system evaluation established in the previous study to demonstrate the application of the 
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setup was structured (Figure 4.9). Two main co-culture conditions were established to evaluate the 
suitability of XFC-3 cells as BDNF-responsive cell candidate in the 3D co-culture bioassay 
system: 1) untransfected A7 cells co-cultured with XFC-3 cells (A7/XFC-3; Top:A7 / Bot:XFC-
3), and 2) BDNF-transfected A7 cells (trA7) co-cultured with XFC-3 cells (trA7/XFC-3; Top:trA7 
/ Bot:XFC-3). Examination of the traced mean neurite length and length distribution showed no 
significant differences between the two conditions as they exhibited highly similar neurite length 
distribution profiles. As XFC-3 cells were shown to exhibit low levels of neurite extension in 
response to 20 ng/mL of BDNF protein, it is perhaps that the amount of BDNF secreted by trA7 
in 24 hours was insufficient to induce neurite extension on XFC-3 cells.  
The second approach evaluated was to determine whether Y-27632-pretreated XFC-3 cells 
would be more responsive to BDNF detection (XFC-3-rki) in the co-culture setup. Thus, two co-
culture conditions were evaluated: 1) untransfected A7 cells co-cultured with Y-27632-pretreated 
XFC-3 cells (A7/XFC-3-rki; Top:A7 / Bot:XFC-3-rki); and 2) BDNF-transfected A7 cells co-
cultured with Y-27632-pretreated XFC-3 cells (trA7/XFC-3-rki; Top:trA7 / Bot:XFC-3-rki). 
Examinations of neurite length distribution profiles showed that XFC-3 cells in trA7/XFC-3-rki 
exhibited overall 2.78 times more neurites compared to A7/XFC-3-rki. Moreover, the number of 
neurites longer than 50 µm in trA7/XFC-3-rki was found to be on average 2.3 times higher than 
that of A7/XFC-3rki. These findings suggest that perhaps Y-27632-pretreated XFC-3 cells may 
have an elevated BDNF sensitivity compared to untreated XFC-3 cells, a characteristic that may 
be employed for BDNF bioactivity evaluation application in the A7/XFC-3-rki co-culture setup.  
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Figure 4.9 Neurite length distribution profile of XFC co-culture with BDNF-transfected A7 cells or untransfected 
cells after 24 hours. XFC cells cultured at the bottom layer were either untreated or treated with Y-27632 rki. Values 
expressed as mean ± s.d., n=3. *p<0.05; **** p<0.0001; n.s. = not significant 
 
4.4.6 XFC-3 cells as gene delivery target 
An aspect of gene therapy development involves the identification of a representative cell 
line for gene delivery system transfection evaluations. Hence, XFC-3 cells were evaluated for their 
transfectability using non-viral gene delivery systems. Three different types of non-viral gene 
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Figure 4.10 Transfection efficiency (A) and viability (B) evaluation of XFC-3 cells transfected with three non-viral 
gene delivery systems: K2-NP, GL-NP, and ƒ-ptSWNT-pDNA. Two different formulations of each non-viral system 


















































K2-NP [K2:DNA (4:1)] ƒ-ptSWNT-pDNA [CNT:DNA (1:1)]
ƒ-ptSWNT-pDNA [CNT:DNA (1:2)] 18-7NH-18 GL-NP [G:P/G:L (2.5:1/1:0)]









































K2-NP [K2:DNA (4:1)] ƒ-ptSWNT-pDNA [CNT:DNA (1:1)]
ƒ-ptSWNT-pDNA [CNT:DNA (1:2)] 18-7NH-18 GL-NP [G:P/G:L (2.5:1/1:0)]








K2-NPs showed the highest level of TE at 63.11.4% with 2L:1g K2:DNA ratio, and 
62.91.9% with 4L:1g K2:DNA ratio and the highest cell viability at 94.40.4% and 
79.73.4%, respectively. The ƒ-ptSWNT-pDNA complexes were able to transfect XFC-3 cells at 
relatively low levels with a TE of 6.71.0% with the 1:1 w/w CNT:DNA ratio, and 9.30.2% with 
the 0.5:1 w/w CNT:DNA ratio. The ƒ-ptSWNT-pDNA complex also induced a relatively high 
level of toxicity that resulted in viability of 28.84.17% and 55.25.0%, respectively. The 18-
7NH-18 GL-NPs were also able to transfect XFC-3 cells and showed a TE of 2.250.36% using 
G:P/G:L ratios of 2.5:1/1:0, and 10.20.7% with G:P/G:L ratios of 2.5:1/1:0.5. Cell viability 
remained high with 97.30.4% and 94.51.2% for the two formulations of GL-NPs.  
As XFC-3 cells were found to be transfectable by non-viral gene delivery systems, they 
were also evaluated for their ability to serve as gene delivery “medic” cells to produce and secrete 
BDNF proteins to induce neurite extension on the receiving XFC-3 cells. To achieve this, XFC-
3/XFC-3 co-culture was established by integration of XFC-3 cells into the “therapeutic protein-
producing” layer of the co-culture bioassay model (Figure 4.11). Thus, four conditions were 
evaluated: 1) untransfected XFC-3 cells co-cultured with XFC-3 cells (XFC-3/XFC-3; Top:XFC-
3 / Bot:XFC-3); 2) BDNF-transfected XFC-3 cells (trXFC-3) co-cultured with XFC-3 cells 
(trXFC-3/XFC-3; Top:trXFC-3 / XFC-3); 3) untransfected XFC-3 cells co-cultured with Y-27632-
pretreated XFC-3 cells (XFC-3/XFC-3-rki; Top:XFC-3 / Bot:XFC-3-rki); and 4) BDNF-
transfected XFC-3 cells co-cultured with Y-27632-pretreated XFC-3 cells (trXFC-3/XFC-3-rki; 
Top:trXFC-3 / Bot:XFC-3-rki). A comparison of the neurite length distribution profiles of the four 
co-culture conditions showed that there were little differences in neurite counts and length 
distribution between XFC-3/XFC-3 and trXFC-3/XFC-3 co-cultures.  
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Figure 4.11 Neurite length distribution profile of XFC-3 cells co-culture with BDNF-transfected XFC-3 cells and 
untransfected cells after 24 hours. XFC-3 cells cultured at the bottom layer were either untreated or treated with Y-
27632 rki. Values expressed as mean ± s.d., n=3.   ** p<0.01; n.s. = not significant 
 
Similarly, a comparison of the two Y-27632-pretreated XFC-3 cells co-culture conditions 
(XFC-3/XFC-3-rki and trXFC-3/XFC-3rki) showed that the number of neurites shorter than 90 
µm was similar amongst the two conditions, but the number of neurites longer than 90 µm was 
approximately 2 times higher in XFC-3/XFC-3-rki compared to trXFC-3/XFC-3-rki. The results 
suggest that while XFC-3 cells can be transfected with non-viral gene delivery systems, the level 
of subsequent protein production efficiency may perhaps be lower in XFC-3 cells and requires 
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In this investigation, we have developed stem cell-derived RGC-like cells with key 
molecular and physiological characteristics resembling that of RGCs. More specifically, a 
particular cell isolate, XFC-3 cells, expressed three key RGC biomarkers Map-2, Rbpms, and 
Tubb3, and exhibited neurite extension upon activation by BDNF, CNTF, Y-27632, and their 
combinations. Given these molecular and physiological characteristics that XFC-3 cells displayed, 
we have integrated XFC-3 cells into the 3D co-culture model as BDNF-responsive cells, towards 
the generation of an astrocyte-RGC co-culture model. Furthermore, the co-culture setup A7/XFC-
3-rki have demonstrated that XFC-3 cells in A7/XFC-3rki conditions were able to confirm the 
bioactivity of BDNF proteins secreted from trA7 by exhibiting neurite extension. Together, these 
finding demonstrated the potential of XFC-3 cells as model RGCs for preclinical development of 
ganglion cell therapeutics. Moreover, the applicability of XFC-3 cells in the A7/XFC-3-rki co-
culture model demonstrated their potential in screening applications, such as a tool for NF gene 
delivery systems screening. 
Utilizing stem cells to generate difficult-to-culture cells in vitro is a promising avenue to 
create useful cell models that can fuel the process of therapeutic discovery. The use of multipotent 
stem cells has an advantage in the application of differentiating target tissue specific cell types, as 
their differentiation diversity is limited to the predetermined cellular lineage. In the application of 
RGCs generation, RSC is one of the most promising stem cell candidates. Mammalian RSCs were 
first described by Tropepe et al. in 2000, where it was shown that the RSCs isolated from ciliary 
epithelium (CE) of the mouse eye expressed stem cell characteristics and was able to differentiate 
into multiple retinal cell types [125]. The work was then followed by the finding of Coles et al., 
who identified human RSCs from the CE of human eyes [126]. The RSCs used in this study were 
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isolated from the retina in the absence of CE as described by Li et al. [121]. The high expression 
of Müller glia biomarkers such as Vim and aldh1a1 in undifferentiated CD1-4 cells and XFC cells 
suggest that these cells may have a Müller glial origin as Müller glial cells have been shown in 
various studies to possess stem cell characteristics [127-129]. Moreover, it was demonstrated in 
different studies that they could differentiate into RGCs [130-132]. Bhatia et al. have further 
suggested that Müller glia has spontaneous proliferative and neuronal marker expression capacity 
that fulfills the characteristics of a true stem cell [133]. On the other hand, while there were reports 
of stem cell-derived RGCs derived from other stem cell types such as embryonic stem cells [134-
137] and induced pluripotent stem cells [136, 138-141]. While primary RGCs remain a possible 
RGC cell source for in vitro investigations, the low abundance of RGCs in commonly used mouse 
strains for glaucoma research such as C57/BL6 and DBA2 peaks at roughly 80,000 cells per eye 
at 9 months old rodents [142]. Coupled with the low efficiency of RGC isolation and spontaneous 
degeneration once isolated, the combination of factors limits the versatility of primary RGCs for 
in vitro investigations. 
Characterization of neurite extension capacity provides further support for the similarities 
between XFC-3 cells and primary RGCs. Stimuli such as BDNF [143-146], CNTF  [143, 147], 
and Y-27632 [147] have shown in various studies for their ability to promote neurite extension in 
RGCs. In this paper, we have shown that XFC-3 cells also exhibit neurite extension in response to 
the same stimuli, thus demonstrated neurite response similarities to RGCs. 
The development of XFC-3 cells has the potential to enhance the cellular aspects of the 3D 
co-culture model as XFC-3 cells express key RGC biomarkers and neurite extension ability in 
response to BDNF. The resultant A7/XFC-3 co-culture demonstrated feasibility for assessing 
BDNF bioactivity as 2.3 times more neurites longer than 50 µm were detected in XFC-3 cells in 
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trA7/XFC-3-rki compared to XFC-3 cells in A7/XFC-3-rki condition. Y-27632-pretreated XFC-3 
cells exhibited enhanced sensitivity to BDNF, which could be explained by the role of rho-kinase 
inhibitors where factors that limit neurite extension were suppressed as a result [148].  
In addition to utilization of XFC-3 cells as BDNF-responsive cells, XFC-3 cells were also 
investigated as BDNF-producing cells in the 3D co-culture system. The results showed that XFC-
3 cells in either XFC-3/XFC-3-rki or XFC-3/XFC-3 conditions did not result in overall higher or 
longer neurite distribution profile compared to the controls. This observation may perhaps be 
attributed to the level of bioavailability of BDNF secreted from trXFC-3 cells, and this will require 
further characterization.  
A number of RGC biomarkers have been used for identification and characterization of 
RGCs, such as Thy-1 (CD90) [149], Rbpms [150], ISL-1 [151], Nef-H, Map-2, Brn3b [152], γ-
synuclein (Sncg) [153], and -tubulin-III (Tubb3) [154]. However, the proportion of RGCs that 
expresses Sncg+ or Brn3+ can vary [155]. Moreover, Sncg was shown to be downregulated with 
decreased retrograded transport of fluorogold from the superior colliculus to RGCs as a result of 
retrograded transport obstruction [156]. Thy-1 is a surface glycoprotein that was identified as a 
key biomarker of RGCs [149]. However, it was suggested that this biomarker was also expressed 
amongst other retinal cell types [157, 158]. Furthermore, the Thy-1 marker was found to be 
expressed dynamically as its expression was downregulated after optic nerve crush-induced IOP 
elevation [159, 160]. Collectively, these findings suggested that the expression of biomarkers is 
dynamic and complex, and these considerations need to be considered in the characterization of 
RGCs since it is arguable that a RGCs could be lacking a particular RGC biomarker (i.e. Thy-1) 
but possess an RGC identity depending on the cellular state and condition. Beyond the dynamic 
expression of biomarkers, further considerations in RGC characterization are required. For 
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example, is the presence of a single molecular biomarker sufficient for identification of RGCs? 
Given the number of different RGC biomarkers described in the literature, is one biomarker more 
representative or important than the other biomarkers? Another aspect of biomarker expression is 
whether there should be a defined level of threshold for a biomarker to be considered “positive” 
expression.  
The misidentification of RGC-5 cell line was a major setback in RGC-related biomedical 
research [118, 119]. With more than 200 publications generated using the cell line in the time 
between the original discovery [161] and the realization of the misidentification, the urgent need 
for an RGC cell model is apparent in the field. The stem cell-derived XFC-3 cells described in this 
paper serve as a promising cell model to bridge the gap in the field of RGC-related therapeutic 
discovery.   
4.6 Conclusion  
The lack of representative RGC models to facilitate effective and efficient in vitro screening 
remains an important obstacle that needs to be addressed. In this paper, we described the 
development of an RGC cell model, XFC-3, that expresses key RGC biomarkers and neurite 
extension capacity. Furthermore, we have demonstrated its application using the previously 
described co-culture model suitable for bioactivity and bioavailability assays of NFs. Overall, 
XFC-3 cells hold great promise as a useful model for preclinical screening and therapeutic 
discovery applications. 
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Chapter 5 Development of retinal multipotent stem cell-derived 
“MiEye” 3D retinal neurosphere model 
 
Majority of this chapter are reflective of an original manuscript published in the journal Precision 
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5.1 Rationale and objective 
In a non-viral approach of delivering therapeutic nucleic acids for glaucoma management, a 
significant challenge lies in efficiently delivering genes into target retinal cells. Majority of non-
viral gene delivery systems that have shown highly effective gene transfer capacity in 2D 
monolayer transfection have failed to translate to comparable levels of gene delivery efficiency in 
vivo. The gap, in part, is a consequence of the lack of correlation of the results generated from 
current standards of TE screening to in vivo feasibility. Recognizing such deficiency, a “mini-
retina” neurosphere model composed of major retinal cell types arranged in a three-dimensional 
tissue-like architecture aimed to bridge in vitro-in vivo gap was developed. The MiEye retinal 
neurospheres aim to serve as a retinal model for the rapid screening of transfection capacity of NP 
systems to retinal cells, towards the generation of in vitro results with higher in vivo translatability. 
5.2 Background 
Glaucoma is a neurodegenerative disease of the retina characterized by multifactorial 
pathophysiology that ultimately results in the loss of retinal ganglion cells (RGCs) [65].  A gene 
therapy approach such as NF gene therapy has the potential to provide extrinsic neurotrophic 
support that can rescue and protect glaucomatous stressed RGCs [162, 163]. Non-viral approaches 
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to deliver therapeutic genes to the retinal cells to carry out therapeutic action for stressed RGCs 
provides many advantages compared to viral approaches such as lower risk of immunogenicity 
and mutagenesis, as well as better patient compliance and large-scale manufacturing feasibility 
[104]. Despite the large number of NP systems that have demonstrated high levels of TE in vitro, 
very few demonstrated effectiveness in vivo. An aspect of this is disconnect between in vitro and 
in vivo TE screening, suggesting that current standards of in vitro models do not sufficiently predict 
in vivo performance and feasibility of NPs. The current standards of in vitro NP gene delivery 
evaluation rely on the assessment of TE in cells cultured in 2D monolayers, which include two 
major pitfalls in cellular modeling from a gene delivery perspective: 1) a lack of multicellular 
tissue spatial architecture; and 2) suboptimal representation of NP biodistribution and kinetics. 
In retinal degenerative diseases such as glaucoma, cell-cell interactions play an important 
role in the pathogenesis through various mechanical and molecular factors near the trabecular 
meshwork and optic nerve head [164-167]. Thus, tissue models such as organotypic explant 
cultures could greatly benefit the understanding of glaucoma pathogenesis and facilitate gene 
therapy development using representative models in vivo. Organotypic explants of the retina were 
explored by various groups to study pathogenesis and drug development applications [168-170]. 
However, preparation of retinal explant culture is difficult. While cultivatable for up to two weeks 
ex vivo, retinal explants spontaneously undergo degeneration upon isolation. 3D retinal models 
generated from stem cells can yield various retinal cell types along with cellular arrangements 
similar to the retina [171, 172]. The ability of stem cells to differentiate autonomously and form 
the optic cup structure in 3D culture model was first demonstrated by Eiraku et al. using mouse 
embryonic stem cells [173, 174]. Following that, there have also been various attempts to generate 
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retinal organotypic cultures [175-177]. Maekawa et al. have generated retinal organotypic cultures 
from mouse embryonic stem cells utilizing mouse and human embryonic stem cells [178].  
Another approach in the construction of 3D models was explored using bioprinting 
technologies, in which cells were printed based on the desired cellular arrangement. Lorber et al. 
have demonstrated that RGCs and glial cells of the retina can be printed using 3D printing 
technology while maintaining viability and neurite outgrowth capacity for both cell types [179]. 
More recently, a study conducted by Kador et al. demonstrated that by combining 3D printing with 
radial electrospun scaffolds, they were able to 3D print RGCs onto electrospun surfaces with 
precise distribution and positioning of RGCs as found in the retina [180]. From a spatial 
arrangement standpoint, 3D printing-based techniques theoretically possess a comparative 
advantage as they allow for more control in dictating cellular location on a tissue-like arrangement 
by “printing” specific cells at specific locations. While the spatial arrangement of the cells cultured 
in 3D culture is either dependent on the resultant conformation from self-aggregation or the 
conformation dictated by the scaffold onto which the cells adhere. While these various 
advancements in different tissue modeling approaches are pivotal in developing in vivo-like 
models for many biological and physiological studies, a relatively simpler 3D model is needed for 
rapid and more predictive screening of non-viral gene delivery systems. 
The mouse multipotent retinal stem cells (CD1-4 RSCs) used in this project have previously 
been described to differentiate into all major retinal cell types in 2D monolayers [121]. In this 
paper, we describe the engineering of 3D spheroids, termed “MiEye” under different culture 
conditions using the CD1-4 RSCs. The RSCs can be seeded into 96-well plates and differentiated 
into multiple retinal cell types while forming spheroids providing an easily scalable model for 
retinal gene delivery assessment.  
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5.3 Materials and methods 
5.3.1 CD1-4 RSC culture 
CD1-4 RSCs isolated from 4-8 weeks old CD-1 mouse were kindly gifted by Dr. Ting Xie, 
Stower Institute for Medical Research and University of Kansas. The purified CD1-4 RSCs were 
cultured in 12-well plates coated with 0.2% gelatin for 3 hours at 37°C and maintained in RSCCM 
media. Culturing medium for CD1-4 (RSCCM) was composed of advanced DMEM/F12 (Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA) media with addition of 1.0 g/L glucose (Sigma-
Aldrich, St. Louis, MO, USA), 1.0 g/L lactose (Sigma-Aldrich), 1.0 g/L BSA (Sigma-Aldrich), 
0.045 g/L proline (Sigma-Aldrich), 2 mM nicotinamide (Sigma-Aldrich), 2 mM L-glutamate 
(Gibco), 1% penicillin/streptomycin (Hyclone), 1% insulin-transferrin-supplement (Gibco), 5% 
knockout serum replacement (Gibco), 20 ng/mL EGF (Gibco), and 20 ng/mL bFGF protein 
(Gibco). Differentiation medium (RSCDM-1) was composed of advanced DMEM/F12 (Gibco) 
with 2% B-27 supplement (Gibco), 1% L-Glutamine (Gibco) and 10 ng/mL bFGF protein (Gibco). 
RSCDM-1 containing 1% N-2 supplement (Gibco) was named RSCDM-2. Maturation medium 
was formulated with 2 mM L-Glutamine (Gibco), 2% B-27 supplement (Gibco), 1% N-2 
supplement (Gibco), 10 ng/mL bFGF protein (Gibco), and 100 ng/mL BDNF protein (Peprotech), 
10 ng/mL glial-derived neurotrophic factor protein (Gibco), and 10 ng/mL insulin growth factor 
protein (Gibco) in advanced DMEM/F12, with (RGCMM-3) or without (RGCMM-4), 2% fetal 
bovine serum (Thermo Fisher Scientific). 
CD1-4 RSCs were cultured on 0.2% gelatin (Sigma-Aldrich) coated 12-well tissue-culture 
treated plate for 3 hours at 37 °C. For maturation of retinal neurospheres, culture surfaces were 
coated with either Matrigel™ (Corning Incorporated, Corning, NY, USA), or combination of poly-
L-ornithine (PLO) (EMD Millipore, Billerica, MA, USA) and laminin (EMD Millipore). For PLO-
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laminin coating, 0.015 mg/mL of PLO were prepared in sterile water and applied on to the glass-
bottom surface of multi-well plates overnight at room temperature. PLO was removed, and laminin 
was coated at a concentration of 2 µg/cm2 overnight at 4 °C. For Matrigel™ coating, 7.6 mg/mL of 
Matrigel™ (Corning) was coated on the culture surface at 100 µL/cm2 volume, and allowed for gel 
formation for an hour at 37°C. 
5.3.2 Generation of MiEye retinal neurospheres 
 The retinal neurospheres model was established through differentiation of CD1-4 RSCs in 
commercially available force-floating three-dimensional 96-well ultra-low adhesive (ULA) 
microplates (Corning). For differentiation of CD1-4 RSCs, 15,000 cells (best seeding density 
compared to 5,000 and 10,000 cells/well) were seeded into each well of the ULA microplate, and 
differentiation was carried out using various protocols consisting of different combinations of 
media, schedules, or surface coating, resulting in the generation of 11 different retinal neurosphere 
types termed MiEye (1-11) with 2-4 spheres for each. MiEye 1-4 were 24-day differentiated retinal 
neurospheres, first initiated through differentiation in RSCDM-1 media for 3 days, which was then 
switched into RSCDM-2 media for 7 more days. Following 10 days of differentiation, spheres 
were transferred onto either PLO-Laminin- or Matrigel™-coated surface for maturation using 
either RGCMM-3 or RGCMM-4 media. MiEye5 was an 18-day differentiated retinal neurosphere, 
first initiated through differentiation in RSCDM-1 media for the first 4 days, followed by 
differentiation in RSCDM-2 for 14 more days. MiEye7 retinal neurosphere was generated by 
further maturating the 18-day differentiated spheres on PLO-Laminin-coated surface for 3 days in 
RGCMM-4. MiEye8 retinal neurospheres were 6-day differentiated spheres, which were initiated 
by differentiating in RSCDM-1 for 2 days. After 2 days of differentiation, the differentiated 
78 
spheres were changed to RSCDM-2 media for 4 more days. MiEye10 was generated by subjecting 
MiEye8 to further maturation on PLO-Laminin for 4 days in RGCMM-4 media. 
5.3.3 NanoString Analysis 
RNA was isolated using a commercially available silica column-based RNA isolation kit, 
PicoPure® RNA Isolation Kit (Arcturus, Thermo Fisher Scientific, Waltham, MA, USA), based 
on the manufacturer’s suggested protocol. Isolated RNA was subjected to gene expression 
profiling for retinal cell biomarkers using the NanoString nCounter Analysis system, a highly 
sensitive and reproducible multiplexed mRNA gene expression quantitation method (NanoString, 
Seattle, Washington, USA). The technology enables direct hybridization of mRNA to its sequence-
specific target reporter and capture probe, which allows for the quantitation of mRNA copy 
number for multiple (up to 800) mRNA sequences simultaneously with high sensitivity for the 
generation of a gene expression profile. Retinal biomarker gene expression analysis was performed 
using a custom code set containing 25 target genes representative of most retinal cell types and 
housekeeping genes as controls. The panel of target genes includes biomarkers representing major 
retinal cell types. ISL-1, Map-2, Nef-H, Pou4f1, Rbpms, Sncg, Thy-1.2, and Tubb3 are 
representative RGC biomarkers; Aqp4, Prdx6 and Slcla3 are representative astrocyte biomarkers; 
Abca8a, ald1a1, and Vim are representative Müller glia biomarkers; and Nrl and Rom1 are 
representative photoreceptor biomarkers. Rpe65, Calb2, Prkca, and Lim2 each individually 
represent RPE, amacrine, bipolar and horizontal cell biomarkers, respectively.  Each reaction was 
analyzed with 100 ng of RNA in a 5µL loading volume, mixed with capture probe and reporter 
probe. The gene profiling experiment was carried out at the Princess Margaret Genomics Centre 
(Toronto, Ontario, Canada). 
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5.3.4 Preparation of K2-NPs  
 K2-NPs were formulated by complexing the K2® lipopolyamine-based proprietary 
transfection reagent (Biontex Laboratories GmBH, München, Germany) with gWiz™ GFP plasmid 
(Aldevron, Fargo, ND, USA) at various ratios for 30 minutes prior to transfection. K2-DNA v/w 
ratios from 1:1 to 10:1, DNA dose ranged from 1 to 10g were formulated and evaluated for TE 
on the retinal neurospheres. Transfection was carried out by first adding 25µL of K2® Multiplier 
into each well for 2 hours. After 2 hours, complexed K2-NPs were added into wells. Nine different 
K2-NPs formulations (F1-F9) composed of various combinations of K2® transfection reagent and 
DNA concentrations were prepared for transfection evaluation (Table 5.1). 
 
Table 5.1 K2-NPs formulated for transfection in MiEye8 retinal neurosphere model 
Formulation K2:DNA ratio  
(µL: µg) 




 reagent (µL) DNA (µg) 
F1 1:1 1:1 1 1 
F2 2:1 2:1 2 1 
F3 4:1 4:1 4 1 
F4 10:1 10:1 10 1 
F5 20:2.5 8:1 20 2.5 
F6 30:5 6:1 30 5 
F7 10:2 5:1 10 2 
F8 20:5 4:1 20 5 
F9 30:10 3:1 30 10 
 
 
5.3.5 Confocal laser scanning microscopy  
 Retinal neurospheres were counterstained with either 5µM Syto™ 62 nuclear stain (Thermo 
Fisher Scientific, Waltham, MA, USA) or 5µM DRAQ5™ nuclear stain (Thermo Fisher Scientific) 
for 30 minutes at 37°C prior to imaging. Neurospheres were imaged using a Zeiss LSM710 
confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Baden-Wü, Germany) with 20x 
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objective. Three-dimensional images of the spheres were captured using the Z-stack functionality 
in the Zen 2009 software, each constituting 20 optical slices of images through the observable 
thickness of the retinal neurospheres. Transfection was measured by the detection of GFP 
expression in the retinal neurospheres. Combined mean fluorescence intensity (cMFI) of the retinal 
neurospheres were obtained by calculating the average of all individual MFI of optical sections of 
the neurospheres captured using z-stack. The cMFI of transfected neurospheres was normalized to 
the MFI of the untreated control neurosphere (background fluorescence). Co-localization between 
GFP expression and nuclei staining were also assessed using Mander’s Overlap Coefficient 
(MOC) for each optical slice.  
5.4 Results 
5.4.1 Generation and characterization of MiEye retinal neurospheres 
The initial studies showed that undifferentiated CD1-4 RSCs themselves were able to form 
stem cell spheres in 3D culture conditions when seeded at cell densities of 5,000, 10,000 and 
15,000 cells in ULA spheroid plates. Spheroids were formed within 24 hours and their morphology 
was maintained for at least 12 days (Figure 5.1).  
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Figure 5.1 Undifferentiated RSC derived retinal neurosphere cultured in ultra-low adhesive spheroid plate at day 3 
and 12. Images were captured with 10x objective using light microscopy 
  
 Using a similar approach, retinal neurospheres were initiated by seeding CD1-4 RSCs 
suspended in differentiation medium in ULA plates. Eleven different MiEye retinal neurospheres 
were prepared using various protocols. A representative workflow of differentiation and 
maturation is illustrated in Figure 5.2A-B. After culturing of the RSCs for 6-10 days, the formed 
differentiated neurospheres were allowed to mature on the coated surface (i.e. PLO-Laminin) to 
evaluate the possibility of inducing the formation of morphological features such as neurite 
extensions. The effect of various combinations of parameters such as retinal neurosphere 
population (5,000, 10,000, and 15,000 cells per sphere), maturation medium (serum / no serum), 
and surface coating (PLO-Laminin/Matrigel™) were evaluated on the structural integrity of the 
spheres. First, a decrease in seeding cell density from 15,000 cells to 5,000 cells resulted in a 
decrease in retinal neurosphere structural stability after 2 days of maturation (Figure 5.3A). 
Furthermore, the decreased structural stability was more obvious in the presence of Matrigel™ 
coating and serum. A decrease in structural stability was evident from size reduction and 
deformation of the spheres, along with increased monolayer cell attachment on the coated surface 
surrounding the sphere. Retinal neurospheres were least structurally stable when maturation was 
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taking place in serum containing maturation media, coupled with Matrigel™-coated surface, where 
retinal neurospheres were completely deformed by day 6 (Figure 5.3B). Seeding density played an 
important role in the sphere structural stability as retinal neurospheres constructed with only 5,000 
cells exhibited complete structural deformation across all culturing conditions by day 6. The retinal 
neurospheres made with 10,000 cells matured in serum-containing medium on either PLO-
Laminin or Matrigel™-coated surface also showed significant deformation. However, retinal 
neurospheres matured in medium without serum on either PLO-Laminin- or Matrigel™-coated 
surface showed greater structural stability. The retinal neurospheres made with 15,000 cells 
maintained the highest structural integrity after 6 days of maturation on various coated surface and 
media. 
Matrigel™- and PLO-Laminin-coated surfaces produced significantly different effect on 
retinal neurosphere integrity profile over 6 days. Maturation on Matrigel™ resulted in four out of 
six retinal neurospheres showing significant structural stability decline with significant 
deformation and size reduction after 2 days. By day 6, five out of six maturation conditions resulted 
in near-complete deformation of retinal neurospheres. On the other hand, PLO-Laminin-coated 
surfaces support retinal neurosphere structural stabilization with all six retinal neurosphere 




















Figure 5.2 Representative differentiation and maturation process of RSCs towards the generation of differentiated 
retinal neurosphere on Matrigel™- (A) and PLO-Laminin-coated surface (B). Images were captured with 10x objective 








Figure 5.3 Effect of neurosphere size on the maintenance of structural integrity during the maturation process on 
PLO-Laminin- and Matrigel™-coated surfaces, with or without serum for 2 days (A) and 6 days (B). Images were 
captured with 10x objective using light microscopy 
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Furthermore, four of the six maturation conditions showed minimal structural de-
stabilization after 6 days. As it was determined that retinal neurospheres with 15,000 cells were 
able to provide the highest morphological integrity, downstream experimentations and evaluations 
were carried out using 15,000 cell seeding density, and eight MiEye retinal neurospheres (MiEye1, 
MiEye2, MiEye3, MiEye4, MiEye5, MiEye7, MiEye8, MiEye10) were considered viable from the 
various combinations of differentiation and maturation conditions (Table 5.2).  
 
Table 5.2 Overview of MiEye retinal neurosphere differentiation and maturation parameters 
Name Description 
Differentiation Maturation 























































































Based on biomarker mRNA gene expression profiling, retinal neurospheres MiEye1, 
MiEye2, MiEye3 and MiEye4, positively expressed multiple biomarkers that represent seven 
different retinal cell types (Table 5.3). Several target genes were expressed across the four retinal 
neurospheres such as Rbpms, Slc1a31, Aldh1a1, Vim, Rom, and Prkca. Selective biomarker such 
as Tubb3 was also positively expressed in MiEye 1 (Figure 5.4A) and MiEye3 (Figure 5.4C), but 
not in MiEye2 (Figure 5.4B) and MiEye4 (Figure 5.4D).  Abca8a was positively expressed in 
MiEye1, MiEye3 and MiEye4, but not in MiEye2. Rpe65 and Prdx6, were detected to be expressed 
at low levels but did not meet the 20 copies thresholds in MiEye1, MiEye2, MiEye3, MiEye4, 
respectively. All four retinal neurospheres positively expressed eight different markers including 
Rbpms, Tubb3. Based on the gene expression profile results, these four differentiated populations 
expressed the markers for most of the retinal cell types such as RGC, astrocyte, Müller glia, 
photoreceptor, RPE, amacrine and bipolar cells, suggesting the possibility that the retinal 
neurospheres contained all these major retinal cell types.  
MiEye5 (Figure 5.4E) was an 18-day differentiated retinal neurosphere, and MiEye7 
(Figure 5.4F) was differentiated with the 18-day differentiation protocol with an additional 3-day 
protocol on PLO-Laminin surface. Both retinal neurospheres showed very different expression 
profiles. MiEye5 positively expressed six gene targets with differential mRNA copies of Rbpms, 
Slc1a3, Abca8a, Aldh1al, Vim and Prkca. On the other hand, MiEye7 positively expressed only 
four gene targets, Rbpms, Slc1a3, Vim, and Prkca, with relatively lower copy numbers. 
MiEye8 (Figure 5.4G) was a 6-day differentiated retinal neurosphere, and MiEye10 (Figure 
5.4H) was generated from the same 6-day differentiation protocol with an additional 4 days of 
maturation process on PLO-Laminin surface. MiEye8 positively expressed six target genes Rbpms, 
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Slc1a3, Abca8a, Aldh1a1, Vim, and Prkca. On the other hand, MiEye10 positively expressed only 
three target genes, Rbpms, Slc1a3, and Vim, at relatively lower expression levels. 
 
Table 5.3 Retinal biomarker mRNA expression profile summary for MiEye retinal neurospheres. Heat map 
categorizes gene expression into three major categories: no expression (n<5; blue), semi-positive expression (5<n<20; 








MiEye1 MiEye2 MiEye3 MiEye4 MiEye5 MiEye7 MiEye8 MiEye10 
RGC CD48 5 7 2 1 3 2 4 5 2 
  ISL-1 6 3 8 1 9 5 3 7 2 
  MAP2 2 4 1 2 8 0 0 0 0 
  Nef-H 0 1 0 3 1 1 0 4 1 
  Pou4f1 2 2 5 2 1 0 2 7 2 
  Rbpms 527 675 620 606 855 362 120 601 120 
  Sncg 3 0 2 3 5 2 0 2 1 
  Thy-1.2 2 3 0 1 0 1 0 1 0 
  Tubb3 40 25 17 61 10 1 3 4 4 
Astrocyte Aqp4 1 1 0 3 2 3 2 1 2 
  Prdx6 4 9 12 11 10 7 1 11 3 
  Slc1a3 272 925 762 734 724 162 24 268 54 
Müller Abca8a 7 36 15 41 34 28 1 31 4 
  aldh1a1 31 204 166 157 200 44 9 40 12 
  Vim 16544 14115 16081 16150 18974 3865 2583 3860 1519 
Photoreceptor Nrl 1 0 2 1 3 0 0 0 0 
  Rom1 30 23 25 29 33 13 2 17 4 
RPE Rpe65 9 8 5 10 11 14 10 3 9 
Amacrine Calb2 5 5 5 3 5 5 3 1 3 
Bipolar Prkca 104 140 152 120 151 32 32 53 14 





Figure 5.4 Retinal biomarker mRNA gene expression profiles of retinal neurospheres MiEye1 (A), MiEye2 (B), 
MiEye3 (C), MiEye4 (D), MiEye5 (E), MiEye7 (F), MiEye8 (G), and MiEye10 (H). Threshold indicator (dotted lines) 
at n=20 is indicative of the threshold for positive expression 
 
Amongst the retinal neurospheres generated, MiEye8 retinal neurosphere was chosen as a 
model retinal neurosphere to demonstrate the proof of concept for transfection studies as it showed 
similarities in differentiated retinal cell type compositions compared to the 6-day differentiated 


















































































































































































































































































































































































































































































































































































































































































































































biomarker expression profile perspective, both 6-day differentiated CD1-4 cells in monolayer and 
6-day differentiated CD1-4 in 3D (MiEye8) showed they consists of multiple target cell types such 
as astrocyte, Müller glial, RGC, and bipolar cells as they both expresses retinal target genes Rbpms, 
Slc1a3, aldh1a1, Vim, and Prkca at similar levels (Figure 5.5). Tubb3, Rom1, genes, Abca8a 
biomarkers were expressed at different levels between 2D and neurosphere, with 10-fold, 1.8-fold, 
and 4.4-fold differences, respectively. 
 
Figure 5.5 Comparative mRNA gene expression profile analysis of 6-day differentiated CD1-4 stem cells in 
monolayers and MiEye8 retinal neurospheres 
5.4.2 Transfection screening of K2-NP non-viral gene delivery systems in MiEye retinal 
neurospheres 
Transfection of MiEye8 retinal neurospheres was carried out using K2-NPs, a non-viral 
gene delivery system shown to have high TE in astrocytes and RGCs cultured in monolayer in our 
previous studies [122]. Nine formulations of K2-NPs were prepared and screened in the MiEye8 
retinal neurospheres. Amongst the different treatments, neurospheres transfected with F3 (4:1 v/w 
















































































































as demonstrated by confocal microscopic observations of GFP expression (Table 5.4). 
Transfection was further assessed by quantitative evaluation of MFI captured in the GFP channel 
throughout the thickness of retinal neurospheres. 
 
Table 5.4 Transfection screening of a panel of K2-NP formulations in MiEye8 retinal neurosphere, CD1-4 derived 
RGC monolayer and A7 astrocyte monolayer 
 
Retinal Cell Models 
MiEye8 Retinal Neurosphere 
CD1-4 derived RGC  
monolayer (Chapter 4) 
















F1 - + n/a n/a - n/a 
F2 - + 63.1±1.4% 94.4±0.4 15.8±2.6% 76.2±1.7 
F3 36.0±55.7 + 62.9±1.9% 79.7±3.3 31.3±1.5% 44.8±2.2 
F4 91.9±30.5 ++ n/a n/a n/a n/a 
F5 - ++ n/a n/a n/a n/a 
F6 - ++ n/a n/a n/a n/a 
F7 - +++ n/a n/a n/a n/a 
F8 - +++ n/a n/a n/a n/a 
F9 - +++ n/a n/a n/a n/a 
Transfection efficiency evaluations: 
* combined (c)MFI = average of the individual MFI of all optical sections of the neurospheres (n=9-12; number of 
sections vary depending on the exact size of each sphere) 
** data from flow cytometry measurements (mean ± s.d.; n=3) - no transfection 
Observed toxicity evaluations: 
+ low toxicity level with minimal debri 
++ medium toxicity level with some debri near neurosphere 





In untreated retinal neurospheres, all cells remained intact and no detached cells or cell 
aggregates were found outside of the neurospheres. Following treatment with K2-NPs using 
increasing concentrations of K2® reagent, increasing number of detached cells and cell debris were 
present around neurospheres, which we have interpreted as increasing levels of toxicity (Table 
5.4).  
In the MiEye8 retinal neurosphere transfected with F3, localized gene expression was 
observed in the superficial layers of the neurosphere (Figure 5.6A). This was also evident through 
analysis of z-stack optical slices (Figure 5.6B), where GFP expression was visible between optical 
slices 4 to 9. The MFI profile for specific regions of interest, as shown in Figure 5.6C-D, illustrates 
presence of GFP-expressing cells. Quantitative analysis of optical slices 4-9 indicated that the 
cMFI of F3-transfected neurosphere were up to 7-fold higher compared to the control neurosphere 
(Figure 5.6E). The cMFI throughout the thickness of the F3-transfected neurosphere was 
36.0±55.7. 
Retinal neurospheres transfected with F4 (10:1 v/w K2:DNA ratio) showed a widely 
scattered GFP expression pattern on the surface of the retinal neurosphere (Figure 5.7A). Analysis 
of z-stack optical slices show that GFP expressions was observed scattered across the sphere in 
optical slices 4 to 11 (Figure 5.7B). MFI analysis showed that the neurosphere transfected with F4 
consistently have higher MFI (up to 1.71-fold) compared to untreated control. The cMFI 
throughout the thickness of the neurosphere was 91.9±30.5. Similarly, MFI profiling in a selected 





Figure 5.6 Z-stack analysis of MiEye8 retinal neurosphere at 120 hours post treatment with F3 K2-NP (4µL:1µg). 
MiEye8 retinal neurosphere was counterstained with 5M of DRAQ5™ nuclei stain (red). Successful transfection is 
indicated by GFP expression (green). A) 3D reconstruction of the MiEye8 retinal neurosphere demonstrating GFP 
expression in the neurosphere surface layer. B) 20 z-stack optical slices captured across the observable thickness of 
the retinal neurosphere showing visible GFP expression in slices 4 to 9. C) Representative illustration MFI analysis 
on GFP and nuclei stain channels through a region of interest (red arrow) on an optical section (slice 6) of the 
neurosphere. Blunt end of the arrow marks the start of the path (0 µm) and the tip of the arrow marks the end of the 
path (111 µm). The corresponding GFP (green) and nuclei stain (red) channel MFI through the path of interest is 






Figure 5.7 Z-stack analysis of MiEye8 retinal neurosphere at 120 hours post treatment with F4 K2-NP (10µL:1µg). 
MiEye8 retinal neurosphere was counterstained with 5M of Syto™62 nuclei stain (red). Successful transfection is 
indicated by GFP expression (green). A) 3D reconstruction of the MiEye8 retinal neurosphere demonstrating GFP 
expression on neurosphere surface. B) 20 z-stack optical slices captured across the observable thickness of the retinal 
neurosphere showing visible GFP expression in slices 4 to 9. C) Representative illustration MFI analysis on GFP and 
nuclei stain channels through the region of interest (red arrow) on an optical section (slice 7) of neurosphere. Blunt 
end of the arrow marks the start of the path (0 µm) and the tip of the arrow marks the end of the path (96 µm). The 
corresponding GFP (green) and nuclei stain (red) channel MFI through the path of interest is shown in (D). E) 





Eight retinal neurospheres with distinct retinal gene expression profiles were generated 
using various differentiation procedures. Through gene expression profiling, it was evident that 
CD1-4 RSCs were able to differentiate in 3D culture, generating retinal neurospheres composed 
of various retinal cell types including RGCs, astrocytes, Müller glial and photoreceptor cells, 
depending on the differentiation procedure. Of particular interest, the 6-day differentiated CD1-4 
RSCs in either 2D or 3D showed similar diversity of cells through gene expression profiles as both 
expresses key biomarkers for astrocytes, Müller glial, astrocyte, and bipolar cells at similar levels. 
The presence of mixed cell types in retinal neurosphere cultures may allow for versatile 
downstream gene delivery system assessment options such as transfection, infiltration, and 
targeting efficiencies. Using the MiEye8, a 6-day differentiated retinal neurosphere expressing 
markers of RGC, astrocyte, Müller glial, photoreceptor and bipolar cells, K2-NPs with various 
compositions were screened. The K2-NP system was a highly effective gene delivery reagent in 
2D monolayers as demonstrated in our previous work, where K2-NP formulation with K2:DNA 
ratio of 4:1 at 1 g pDNA per dose showed 60% TE in monolayer XFC retinal ganglion cells 
(Table 5.4) [122]. In MiEye8, K2-NPs with the same K2:DNA ratios of 4:1 at 1 g pDNA per 
dose (F3) showed lower TE and the transfection was localized to the surface cellular layers of the 
neurosphere. K2-NP formulation (F4) with K2:DNA ratios of 10:1 at 1 g pDNA per dose also 
showed lower transfection compared to cells in monolayers, but with a more uniformly scattered 
pattern across the surface of the neurosphere. In both cases, transfected cells were localized on the 
surface of the sphere with very limited signs of gene expression in the interior of the spheres. 
Increasing the K2:DNA ratio and DNA per dose did not improve the TE, however, toxicity 
increased. More specifically, higher concentrations of K2® transfection reagent resulted in higher 
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toxicity, as observed by the increasing amounts of cellular debris around the spheres. Differences 
in NP toxicity profile was also observed between 3D neurosphere and 2D cell monolayers as 
neurospheres appears to have higher resistance to NP toxicity compared to cells cultured in 2D 
monolayers. For example, in the case of F3 K2-NP transfection, CD1-4 derived RGCs and A7 
cells culture in 2D monolayer were more susceptible to toxicity compared to MiEye8 neurosphere.  
Assessment of the gene delivery capacity of NPs through evaluation of the cMFI of 
neurospheres is an alternative approach to flow cytometry of individual cells from 2D cultures as 
it measures the relative level of a reporter protein that is produced by transfected cells. Utilizing 
fluorescence intensity and cMFI as a means of evaluating neurospheres in this paper has allowed 
the characterization of transfection by K2-NPs. Such evaluation of TE analysis could also be 
applied in other forms of tissue-like cultures and in vivo to approximate TE, where dissociation of 
tissue structure into individual cells for single-cell transfection analysis is inefficient and 
challenging.  
As expected, TE of cells in 3D were significantly lower (~2~4%) compared to cell 2D 
monolayer (15-63%) in cells transfected with the same NP system, which could be attributed to 
several factors. One of the major differences in a 3D culture-based assay is the architectural and 
spatial properties. From a cell-nano exposure perspective, traditional 2D monolayer culture allows 
for higher cell-nano exposure, where cell populations are distributed across the culture surface and 
can be exposed to NPs more uniformly. In 3D culture, on the other hand, lower cell-nano exposure 
can be attributed to the tissue-like cellular arrangement, where the outermost cell layers have the 
highest cell-nano contact with gradual decrease with increasing depth towards the center of the 
sphere. Aside from architectural and spatial factors, cell proliferation factors could also influence 
transfection. Majority of the commonly used cell lines for in vitro studies were immortalized cell 
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lines that proliferate at a high rate in cell culture, while primary cells and cells found in vivo either 
do not proliferate or typically proliferate at a much lower rate. Various studies over the years have 
shown that cell cycle plays a role in gene delivery, particularly for non-viral based NPs that lack 
the efficient transduction machinery unlike viruses [181]. Moreover, the difficult part of 
transfection is not necessarily cellular entry, but rather translocation of pDNA to the nucleus [181]. 
Delivery of pDNA before mitosis was suggested to increase the level of transgene expression [182, 
183], and was suggested that transfection during cell division results in significantly higher level 
of expression in part due to nuclear envelope split, thus assisting pDNA in nuclear entry [184]. As 
cells in MiEye8 constitute tissue-like multicellular arrangement coupled with limited proliferation 
capacity compared to immortalized cell lines that divide indefinitely, it therefore captures key 
characteristics of cells in vivo, in an in vitro modality. Altogether, the combinations of various in 
vivo relevant structural and cellular properties, retinal neurospheres such as MiEye8 have the 
potential to serve as a tool for predicting in vivo performance of NPs. It is recognized that a 3D 
retinal model that consists of a complete representation of the retinal cell type diversity, 
arrangements, and functions of the retina could be an important tool for the understanding of retinal 
biology and retinal therapeutic discovery. The significance of the MiEye retinal model described 
in this paper is two-fold: 1) the model is an important first step towards the generation of a 
complete retina model; and 2) the model demonstrates the potential towards the generation of a 





In summary, in this paper the development of a 3D retinal neurosphere model was 
demonstrated. Among neurospheres grown in eleven different culture conditions, a 6-day 
differentiated neurosphere, MiEye8, have shown value as a “mini-retina”-like model that contains 
the major retinal cell types and can be used towards a more in vivo-relevant screening of non-viral 
gene delivery systems.  
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Chapter 6 Gemini surfactant NP system physicochemical property 
optimization 
6.1 Rationale and objective 
Previous work utilized regular plasmid (RP) as the vector to encode therapeutic protein 
sequences and for GL-NP systems construction. However, MC offers significant advantages such 
as longer transgene expression and lower risk of inflammatory response resulting from the absence 
of bacterial sequences normally found in RP vector backbone. In this study, the effect of pDNA 
construct size has on the physicochemical properties of NPs was investigated using RP and MC 
pDNA. Furthermore, optimization of NP physicochemical properties was also explored through 
incorporation of sonication and TNPC in the manufacturing process. 
6.2 Background 
A pDNA vector consists of two major components: a vector backbone and a transgene 
expression cassette. In a traditional RP, significant portion of the vector backbone are encoded 
with bacterial sequences and antibiotic resistance gene(s) used in the production and selection of 
pDNA in prokaryotic manufacturing system, but such sequences are non-essential and undesirable 
in mammalian cells. The presence of bacterial sequences such as CpG in pDNA was shown to 
contribute to inflammatory immune responses, whereas CpG-free pDNA was shown to have 
significantly reduced inflammatory risks [185]. Furthermore, bacterial sequences have also been 
shown to shorten the duration of gene expression in mammalian cells as a consequence of 
transcription silencing associated with histone modification mechanisms [186]. MC is a novel type 
of pDNA construct that is free of non-essential bacterial sequences in the vector backbone, which 
can effectively reduce construct size while maintaining the target sequence expression capacity 
[187]. Studies have shown that MC have a significant role in pDNA gene therapy as it results in 
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longer and persistent transgene expression in various gene transfer studies [188-191]. Elevated 
levels of transgene expressions resulted from MC compared to RP have been suggested due to 
improved active chromatin and transcription activity compared to RP [192]. In this chapter, the 
main objective was to evaluate whether MC can also improve the physicochemical properties of 
NP systems formulated with MC. In addition, whether the incorporation of sonication and TNPC 
in the manufacturing process can further improve the physicochemical properties of NP systems.  
6.3 Materials and methods 
6.3.1 RP and MC pDNA constructs production 
Different nucleic acid constructs were used as model RPs such as pEF1-BDNF-IRES-GFP, 
pEF1-TNFR-IRES-GFP, pCMV-TNFR-IRES-GFP, and gWiz™ GFP. pEF1-BDNF-IRES-GFP, 
pEF1-TNFR-IRES-GFP, and pCMV-TNFR-IRES-GFP constructs were prepared through cloning 
of either BDNF or tumor necrosis factor receptor (TNFR) sequences into MN530A-1 or MN501A 
vector (System Biosciences, Palo Alto, CA, USA), which serve as parent plasmids for MC 
production. A commercially available construct gWiz™ GFP reporter vector was also used as a 
model RP construct (Aldevron, Fargo, ND, USA). MC constructs mcEF1-BDNF-IRES-GFP, 
mcEF1-TNFR-IRES-GFP, and mcCMV-TNFR-IRES-GFP were produced by first transforming 
the respected cloned parent plasmids pEF1-BDNF-IRES-GFP, pEF1-TNFR-IRES-GFP, and 
pCMV-TNFR-IRES-GFP into ZYCY10P352T E.coli. Transformed E.coli were grown until 
desired optical density according to manufacturer’s protocol. Initiation of MC production in the 
transformed E.coli was activated through arabinose-activated endonuclease activity for 5 hours at 
30ºC. MCs were extracted at the end of the arabinose induction period. Plasmid design, 
construction, and scale-up were performed by Dr Nafiseh Nafissi. A commercially available vector 
pUMVC1 reporter plasmid (Aldevron) was used as a model MC in selective studies.  
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6.3.2 Cy®5 labeling of RP and MC  
pDNA used in FCS were labelled using Label IT® Cy®5 nucleic acid labeling kit (Mirus 
Bio LCC, Madison, WI, USA) according to manufacturer’s protocol. Labelled pDNAs were 
purified by ethanol precipitation followed by membrane filtration using Amicon 3kDa centrifugal 
filters (EMD Millipore, Billerica, MA, USA). Labeling density was calculated using the base:dye 






The extinction coefficient of nucleic acid bound dye (ɛdye) for Cy
®5 used is 250,000. The extinction 
coefficient of nucleic acid (ɛbase) for double stranded DNA is 6,600. 
6.3.3 NP preparation 
K2-NP was prepared according to the manufacturer’s protocol. Briefly, K2-NP were 
formulated by complexing one of the RP or MC pDNA with K2® transfection agent (Biontex 
Laboratories GmBH, München, Germany) at ratios of 2 µL of K2® per 1 µg of pDNA. GL-NPs 
were prepared by a two-step formulation process. First, gemini-pDNA (GP) complex was formed 
by combining GS and pDNA at 10:1 charge ratio, and incubated for 15 minutes at room 
temperature, followed by addition of desired ratios of 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE; Avanti Polar Lipids, Alabaster, AL, USA) vesicles, forming the 
final GL-NPs upon incubation of 30 minutes at room temperature. DOPE vesicles were prepared 
by first dissolving 1mM DOPE in 9.25% w/v sucrose solution (pH 9) with brief bath sonication, 
followed by processing of DOPE solution through the LV1 Microfluidizer (Microfluidics Inc., 
Newton, MA, USA) for three-passes.  
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6.3.4 Dynamic light scattering 
Size distribution analysis was performed using Zetasizer Nano ZS (Malvern Instruments, 
United Kingdom). Three separate measurements were taken using 50 µL samples. Size distribution 
was recorded, and the z-average was taken as average size with 10 runs per measurement. Zeta 
potential analysis was performed by a combination method of phase analysis light scattering 
(PALS) and a patented mixed-mode measurement technique (M3) using Zetasizer Nano ZS 
(Malvern Instruments). Each sample was diluted using ultrapure water at a 1:20 (v/v) ratio and 
measured using capillary cell.   
6.3.5 Fluorescent correlation spectroscopy  
 FCS measurements were performed on a Zeiss LSM 710 confocal laser scanning 
microscope with Confocor 3 systems (Carl Zeiss AG). NPs were prepared with Cy®5-labelled 
gWiz™ GFP and pUMVC1 pDNA. Free Cy®5 or Cy®5-labelled pDNA was excited using 633nm 
He-Ne laser and reflected by a dichroic beam splitter (488/633), which is focused 200 µm into the 
sample through Apochromat NA 1.2 water-immersion 40x objective lens. Emission spectra were 
collected through a 580 nm long-pass filter and recorded by an avalanche photodiode detector. 
FCS measurements were performed in 200 µL volumes of GL-NPs in a CELLview 4-well chamber 
with glass-bottom coverslip (Grenier-Bio One, Frickenhausen, DE). All samples were measured 







6.4.1 Effects of pDNA size and particle physicochemical properties: a case study using 
commercial NP system 
 A systematic study to evaluate the effect of pDNA construct lengths on NP properties were 
initially investigated using K2® nanoparticle system formulated with seven different pDNA 
constructs. The constructs fall into three major sizes categories: small (4.4 – 4.7kb), medium (8.4 
– 8.5kb), and large (>14kb) (Table 6.1), where MCs fit into the “small” category, while RPs fits 
into the “medium” category, and a “large” construct with 14kbs was incorporated for comparison. 
Each MC used in this study was derived from its corresponding RP (i.e. pEF1-BDNF-IRES-GFP 
is the RP of mcEF1-BDNF-IRES-GFP). 
 
Table 6.1 Physicochemical properties of K2-NP formulated with seven different plasmid constructs that varies in 
construct size. Values expressed as mean ± s.d., n=3 
Size Category Construct Size (kbp) Z-average (nm) PDI Zeta Potential (mV) 
Small 
mcEF1-BDNF-IRES-GFP 4.7 86.2 ± 0.5 0.19 53.3 ± 0.4 
mcEF1-TNFR-IRES-GFP 4.5 78.6 ± 0.6 0.19 48.5 ± 0.4 
mcCMV-TNFR-IRES-GFP 4.4 83.2 ± 1.8 0.16 52.2 ± 1.8 
Medium 
pEF1-BDNF-IRES-GFP 8.7 102.5 ± 1.0 0.18 52.9 ±0.8 
pEF1-TNFR-IRES-GFP 8.5 109.6 ± 3.2 0.25 45.3 ± 2.9 
pCMV-TNFR-IRES-GFP 8.4 93.9 ± 1.0 0.16 51.6 ± 1.3 
Large phTERT 14.0 122.4 ± 6.4 0.28 53.8 ± 3.2 
 
The results showed a positive correlation between nucleic acid construct size and particle 
size of K2-NPs systems (Figure 6.1). K2-NPs constructed with three different MCs (mcEF1-
BDNF-IRES-GFP, mcEF1-TNFR-IRES-GFP, and mcCMV-TNFR-IRES-GFP) resulted in 
particles with an average size of 82.73.47 nm. In comparison, K2-NP formulated with the three 
corresponding RPs (pEF1-BDNF-IRES-GFP, pEF1-TNFR-IRES-GFP, and pCMV-TNFR-IRES-
GFP) resulted in particles with an average size of 102.07.0 nm. Particles formulated with the 
14kb phTERT construct resulted in particle size of 122.46.4 nm.  
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Figure 6.1 Effect of construct size have on the particle size of K2-NP. Construct size falls in three main size ranges: 
small, medium, and large. Values expressed as mean ± s.d., n=3 
 
Particle size comparison showed that NPs formulated with the MC version of the same 
expression cassette also consistently resulted in smaller NPs compared to its RP counterparts in 


















































Figure 6.2 Particle size comparison between K2-NPs formulated with either RPs or its corresponding MCs. Values 
expressed as mean ± s.d., n=3 
 
6.4.2 Effect of pDNA construct size on GL-NP physicochemical properties 
To evaluate the impact MCs have on the physicochemical properties of GL-NPs, two sets 
of GL-NPs were constructed for evaluation: 18-3-18 and 16-3-16 GL-NPs formulated with either 
RP (gWiz™ GFP; 5.7kb) or with MC (pUMVC1; 4.0kb).  18-3-18 GL-NPs formulated with either 
RP or MC both resulted in similar particle sizes of 140.4±1.1 nm and 151.3±0.8 nm, respectively 
(Figure 6.3). Similarly, 16-3-16 GL-NPs formulated with either RP or MC resulted in similar 
particle sizes of 136.3±1.3 nm and 143.6±1.1 nm, respectively. Particle size uniformity amongst 
the particles were consistently high amongst the GP complexes and GL-NPs, and largely remained 
highly similar between RP and MC counterparts with the exception of 16-3-16 GL-NPs, where a 
larger difference of PDI were observed between RP and MC containing NPs, with values of 0.025 














































Figure 6.3 Particle size and PDI analysis of 16-3-16 and 18-3-18 GL-NPs formulated with either RP or MC plasmids. 
Values expressed as mean ± s.d., n=3 
 
6.4.3 Assessment of pDNA in GL-NPs using fluorescence correlation spectroscopy 
GL-NPs formulated with either RPs or MCs were further characterized for number of 
pDNA copy number per particle by FCS between the types of GL-NPs. As FCS utilizes a 
fluorescence-based spectroscopy technique, the pDNA used in the construction of GL-NPs in this 
set of experiment were substituted with Cy®5-labelled RP (gWiz GFP-Cy5) and MC (pUMVC1-
Cy5). A comparison of RP-containing and MC-containing GP complexes and GL-NPs 
demonstrated differences in autocorrelation curves (ACC) (Figure 6.4). More specifically, the 
ACC of MC-containing 16-3-16 GL-NPs indicated a downward shift relative to RP-containing 16-
3-16 GL-NPs, suggesting higher number of fluorophores per particle were present in MC-
































































































































































RP (gWiz GFP) MC (pUMVC1)
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and RP-containing 18-3-18 GL-NPs indicated no shifting of the curve, suggesting that differences 
in the number of fluorophores per particle were not detectable.  
 






















































RP (gWiz GFP-Cy5) MC (pUMVC1-Cy5)
107 
An analysis of counts per particle (kHz) measurements for free Cy®5 and Cy®5-labelled 
RP- and MC-containing GL-NPs indicated that 16-3-16 GL-NPs contained 1-8 copies of RPs or 
1-6 copies of MCs (Table 6.2). On the other hand, 18-3-18 GL-NPs contained 1-10 copies of RPs 
and 1-9 copies of MCs. A further analysis of the distribution of plasmid copy number per particle 
of GL-NPs showed that specific GL-NPs such as MC-containing GL-NPs may result in particles 
with more homogenous pDNA copy number per particle compared to RP-containing GL-NPs 
(Figure 6.5). For example, 84% of MC-containing 18-3-18 GL-NPs contained 1 to 3 copies of 
MCs per particle, and only 16% of particles contained more than 3 copies of MCs per particle. On 
the other hand, only 51% of RP-containing 18-3-18 GL-NPs contained between 1 to 3 copies of 
RPs, and 49% of particles contained more than 3 copies of RPs. 
 














Minimum 1 1 1 1 
Maximum 7 6 10 9 





Figure 6.5 Estimation of number of pDNA copy number per RP- (A,C) or MC- (B, D) containing 18-3-18 GL-NPs 


















































18-3-18 GPL-NP gWiz GFP 
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Using GL-NP diffusion time and diffusion coefficient to derive particle size through 
Stokes-Einstein equation, hydrodynamic radius for RP- and MC-containing 18-3-18 GL-NPs were 
estimated to be 878.0 nm and 495.7 nm, respectively (Table 6.3). The hydrodynamic radius of RP- 
and MC-containing 16-3-16 GL-NPs were 832.9 nm and 377.7 nm, respectively. Interestingly, the 
calculated hydrodynamic radius showed that RP-containing 16-3-16 and 18-3-18 GL-NP were 
consistently larger than the MC-containing 16-3-16 and 18-3-18 GL-NP, which correlated with 
the larger number of RPs found in GL-NPs. The FCS-derived hydrodynamic radius for these 
particles were larger than the actual measure particle sizes by zetasizer.  
 
Table 6.3 16-3-16 and 18-3-18 GL-NPs particle size calculation extrapolated from FCS measurements using Stokes-
Einstein equation 
Nanoparticle 
Diffusion time  
(µs) 




16-3-16 GL-NP gWiz™ GFP-Cy
®
5 5330.109 2.93E-12 832.9 
16-3-16 GL-NP puMVC1-Cy
®
5 2417.128 6.46E-12 377.7 
18-3-18 GL-NP gWiz™ GFP-Cy
®
5 5619.077 2.78E-12 878.0 
18-3-18 GL-NP pUMVC1-Cy
®
5 3172.176 4.93E-12 495.7 
 
6.4.4 GL-NP formulation optimization by sonication 
The currently used GL-NP formulation protocols in our laboratory (see section 4.3.3) 
yields NPs with average particle sizes and PDIs, in ranges of 100-500 nm and 0.2-0.6, respectively, 
depending on composition. However, improvement of size distribution and reduction of 
aggregation still would be useful. Hence, sonication and high-pressure homogenization were tested 
to determine whether better particle uniformity can be achieved. Various sonication and 
homogenization conditions were evaluated to determine the optimum conditions. Using 12-3-12 
GL-NPs as the model GL-NP system, bath sonication for 15, 30, and 60 minutes, or high-pressure 
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homogenization (one- or two-passes) were evaluated (Figure 6.6). Based on the results, 15-minutes 
sonication was the optimal sonication time as it reduced 12-3-12 GL-NP particle size by 60%, 
from 415.6±20.2nm to 167.1±1.2 nm, compared to non-sonicated particles. The homogeneity of 
particle size distribution has also improved after 15-minutes of sonication as PDI was reduced by 
about 40%, from 0.36±0.05 to 0.22±0.01, compared to non-sonicated particles. While extending 
the durations into 30- or 60-minutes sonication periods still resulted in smaller particle sizes 
compared to non-sonicated GL-NPs, the particle size and particle size heterogeneity have 
increased compared to particles sonicated for 15 minutes. Sonication for 30 or 60 minutes resulted 
in particle size of 194.4±4.9 nm and 226.5±6.5 nm, which was 16 % and 36% larger than the 
particle size of GL-NPs sonicated for 15 minutes. PDI also increased from 0.22±0.01 to 0.33±0.03 
and 0.37±0.01 for 30- and 60-minutes-sonicaed particles, which increased by approximately 49% 
and 71% compared to 15-minutes sonicated particles.  
High-pressure homogenization had little benefit to improve particle size and particle size 
homogeneity as one-pass and two-pass homogenization resulted in particle size of 348.6±13.0 nm 
and 3030.0±251.7 nm, respectively. Corresponding PDI values also increased from 0.36±0.05 to 
0.38±0.02 and 0.43±0.18 after one-pass and two-pass high-pressure homogenization, respectively. 








Physical Processes Z-average (nm) PDI 
Self-Assembly 415.5±20.2 0.36±0.05 
Sonication (15 minutes) 167.1±1.2 0.22±0.01 
Sonication (30 minutes) 194.4±4.9 0.33±0.03 
Sonication (60 minutes) 226.5±6.5 0.37±0.01 
High-Pressure Homogenization (one-pass) 348.6±13.0 0.38±0.02 
High-Pressure Homoegnization (two-passes) 3030.0±251.7 0.43±0.18 
Figure 6.6 12-3-12 GL-NP treated with either sonication or high-pressure microfluidic homogenization 1-hour post 
self-assembly.  Values expressed as mean ± s.d., n=3 
  
An analysis on the particle size polydispersity index (Figure 6.7) showed the change in 
GL-NP population size distribution after sonication and homogenization. Prior to any further 
processing, self-assembled GL-NPs showed bimodal population distribution with peaks at 601.2 
nm (83%) and 140.4 nm (16%). Upon 15 minutes of sonication, the bimodal distribution resulted 
in unimodal distribution with a single peak presented at 224.9 nm, which demonstrated a rather 
homogenous population. Further induction of sonication for a total of 30 minutes resulted in a shift 
of the unimodal distribution towards bimodal distribution with the rise of a secondary peak, with 
a new distribution profile of two peaks at 232.7 nm (95%) and 4717.0 nm (5%). Sonication for a 

























































































































































































compared to 30-minutes sonication. Collectively, it was evident that 15-minutes sonicated 12-3-
12 GL-NPs was the most optimal condition to generate optimal particle size and particle size 
homogeneity amongst the conditions tested. 
 
 
Self-Assembled Self-Assembled + 15 mins sonication 
  
Self-Assembled + 30 mins sonication Self-Assembled + 60 mins sonication 
  
Self-Assembled + one-pass high-pressure homogenization Self-Assembled + two-passes high-pressure homogenization 
  







6.4.5 GL-NP optimization by TNPC 
The effect of TNPC per unit volume on NP physicochemical properties was also evaluated  
as different concentrations of NP formulations are often needed to accommodate the 
administration volume limitation that are specific to the route of administration. Furthermore, it 
also allows for the determination of optimal NP concentrations that can be utilized in the 
manufacturing process to generate GL-NPs with optimal physicochemical properties through 
concentration adjustments. In order to evaluate the effect of TNPC have on the NP 
physicochemical properties, RP- and MC-containing 12-3-12 and 16-3-16 GL-NPs with two 
different GL-NP concentrations (1X [= routinely used concentration] or 2X [= two times the 
routinely used starting concentration of all components]) were formulated. Thus, resulting in 1X-
TNPC and 2X-TNPC particles for each of the following GL-NPs: RP-containing 12-3-12 GL-NPs, 
MC-containing 12-3-12 GL-NPs, RP-containing 16-3-16 GL-NPs, and MC-containing 16-3-16 
GL-NPs.  
Based on the results, GL-NPs formulated with 2X-TNPC consistently generated smaller 
12-3-12 GL-NPs and 16-3-16 GL-NPs (Figure 6.8). For example, both 2X-TNPC RP-containing 
12-3-12 GL-NPs and 16-3-16 GL-NPs resulted in smaller particle size compared to 1X-TNPC RP-
containing 12-3-12 GL-NPs and 16-3-16 GL-NPs with differences of 33.3% and 63.0%, 
respectively. Similarly, 2X-TNPC MC-containing 12-3-12 GL-NPs and 16-3-16 GL-NPs resulted 
in smaller particle size compared to 1X-TNPC MC-containing 12-3-12 GL-NPs and 16-3-16 GL-
NPs, with average differences of 20.4% and 22.3%, respectively. The particle size distribution for 
2X- and 1X- TNPC GL-NPs resulted in similar levels of homogenous particle size distribution as 
described by unimodal particle size distribution (Figure 6.9) and PDI ranged between 0.20 and 
0.28.  
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In terms of particle surface charge, zeta potential measurements showed increase in zeta 
potential in GL-NPs constructed at 2X-TNPC compared to GL-NPs constructed at 1X-TNPC. 
More specifically, 2X-TNPC RP-containing 12-3-12 GL-NPs and 16-3-16 GL-NPs resulted in 
higher zeta potential compared to 1X-TNPC RP-containing 12-3-12 GL-NPs and 16-3-16 GL-NPs 
with differences of 19.5% and 12.8%, respectively. Similarly, 2X-TNPC RP-containing 16-3-16 
GL-NPs and 2X-TNPC MC-containing 16-3-16 GL-NPs resulted in higher particle surface charge 
compared to their respected 1X-TNPC counterparts. Altogether, these findings showed that 
changes in GL-NP concentration could result in changes in the physicochemical properties of GL-
NPs. Furthermore, 2X-TNPC GL-NPs could result in the generation of GL-NPs with smaller 
particle size and higher surface charge amongst different GL-NP systems. 
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Figure 6.8 Physicochemical characterization of 12-3-12 (A-C) and 16-3-16 (D-F) GL-NPs formulated at 1X-TNPC 



















































































































































12-3-12 MC-GL-NP (1X) 
 
12-3-12 RP-GL-NP (1X) 
  
12-3-12 MC-GL-NP (2X)  12-3-12 RP-GL-NP (2X)  
  
16-3-16 MC-GL-NP (1X) 16-3-16 RP-GL-NP (1X) 
  
16-3-16 MC-GL-NP (2X)  16-3-16 RP-GL-NP (2X)  
  
Figure 6.9 Particle size distribution analysis of 12-3-12 and 16-3-16 GL-NPs formulated at 1X-TNPC or 2X-TNPC 
with either RP or MC 
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6.4.6 GL-NP optimization by combination of sonication and TNPC 
Based on the earlier investigation of sonication and TNPC effects on GL-NP 
physicochemical properties, it was evident that these processes could be evaluated for a variety of 
GL-NPs. A panel of first-generation and second-generation GL-NPs were generated: 12-3-12, 12-
4-12, 12-6-12, 12-8-12, 12-10-12, 12-12-12, 12-16-12, 16-3-16, 18-3-18, 12-7NH-12, 12-7N-12, 
and Py-3-12. The twelve different GL-NPs were formulated at two concentrations (1X-TNPC and 
2X-TNPC), and 15 minutes of sonication processing. 
Nine out of twelve GL-NPs formulated at 2X-TNPC compared to 1X-TNPC GL-NPs 
resulted in smaller particle size (Figure 6.10). More specifically, the 12-m-12 series GL-NPs (with 
the exception of 12-7NH-12) formulated at 2X-TNPC consistently resulted in smaller particle size. 
In contrast, 16-3-16, 18-3-18, and 12-7NH-12 GL-NPs all exhibited a larger particle size. In 
addition to particle size, the particle size homogeneity was also found to have increased in eight 
out of twelve GL-NPs prepared in 2X-TNPC (Figure 6.12), evident from reduction of PDI and the 
presence of unimodal particle size distribution pattern compared to 1X-TNPC (Figure 6.11). 
Except for selected GL-NPs such as 12-8-12, 12-7NH-12, and Py-3-12 GL-NPs, PDI was found 
to have increased instead. In terms of particle surface charge, an increase in particle surface charge 
was observed in GL-NPs prepared by 2X-TNPC compared to 1X-TNPC in ten out of twelve GL-






Table 6.4 Physicochemical characterization of GL-NP (1X- or 2X- TNPC) formulated with 12-s-12, m-3-m, and Py-
3-12 using RP. Z-average (A), PDI (B), and zeta potential (C). Values expressed as mean ± s.d., n=3 
Conditions/Properties GL-NPs 
TNPC Properties 12-3-12 12-4-12 12-6-12 12-8-12 12-10-12 12-12-12 12-16-12 
1X 
Z-average (nm) 275.8±7.2 194.8±1.6 250.9±5.0 240.1±2.9 233.7±1.5 233.4±3.1 228.0±3.4 
PDI 0.38±0.01 0.37±0.01 0.28±0.01 0.37±0.02 0.39±0.01 0.38±0.01 0.30±0.02 
Zeta Potential (mV) 31.1±1.2 21.8±0.5 28.1±2.7 13.6±0.8 32.8±4.5 36.3±1.1 40.2±2.6 
2X 
Z-average (nm) 173.0±0.8 185.4±0.7 130.1±0.6 175.5±1.2 172.2±2.2 174.9±1.1 159.9±1.1 
PDI 0.16±0.00 0.22±0.01 0.26±0.00 `0.42±0.00 0.31±0.01 0.36±0.04 0.28±0.00 
Zeta Potential (mV) 46.0±1.6 29.3±6.4 39.1±4.4 44.1±1.3 46.8±5.1 53.2±4.5 57.1±2.9 
Conditions/Properties GL-NPs 
TNPC Properties 16-3-16 18-3-18 12-7NH-12 12-7N-12 Py-3-12 - - 
1X 
Z-average (nm) 135.9±3.3 433.2±126.8 204.7±1.5 222.8±1.8 168.8±2.3 - - 
PDI 0.20±0.01 0.35±0.16 0.16±0.02 0.14±0.02 0.20±0.01 - - 
Zeta Potential (mV) 36.7±0.4 55.5±4.3 39.9±2.1 41.2±5.9 34.6±0.1 - - 
2X 
Z-average (nm) 166.1±6.2 439.9±38.3 242.3±4.5 204.6±3.2 131.6±1.6 - - 
PDI 0.13±0.03 0.26±0.08 0.19±0.05 0.10±0.04 0.26±0.00 - - 




Figure 6.10 Physicochemical characterization of RP-GL-NPs formulated with 12-s-12, m-3-m, and Py-3-12 at either 
















































































































































































































12-3-12 GL-NP (1X) 12-4-12 GL-NP (1X) 12-6-12 GL-NP (1X) 
   
12-8-12 GL-NP (1X) 12-10-12 GL-NP (1X) 12-12-12 GL-NP (1X) 
   
12-16-12 GL-NP (1X) 16-3-16 GL-NP (1X) 18-3-18 GL-NP (1X) 
   
12-7NH-12 GL-NP (1X) 12-7N-12 GL-NP (1X) Py-3-12 GL-NP (1X) 
   
Figure 6.11 Particle size distribution profile of GL-NPs formulated with 12-s-12, m-3-m, and Py-3-12 at 1X-TNPC  
 
12-3-12 GL-NP (2X) 12-4-12 GL-NP (2X) 12-6-12 GL-NP (2X) 
   
12-8-12 GL-NP (2X) 12-10-12 GL-NP (2X) 12-12-12 GL-NP (2X) 
   
12-16-12 GL-NP (2X) 16-3-16 GL-NP (2X) 18-3-18 GL-NP (2X) 
   
12-7NH-12 GL-NP (2X) 12-7N-12 GL-NP (2X) Py-3-12 GL-NP (2X) 
   




The incorporation of MC in NPs is a promising approach towards the development of more 
efficient gene therapy systems as MC can provide a safer and more effective means of encoding 
therapeutic protein sequences for pDNA gene therapy applications. The absence of the bacterial 
backbone not only decreases overall construct size, but it also reduces the risk of unwanted 
immunogenic responses. Aside from this, another important aspect of MC is the potential 
improvement of the physicochemical properties of NPs. As shown in the results, MC incorporation 
resulted in smaller K2-NPs and improved the TE when compared to its RP counterparts. 
Furthermore, GL-NPs constructed with MC were able to generate more GL-NPs with more 
homogenous pDNA copy number per particle. Interestingly, it was found that RP-containing GL-
NPs have more plasmid per particle on average compared to MC-containing GL-NPs. One 
explanation could be the influence of Cy®5 (M.W.= 761.38g/mol) labelling on pDNA, where the 
presence of Cy®5 fluorophores on pDNA could have resulted in differences in nucleic acid coiling 
and pDNA-GS electrostatic interaction in the GL-NP system. Moreover, the number of Cy®5 
present on gWiz GFP-Cy5 (n=10.930±0.605 fluorophores per plasmid) and pUMVC1-Cy5 
(n=47.215±7.693 fluorophores per plasmid), could also contributed to changes in GL-NP 
complexation properties. A higher pDNA copy number per particle in RP-containing GL-NPs 
further correlates with the finding that the particle size of RP-containing GL-NPs is larger than 
MC-containing GL-NPs. Nonetheless, the estimated number of plasmids in the GL-NPs was found 
to be in the range between 1 to 10 pDNA, which falls in the range of plasmid number count 
reported by Dong et al. [193]. Future pDNA quantitation could focus on optimizing Cy®5 labelling 
efficiency down to single Cy®5 per pDNA in order to generate a more representative modeling 
and estimation of plasmid construct copies in GL-NPs.  
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pDNA copy number was suggested in many studies to be associated with the outcome of 
transgene expression in gene transfer. Nuclear pDNA copy number was suggested to influence the 
level of transgene expression in a study that investigated the copy number required for successful 
transgene expression using lipid-based (Lipofectamine™) and polymer-based (PEI) NPs [194]. 
This study showed that on average, each transfected nucleus contained 75 to 50,000 copies of 
pDNA. Furthermore, it was suggested that there might be a pDNA copy threshold within the 
nucleus for transgene expression as pDNA copy numbers beyond 3,000 copies per nucleus only 
marginally elevated subsequent gene expression. A subsequent comparison showed that 2817 and 
876 copies of pDNA per nucleus was found in high-expressing and low-expressing cells, 
respectively, where high-expressing cells expressed 2-fold more proteins than the low-expression 
population [194]. Intracellular trafficking studies have suggested that dissociation of pDNA from 
the cationic polymer complexes is not a necessity for nuclear entry [195]. Furthermore, one 
possible mechanisms of nuclear entry may be associated with the anionic groups of phospholipid 
or lysosomal membrane that may have complexed with pDNA or NP components throughout the 
process prior to nuclear entry [195]. As smaller constructs may result in smaller NPs, it is also 
possible that particles could dissociate into smaller pDNA-nanomaterial (pDNA-nano) complexes, 
which may improve nuclear entry through the nuclear pores or nuclear membrane fusion capacity. 
In a recent study, it was found that most of the pDNA delivered with NPs were localized in 
cytoplasm, and the majority of pDNA remained bound to components of the NPs, which suggests 
that a significant number of pDNA entering the nucleus were bound to some amounts of 
nanomaterial. Dissociated pDNA-nano complexes that are less than 26 nm may improve the 
nuclear entry of pDNA into the nucleus [184]. 
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Previous studies in our laboratory have investigated the physicochemical properties of GL-
NPs with different assembly order of pDNA, GS, and lipids. The rationale behind the approach of 
sonicating assembled GL-NPs was to introduce external forces that may possible results in the 
formation of smaller particle. Based on the shift in particle size distribution profile from a bimodal 
distribution to a unimodal distribution shown in the results, it suggests that sonication may induce 
a systematic structural rearrangement of the GL-NP systems. Further sonication beyond 15 
minutes resulted in the formation of macroaggregated populations, which indicates that excess 
sonication is deleterious to optimal complexation and colloid stabilization. In addition, the finding 
that NP formulation concentration could improve the physicochemical properties of GL-NPs 
shows that TNPC is an important factor of consideration in GL-NP manufacturing. 
6.6 Conclusion 
In summary, the results have shown that pDNA construct size can also improve the 
physicochemical properties of GL-NPs. Furthermore, it was identified that sonication and TNPC 
were two parameters that could improve GL-NP physicochemical properties, which could be 






Chapter 7 Development of GS-functionalized carbon nanotube for 
pDNA delivery to retinal cells  
7.1 Rationale and objective 
In addition to GL-NP systems development, our laboratory also concurrently explores other 
novel nanomaterial entities that may have the potential to be utilized as gene delivery vehicles. 
CNTs are one of the candidate nanomaterials that are capable of binding nucleic acids and could 
be utilized in gene delivery applications.  
7.2 Background 
CNTs are a novel class of carbon-based nanomaterials with unique electronic, mechanical, 
and optical properties that can be utilized for a wide range of biomedical and pharmaceutical 
applications [196, 197]. CNTs can be broadly divided into two main types based on the number of 
graphene layers that constitute the cylindrical tube structure of CNTs into single-wall carbon 
nanotubes (SWNT) and multi-wall carbon nanotubes (MWNT) [198]. CNTs were explored for a 
variety of pharmaceutical and biomedical applications [199-206]. In the scope of gene therapy 
applications, CNTs have also been heavily explored as promising candidate gene delivery systems 
in studies that demonstrated their ability to interact with and compact nucleic acids [207-209], 
provide protection to nucleic acids from enzymatic degradation [210], and achieve cellular 
delivery for transgene expression [211]. 
Given the hydrophobic nature of CNTs, one of the main areas of development for 
pharmaceutical applications involves solubilizing nanotubes into solution, in order to complex 
with therapeutic molecules and carry out therapeutic action. Solubilization can be achieved 
through surface modifications of CNTs, which can result in functionalized carbon nanotubes (ƒ-
CNTs) containing moieties that reduce the hydrophobicity and aid solubilization. The use of 
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surfactants to functionalize and solubilize CNTs were explored using various non-ionic, cationic, 
anionic, and mixed surfactants [212-218]. Of particular interest in our laboratory, cationic gemini 
surfactant (GS) are effective in dispersing CNTs through hydrophobic interactions between the 
carbon alkyl chain and CNT walls. The cationic nature of the GS may provide an enhanced 
interaction between ƒ-CNT and nucleic acid through electrostatic interactions.  
In this study, ptSWNTs was utilized as the CNT candidate and it was found that the SWNTs 
could be dispersed by non-covalent functionalization with GSs, generating GS-functionalized 
ptSWNTs (ƒ-ptSWNTs) that were able to complex with pDNA. Furthermore, the preliminary 
results demonstrated the potential of a ƒ-ptSWNT gene delivery system for retinal gene therapy 
applications.  
7.3 Materials and methods 
7.3.1 Carbon nanotube dispersion and ƒ-ptSWNT formulation  
PureTubes™ SWNTs (ptSWNT), surfactant-eliminated, was purchased from NanoIntegris 
Inc (Raymor Industries Inc., Boisbriand, QC, Canada). A 0.1% w/v 12-3-12 surfactant solution 
was prepared by dissolving 12-3-12 GS in sterile nuclease-free water at a concentration of 1 
mg/mL and sonicated. ƒ-ptSWNTs were prepared by dispersing ptSWNTs in 0.1% w/v 12-3-12 
GS solution at 10 g/mL and sonicated using a Branson bath sonicator at 40 kHz frequency 
(Branson Ultrasonics Corporation, Danbury, CT, USA). ƒ-ptSWNT-pDNA complexes were 
constructed by complexing ƒ-ptSWNT with gWiz™ GFP pDNA (Aldevron, Fargo, ND, USA) at 
desired concentrations and ratios for 15 minutes at room temperature. 
7.3.2 Transfection of A7 astrocyte cells  
A7 rat astrocytes (a gift from Dr Jeremy Sivak, University of Toronto; [109, 110]) were 
cultured in DMEM/high glucose media (HyClone, GE Healthcare Life Sciences, Logan, Utah, 
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USA) supplemented with 10% FBS and 1% Pen/Strep at 37 °C in a 95% air and 5% carbon dioxide 
atmosphere. ƒ-ptSWNT-pDNA complexes were first evaluated and optimized in monolayer 
cultures of A7 astrocytes. Cells were seeded at seeding density of 50,000 cells/well (n=3 each) 
into clear 24-well culture plates (Grenier Bio-One, Monore, NC, USA) and transfected using ƒ-
ptSWNT-pDNA complexes. TE and viability was assessed after 24 hours of incubation using the 
Attune Flow Cytometer (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). TE 
was measured based on GFP expression and viability was measured based using a mitochondrial 
activity dye Mitotracker™ Deep Red (Invitrogen™, Thermo Fisher Scientific).  
7.4 Results 
7.4.1 Dispersion and characterization of ptSWNT in 0.1% 12-3-12 GS solution 
ptSWNTs were SWNTs with a mean diameter and length of 1.4 nm and 1 m, respectively. 
ptSWNTs, like most CNTs, are hydrophobic as a result of the non-polar aromatic carbon structure. 
Hence, dispersion of CNTs often involves surface modification of CNTs through addition of polar 
functionalization. In this experiment, four concentrations of 12-3-12 GS solution (0.1%, 0.05%, 
0.01%, 0.005% w/v) were explored for dispersion of ptSWNT 10 g/mL (0.001% w/v). GS 
concentration-dependent dispersion was observed with distinct characteristics of dispersion and 
aggregation (Figure 7.1). Dispersion of ptSWNTs using 0.1% 12-3-12 GS solution was the most 
effective with no signs of visible particles. In addition, centrifugation and sedimentation tests also 
demonstrated the absence of aggregates and or sedimentation of ƒ-ptSWNTs. Dispersion of 
ptSWNTs with 0.05% 12-3-12 GS solution produced partially dispersed ptSWNTs. The dispersion 
was grey with visible ptSWNT particles distributed across the volume. The 0.01% and 0.005% GS 




Figure 7.1 ptSWNT dispersions in 0.1% (A), 0.05% (B), 0.01% (C), and 0.005% (D) 12-3-12 GS solution 
 
As ptSWNTs dispersed most optimally using 0.1% w/v 12-3-12 GS solution at 10 µg/mL 
compared to the other three concentrations tested, further characterization and studies were carried 
out using ƒ-ptSWNTs generated from this condition.  
7.4.2 Implications of ƒ-ptSWNT-pDNA mediated gene delivery to retinal astrocytes  
To evaluate gene delivery capacity of ƒ-ptSWNT-pDNA complexes to retinal cells, a series 
of ƒ-ptSWNT-pDNA complexes with different combinations of CNT:DNA ratios were formulated 
(Figure 7.2). Three measurements were collected in this study: percentage of viable population, 
TE of the cells in viable population, and metabolic active cells in viable population. Percentage of 
viable population measures the percentage of A7 cells that remained viable and attached on the 
culture surface after ƒ-ptSWNT-pDNA complex treatment. TE of the viable population measures 
the percentage of cells from the viable population that were transfected by ƒ-ptSWNT-pDNA 
complexes. Metabolically active cells of the viable population measures the percentage of cells 
that are metabolically active from the viable population. The reporting of the percentage of viable 
cells is important in this investigation as it was found that treatment with ƒ-ptSWNT-pDNA 
complexes could result in significant reduction of viable A7 cell population (i.e. cells lost / 
disintegrated).  
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In the 1 g pDNA per dose evaluation, four ratios of ƒ-ptSWNT-pDNA complexes were 
evaluated and it was found that while ƒ-ptSWNT-pDNA complexes constructed with a CNT:DNA 
ratio of 1:1 were able to demonstrate highest level of TE, it also resulted highest level of toxicity 
(Figure 7.2A). The percentage of viable population was found to be only 25.24.6%, 
demonstrating a toxicity that resulted in approximately 75% A7 cell loss. Amongst the cells that 
remained viable and attached on culture surface, where 85.38.6% of cells were transfected and 
83.82.7% of cells were metabolically active. Evaluation of ƒ-ptSWNT-pDNA complexes 
constructed with increasing CNT:DNA ratios of 1:2, 1:3, and 1:4 resulted in increasing viable 
population, and decreasing TE of the viable population. Amongst the 4 ratios, transfection using 
ƒ-ptSWNT-pDNA complexes constructed with CNT:DNA ratio of 1:4 resulted in the highest 
viable population of 39.18.8%, but lowest TE level of 2.11.5%.  
In the 3 µg pDNA per dose evaluation, the results showed that ƒ-ptSWNT-pDNA 
complexes constructed with increasing CNT:DNA ratios of 1:3, 1:6, 1:9, and 1:12 resulted in 
increasing viable population from 37.48.9% to 54.12.5%, but resulted in decreasing TE of the 
viable population from 54.72.6% to 34.45.0% (Figure 7.2B). Moreover, the percentage of 
metabolically active cells from viable population remained in range between 76.71.9% and 
65.53.2%. Interestingly, ƒ-ptSWNT-pDNA complexes constructed with CNT:DNA ratios of 
1:15 and 1:30 were not able to transfect A7 cells.  
In the 5 µg pDNA per dose evaluation, it was found that ƒ-ptSWNT-pDNA complexes  
constructed with increasing CNT:DNA ratios at 1:5, 1:10, 1:15, and 1:20 resulted in increasing 
viable population between 32.55.0% and 65.33.3%, with TE of viable population between 
55.53.5% and 44.52.0% (Figure 7.2C). Interestingly, ƒ-ptSWNT-pDNA complexes constructed 
with CNT:DNA ratios of 1:25, 1:50, 1:67 and 1:100 did not transfect the viable cell population.  
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Figure 7.2 TE and viability of A7 astrocytes following transfection with ƒ-ptSWNT-pDNA constructed with either 





































































































In this study, the results showed that ptSWNTs can be stably dispersed in 0.1% 12-3-12 GS 
solution to generate ƒ-ptSWNTs, which can be further developed into ƒ-ptSWNT-pDNA 
complexes upon complexation with pDNA. High aspect ratio gene delivery systems such as ƒ-
ptSWNT-pDNA complex possess a unique mode of cellular interaction that differs from the low 
aspect ratio spherical NP systems, where additional geometrical considerations such as tube length 
and angle of entry as part of nano-cell interaction are to be taken into consideration. Shi et al. has 
suggested that MWNTs enters the cell tip-first, with favorable entry angle between 45 to 90 
degrees [219]. Consistent with these findings, Huang et al. also suggested in a simulation study 
involving free energy analysis of the geometry of NP uptake that high aspect ratio materials that 
are initially in a laying-down horizontal position with the length of nanotube parallel to the cell 
surface would undergo rotation to a standing-up position until the completion of endocytic 
pathway [220]. The possibilities for passive entry of CNTs also exist as it was demonstrated that 
using MWNTs attached to an AFM probe to execute controlled CNT piercing of the cellular 
membrane does not cause membrane or cellular damages [221]. 
Toxicity is a major obstacle in CNT development. Some studies have suggested a 
contribution to toxicity from disrupted endocytosis due to length-dependency that was particularly 
amplified in cells transfected with CNTs through tip-first entry mechanism [219]. Recent studies 
by Zhu et al. suggested that the length and the stiffness of CNTs play a role in inducing lysosomal 
damage in cells as there exists a critical length that can be entrapped within the lysosome before 
the induction of cell death from lysosome damage [222]. As a result, longer and stiffer CNT entities 
(i.e.1µm long and rigid MWNTs) were shown to penetrate through the lysosomal membrane, while 
shorter and flexible MWNTs were found to be entrapped within cytoplasmic vesicles [222]. As 
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CNTs in this study consisted of wide range of CNT lengths that may include lengths in the 
micrometer range, this may be a contributing factor to the toxicity. While sonication could have 
reduced CNT length, the resulting CNT length has yet to be characterized. Shorter CNTs may have 
showed for better viability coupled with enhanced gene delivery capacity. A study by Geng et al. 
showed that SWNTs with length between 10 and 30 nm can be integrated into mammalian cell 
membranes, forming rigid CNT porins that mimic the electrical conductance of native lipid 
membrane and capable of transmembrane transport of ion and DNA [223].  
A critical aspect of CNT formulation for biomedical application lies in the dispersion of 
CNTs as it requires surface functionalization for dispersion in water-based aqueous solution. The 
lowest GS solution concentration for CNT dispersion was 0.1% w/v 12-3-12 GS amongst the 
conditions evaluated. While effective for dispersion, the free (unbound) GS in the effective 
CNT:DNA ratio was consequently high, which could have further contributed to the toxicity of 
the cells exposed [178].  
7.6 Conclusion  
Overall, results in this study showed that CNT-based gene delivery system ƒ-ptSWNT-
pDNA complex can deliver pDNA to A7 cells in vitro. However, the significant amount of toxicity 
due to free GS in the A7 cells treated with ƒ-ptSWNT-pDNA is a concern that needs to be 
addressed to resolve the issues surrounding toxicity. Moreover, investigation is needed to identify 
the most optimal parameter by investigating the effect of various GS with different alkyl chain 
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8.1 Summary 
Research described in this dissertation aimed to contribute to the development of retinal non-
viral gene therapy through developments of in vitro screening modalities and non-viral gene 
delivery systems. The concurrent developments in the two areas aimed to provide synergism to 
drive the overall development of non-viral NF gene therapy for glaucoma. 
In vitro models are an integral part of therapeutic development as libraries of therapeutic 
compounds and entities are typically screened using in vitro models prior to downstream 
development and optimization in vivo. Effective in vitro models that can facilitate in vivo efficacy 
and translatability are therefore an important avenue of innovation. Research in Chapter 3, Chapter 
4 and Chapter 5 present advancements of three in vitro models that address multiple levels 
ofdeficiencies. 
Chapter 3 addresses the need for an in vitro co-culture that can model cell-to-cell interactions 
required for the proposed NF supplementation approach of RGC rescue through pDNA gene 
therapy. Unlike direct drug-receptor interactions of target cells in conventional small molecule 
therapeutics to induce therapeutic action, the proposed pDNA gene therapeutic approach is a two-
stage process that involves an intermediary “medic” cell population that serves to produce 
therapeutic proteins in situ required to carry out therapeutic actions. Hence, two parameters that 
133 
may be useful in assessing therapeutic potential of a system are the bioavailability and bioactivity 
of therapeutic proteins that can be produced by medic cell. To address this issue, a co-culture 
bioassay platform as an essential tool for the assessment of gene delivery systems was developed. 
Using transwell insert setup, it demonstrated that the co-culture setup allows for effective culturing 
of two cell populations in separate compartments within a well, communicable through a 
membrane with pores that allows for molecule passage, simulating “medic” and “stressed” cell 
microenvironment. The co-culture setup provides a controlled environment to demonstrate 
therapeutic effects that are induced by therapeutic proteins produced from “medic” cells, 
eliminating the possibility of direct cell-to-cell interactions. A gap bridged by culture medium 
between the two cell layers is also an added advantage in demonstrating that therapeutic proteins 
secreted from the “medic” cells are transported through the medium to “stressed” cells. Dosing is 
another complex question in the pDNA therapy: 1) the optimum pDNA and NP dose required to 
carry out efficient transfection of “medic” cells upon administration, and 2) the controllability of 
therapeutic protein dose secreted from the transfected “medic” cells to carry out therapeutic action 
on “stressed” cells. Assessments incorporated in this in vitro bioassay facilitate the quantitationof 
the therapeutic protein and confirmation of its bioactivity produced by transfected cells. The 
bioactivity of the secreted therapeutic protein assessed through measuring the level of neurite 
extension exhibited by the “stressed” cell, which is represented by the neurite extension activity 
of SH-SY5Y in this modality. Altogether, this co-culture modality was demonstrated to be a 
feasible and versatile system that can be incorporated into the process of in vitro evaluation of 
gene delivery systems. Moreover, the versatility of the described system enables the utilization of 
different cellular combinations through the substitution of either “medic” or “stressed” according 
to the specific research question. For example, “medic” cell population can be substituted with 
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other retinal cell types to evaluate their capacity to serve as “medic” cell candidates in the retina. 
Similarly, “stressed” cells can be substituted with representative RGC cell models such as stem 
cell-derived RGCs described in Chapter 4. 
Lack of a representative RGC cell model remains a major hindrance for RGC-aimed 
therapeutic development. While the co-culture model presented in Chapter 3 utilized an alternative 
model cell line, SH-SY5Y cells, for neurite extension study based on its BDNF responsiveness, 
the need for a RGC cell model is a requirement for the evaluation of specific neuroprotective effect 
and efficacy on RGCs. One possible approach is to utilize primary RGCs isolated from rodents or 
even post-mortem human retinas to serve as model cells, but the low abundance of RGCs, the 
difficulty for efficient isolation, and more importantly, the short viability of isolated primary RGCs 
limit the range of applications. For close to a decade, RGC-5 cells were thought to be a model 
RGC cell line until it was officially announced to be misidentified in 2013 [119]. As a result, a 
reliable RGC cell model is urgently needed, which have thus inspired scientists to explore 
innovative ways to generate model RGCs such as using stem cells. The use of stem cells and 
directing them to RGC fate opens a wide range of possibilities such as the generation of mitotic or 
immortalized RGCs. Research presented in Chapter 4 described the generation of a stem cell-
derived RGC-like cells from multipotent RSCs isolated from CD-1 mouse retina (termed XFC-3), 
which displays major characteristics of RGCs. First, through multiplexed gene expression 
profiling, XFC-3 cells demonstrated the expression of three key RGC biomarkers Map-2, Rbpms, 
and Tubb3. Secondly, XFC-3 cells have neurites that can extend upon activation by BDNF, CNTF, 
Y-27632 and their combinations. While promising, this cell model requires further 
characterizations to confirm its representativeness compared to RGCs in vivo. An important 
question that one must ask in the characterization of RGCs is what characteristics are required to 
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be defined as a representative RGC model? Genetic heterogeneity in human population and 
diseases are one of the major contributors to disease complexity and subsequent treatment outcome 
variability. Likewise, heterogeneity also exists within the RGC population. A recent paper 
published by Sanes and Masland describe the existence of at least 30 different types of RGCs, 
which are heterogeneous morphologically, physiologically, molecularly and functionally [63]. 
Moreover, different subtypes of RGCs respond to stressors differently [224]. For example, a study 
that compared the level of survival amongst eleven different subtypes of RGCs following optic 
nerve transection showed that five subtypes had a significantly higher capacity to withstand optic 
nerve transection [225]. Knowing such heterogeneity exist within the ganglion cell population, the 
criterion of characterization must be defined with care.  
In Chapter 5, the main objective was to bridge the disconnects between in vitro and in vivo 
in the context of gene delivery screening as many promising NP systems tested in vitro fail to 
translate comparable levels of gene delivery efficiency in vivo. By harnessing the differentiation 
capacity of multipotent RSCs, a “mini-retina” MiEye model that consists of multiple retinal cell 
types arranged in tissue-like arrangement to serve as a more in vivo-like preclinical gene delivery 
screening platform was developed. Using a commercial gene delivery system, the application of 
the MiEye system towards the generation of more in vivo translatable gene delivery system 
screening results was demonstrated. Additionally, there are other benefits as well to using such 
organotypic-like cultures for more advanced screening of NP properties such as targeting 
efficiency and tissue infiltration capacity. Furthermore, in-depth evaluation will be needed to 
characterize the distribution and arrangements of retinal cell types in the MiEye model. 
Collectively, the three aspects of in vitro modalities (Chapters 3-5) developed as tools aim to 
facilitate future developments in RGC NF gene therapy systems.  
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Concurrently with the development of in vitro models, research in the optimization of non-
viral gene delivery systems were also explored. In Chapter 6, research that aimed to expand our 
knowledge of the GL-NP gene delivery systems was described, with an emphasis to optimize the 
physicochemical properties of the NP systems by incorporating MC and manufacturing 
considerations. Through a series of physicochemical studies, it was shown that NPs formulated 
with MCs can have smaller size, smaller particle size distribution, and higher homogeneity in terms 
of the number of pDNA per particle. On the other hand, GL-NP physicochemical properties were 
also shown to be improvable by manufacturing processes, specifically through sonication and 
TNPC considerations. The incorporation of a 15-minute sonication step and 2X TNPC was able to 
reduce particle size, particle size distribution, and zeta potential.  Altogether, these findings 
contribute to our understanding and manufacturing of GL-NP systems. 
In Chapter 7, an investigation on the application of CNTs for retinal gene delivery was 
described. In this work, non-covalent functionalization of SWNT was optimized using GS and 
eighteen different ratios of ƒ-ptSWNT-pDNA complexes were subsequently formulated and tested 
for retinal cell gene delivery. Screening of ƒ-ptSWNT-pDNA complexes in A7 astrocytes 
demonstrated that the CNT-based gene delivery system has the capacity to provide high gene 
delivery efficiency, however, the level of toxicity was high. Nonetheless, the results suggest that 
if the toxicity concern can be resolved, ƒ-ptSWNT-pDNA system would be a promising gene 
delivery system for the retina.  
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8.2 Perspectives and future directions 
8.2.1 Neuroprotection therapy for RGC in glaucoma  
The neuroprotective therapeutic approach depicted in this research aims to deliver gene 
therapy locally to the retina, for a localized retinal cell transfection and subsequent localized NF 
production and supplementation action. As optic nerve extends into the brain, it may be beneficial 
to consider the site of optic nerve innervation as a secondary therapeutic target site to explore 
additional means of enhancing RGC survival. A recent study in a cat model with mild optic nerve 
crush demonstrated that when BDNF protein was administered in both the eyes and the brain, RGC 
survival was enhanced compared to RGCs that were only treated in the eyes [73]. Delivering NFs 
to the site of axon innervation have two implications towards axonal repair. Firstly, in a situation 
where TrkB receptors in the retina are downregulated and axoplasmic transport is not 
compromised, TrkB receptors that are present in the axons at the site of innervation can internalize 
exogenous BDNF and retrogradely transport it to the retina. In addition to supporting RGC 
survival, BDNF may also play a role in the maintenance of axonal innervation to LGN. While an 
attractive concept, delivering NFs to the innervation site in the brain would be even more 
challenging than delivery to the retina. Recent studies achieved gene expression in the retina after 
local administration of viral and non-viral gene delivery systems in the eye through injection and 
topical administrations [42, 76]. However, controlled delivery to areas of the brain is much more 
complicated due to the presence of complex barriers such as the blood-brain barrier. Potential 
routes of administration for delivery to sites of the brain may utilize intraocular and intranasal 
routes of administration as delivery through either routes have shown potential to access the brain 
[21]. 
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 While NF gene therapy is a promising strategy to overcome NF deficiency-mediated 
pathogenesis, it is important to keep in mind that glaucoma is a multifactorial disease that consists 
of other contributing factors towards the pathogenesis. As a result, a therapeutic approach that 
aims to address multiple stressors simultaneously may yield synergistic therapeutic outcomes. For 
example, glial-mediated tissue remodeling at the lamina cribrosa (LC) under glaucomatous stress 
could greatly influence the degree of optic nerve regeneration and remyelination. LC is one of the 
initial sites of glaucomatous damage as thickening of the prelaminar tissue, bowing of the LC and 
changes to the extracellular matrices collectively inflict stress on the optic nerve. Glial cells also 
play an important role in the pathogenesis as the activated form of glial cells secrete various 
extracellular matrix proteins that contribute to the formation of scarring, which may impede the 
restructuring of the optic nerve [226]. In this context, gene silencing strategies to suppress fibrotic 
genes could be used as an add-on treatment to overcome glial scar formation. Glial cells are 
traditionally known for their supportive roles in the CNS, however, reactive glial cells in glaucoma 
were shown to play mixed roles. Despite these mixed implications, it is important not to overlook 
the potential benefit that glial cells could provide. A recent study found that an intraocularly 
injected population of genetically modified neural stem cells overexpressing CNTF preferentially 
differentiated into astrocytes and were neuroprotective to RGCs [227]. Taken together, NFs and 
glial cells can both play important roles in the regeneration of the optic nerve axons. 
8.2.2 Tissue-like in vitro modalities for glaucoma drug discovery 
The pathophysiology of glaucoma is known to be multifactorial and its development is 
attributed to multiple molecular and mechanical factors throughout the eye, with emphasis at sites 
of trabecular meshwork, LC, and retina. Limitations in the modeling of key clinical features in 
vitro is a significant hindrance in deciphering the precise cause and effect interactions as intricate 
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cellular and molecular mechanisms are often difficult to control and discern directly in vivo. In 
addition to the modalities described in the earlier chapters, studies in recent years have shown 
promising advancements in 3D culture and its ability to produce more representative models that 
are able to better describe key molecular and structural events found in vivo. For example, 
Dautriche et al. have developed a 3D Schlemm’s canal model by culturing primary cells on SU-8 
synthetic scaffold [228]. It was shown that the 3D cultured primary human Schlemm’s canal cells 
had in vivo-like physiology and expression profile through features of human Schlemm’s canal 
pore formation and VE-cadherin and PECAM1 gene expression. As a result, this model serves as 
a tool for in vitro screening of human Schlemm’s canal-based mechanism or drug discovery. 
Torrejon et al. have also utilized SU-80 synthetic scaffold to generate an ocular three-dimensional 
culture. More specifically, they have created a three-dimensional human trabecular model by 
culturing human trabecular meshwork cells on the SU-80 scaffold [229]. The 3D cultured 
trabecular meshwork was reported to exhibit trabecular meshwork physiology and expression of 
markers such as alpha-smooth muscle actin, myocillin, and alpha-beta-crystallin. This model was 
further modified to establish a steroid-induced glaucoma disease model of trabecular meshwork 
with characteristics of ECM overproduction and outflow resistance [230]. Thus, it can be utilized 
as an in vitro model for trabecular meshwork mechanism characterization and therapeutic 
development. Osmond et al. also developed a trabecular meshwork 3D culture model, but utilized 
collagen and collagen-chondroitin scaffold to improve the SU-80 scaffold based 3D culture 
through the incorporation of key ECMs found in trabecular meshwork such as collagen and 
collagen-chondroitin sulfate [231]. Together, these ocular 3D cultures demonstrated to be a 
gateway towards modeling key in vivo mechanical physiology and cellular interactions in vitro. 
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A different approach in the construction of 3D models was explored using bioprinting 
technologies, in which cells could be printed based on desired cellular arrangements. Utilizing 3D 
bioprinting techniques, Lorber et al. showed that RGCs and glial cells of the retina can be printed 
using 3D while maintaining its viability and neurite outgrowth capacity [179]. More recently, a 
study conducted by Kador et al. showed that by combining 3D printing with radial electrospun 
scaffolds, they were able to 3D print RGCs onto an electrospun surface with precise distribution 
and positioning of RGCs as found in the retina [180]. From a spatial arrangement standpoint, 3D 
printing-based techniques theoretically possess a comparative advantage as they allow for more 
control in dictating cellular positioning on a tissue-like arrangement by “printing” specific cells at 
a specific location. While the spatial arrangement of the cells cultured in 3D culture is either 
dependent on the resultant conformation from self-aggregation or the conformation dictated by the 
scaffold in which the cells adhere. However, much remains to be investigated in terms of feasibility 
and functionality of the resulting printed tissue-like structures. Nonetheless, the concurrent 
advancements with the two main approaches in constructing tissue-like structures in vitro 
demonstrates the possibility for such advanced culture system to be useful part in the modeling of 
intricate cell interactions found in vivo.  
8.2.3 Understanding protein corona in ocular biological fluids 
 Using NPs as vehicles to deliver therapeutic genes to target cells encompass great promises 
in the future of therapeutic landscape and there are many aspects that need to be investigated to 
unleash the full potential. The presence of protein corona (PC) on NP, a phenomenon first 
described by Cedervall et al. in 2007 [232], is perhaps one of the most significant, yet overlooked  
factor that is limiting the therapeutic potential of NPs in vivo. PC formation is a dynamic process 
that occurs spontaneously on NP surfaces in the biological system, where biomolecules in the 
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biological system undergo dynamic surface modifications. Studies of PCs to date have primarily 
investigated using blood as the model biological medium [232-236], but little is known about the 
characteristics of PCs in other biological fluid medium. A more comprehensive understanding of 
PCs in different biological fluids may greatly improve the design of NPs and facilitate the clinical 
translation of nanomedicine. In the context of ocular nanomedicine, the three main biological 
fluids of the eye are tear film, aqueous humour, and vitreous humour. Tear film is the ocular fluid 
that lines the surface of cornea, preventing the entry of foreign entities into the eye while 
maintaining the hydration of the corneal surface. In a tear film protein study, Zhou et al. have 
identified 1543 proteins in human tear, in which selective proteins such as lysozyme, lactoferrin, 
secretory IgA, and lipocalin had the highest abundance [237]. Aqueous humour is the ocular fluid 
that occupies the anterior segment of the eye between the lens and cornea. In a study conducted by 
Chowdhury et al., they reported an identification of 676 proteins in human aqueous humour, which 
were largely composed of albumin, transferrin, antitrypsin, haploglobin, fibrinogen, IgG, and IgA 
[238]. Likewise, Murthy et al. reported similar levels of proteins identified in human aqueous 
humour in their study [239]. Vitreous humour is the ocular fluid that occupies the posterior segment 
of the eye between the lens and the retina. In a human vitreous proteomics analysis Murthy et al. 
reported 1205 proteins in the human vitreous [240]. In a more recent analysis, Mirzaei et al. 
described 4984 proteins in the vitreous humour [241], which are mainly composed of albumin, 
collagen, hyaluronic acid, and hyalocyte. Majority of the PC characterizations to date utilizes 
blood as the model biological medium as protein source, but studies that compare the differences 
in blood and tear film proteome, for example by Farrah et al., showed that approximately only 
28% of the proteins found in blood are also found in tear film [242]. As PCs are from the available 
proteins in the biological medium, the significant differences between blood and tear film 
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proteome suggest the possibility that PC fingerprints can be significantly different in blood 
compared to tear film for the same NP. Both tear film and vitreous are the first biological medium 
of contact for NPs administered either topically or intravitreally. Thus, a more specific 
characterization of PCs tailored to the route of administration may improve NP in vivo efficacy. 
To add an additional layer of complexity in the understanding of PC, a disease-state based change 
in PCs would be an important avenue of investigation as differences in proteomic expression were 
reported between healthy human subject and glaucoma patient in aqueous humour [243-246] and 
vitreous [241]. Nonetheless, a more in-depth understanding of the PCs with focus on the first 
biological fluid medium that NPs may be in contact with upon administration is an important 
avenue for a more effective NP design and formulation for in vivo success.  
8.3 Concluding remarks 
Glaucoma is a neurodegenerative disease that can greatly affect the quality of life of 
individuals and families affected. While multifactorial, loss of visual function in glaucoma is a 
result of RGC cell death. Hence, therapeutic approach that can directly improve the health of RGCs 
could have the possibility to directly impede, or even reverse the continuous degeneration of 
damaged RGCs. Therapies, such as NF gene therapy, possess the potential to achieve such 
possibility through a localized supplementation of NF to stressed RGCs and rescue them from a 
degenerative condition. Moreover, such therapy could particularly benefit individuals who are 
suffering from NTG or continuous vision loss after IOP reduction treatments. The research and 
perspectives iterated in this dissertation were developed with the goal to facilitate research in NF 
gene therapy development, and as well reflect on the challenges that need to be overcome to bring 
forth nanomedicine gene therapy treatments to the clinic.  
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Appendix A Method development to study the neuroprotective effect of 
BDNF expressed by non-virally transfected RGCs on oxidatively stressed 
RGCs 
 
The objective was to evaluate different three-dimensional culture formats for its feasibility 
and suitability for downstream retinal co-culture model development and therapeutic evaluation. 
At the beginning of the project, RGC-5 cell line was used as a model cell line and considerable 
work was done to develop healthy RGC/oxidatively stressed RGC co-culture in 3D culture to test 
the effect of BDNF on rescuing oxidatively stressed RGC. Subsequently, the false identity of the 
RGC-5 cell line was discovered and therefore further work with this cell line was discontinued. 
The results presented here; however, demonstrate methodology development and support the 
incorporation of the new RGC cell line generated from retinal stem cells. 
 
Hydrogen peroxide mediated oxidative stress decreases RGC-5 viability in a dose-
dependent manner 
 
RGC-5 cells were exposed with five different concentrations of hydrogen peroxide 
(300µM - 700µM) over 24 hours, it was found that there is a dose-dependent response between 
the level of hydrogen peroxide and the viability of RGC-5 where increasing concentration of 
hydrogen peroxide decreases the viability of RGC-5. The effective concentration (EC50) of 




RGC-5 viability over 24 hours of hydrogen peroxide exposure at concentrations (300µM – 700µM) in traditional 
monolayer 
 
Development of “mini-retinas” model in three-dimensional cell culture system  
 
NF gene therapy, a therapeutic approach that is achieved through the delivery of NF 
encoded pDNA such as BDNF to targeted cell candidates, NP-transfected cells would be 
genetically modified to produce BDNF proteins. BDNF-transfected cell population is given the 
name of “medic cell” due to its role in the production and delivery of the therapeutic gene to the 
stressed cells. To evaluate the neuroprotective effect of BDNF in a more in vivo-like condition 
with in vitro model, three types of retinal model were developed.  
Contact-dependent model was developed using RAFT® 3D culture system, where the 
stressed and medic populations are cultured in their independent layers that are right on top of 
each other. Contact-independent model was developed using the Alvetex 3D culture scaffold. 
Both medic cells and stressed cell populations are cultured in their independent polystyrene 
scaffold matrix that is separated by the well-insert. The delivery of NF is achieved as both 



























populations are cultured in the same media. The mini-eye neurosphere model is created using the 
Perfecta hanging-drop culture system, where retinal cells are cultured in the form of spheroids. 
 
Modeling of three different types of “mini-retinas” for various in vitro evaluation of gene therapy mediated rescue on 
the RGC. A) Illustrates the principle of NF gene therapy. B) Contact-dependent model established using bioscaffold-
based system. C) Contact-independent model established using polystyrene-based system. D) Mini-eye neurosphere 
model established using hanging-drop method system. 
 
Hydrogen peroxide induced oxidative stress also observed in RGC-5 cultured in three-
dimensional cell culture 
 
The susceptibility of the RGC-5 cultured in 3D culture in response to hydrogen peroxide 
RGC-5 hydrogen was evaluated, and it was found that RGCs cultured in the RAFT® 3D cell 
culture system showed a dose-dependent decrease in viability of RGC-5 cells in response to 
increasing levels of hydrogen peroxide concentration over 48 hours period. 
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RGC-5 viability over 24 hours of hydrogen peroxide exposure at various concentrations (300µM – 700µM) cultured 
in 3D cell culture using RAFT® culture system. 
 
Optimization, characterization of “mini-retina” neurosphere culture and bioassay for 
cellular health 
 
The seeding density plays a critical role in the formation of neurosphere with proper size 
and morphology. RGC-5 were seeded in the hanging drop at various initial population from 100, 
200, 500, 1000, 1500, 2000, and 25000 cells and the cells were monitored daily for spheroid 
formation progress and the images were taken on day 1 and day 3. A seeding density between 
200 cells to 1000 cells demonstrated to be the most optimal for generating neurosphere with 
controllable morphology and size.   
 



























Neurosphere formation after one and three days culturing at 37ºC in Perfecta 3D® 96-well hanging drop plate. 
Optimization of the seeding density was necessary since neurosphere formation is dependent on the seeding density 
and it differs from cell line 
 Viability of the neurosphere was by staining the neurosphere with Calcein AM and 
viewed with confocal microscopy with Z-stack option. The viability of the neurosphere across 
the thickness of the neurosphere was evaluated with positive viability profile. 
 
 
Images of a neurosphere sections organized from the apical layer and descending to its basal layer. The neurosphere 






Appendix B Retinal biomarker mRNA gene expression profile 
 




Retinal biomarker mRNA gene expression profile of RGC-5 (A) and 661W (B) cells. Horizontal dotted line 
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Retinal biomarker mRNA gene expression profile of 6-day differentiated RSCs (A) and 14-day differentiated RSCs 
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Appendix C Transfection of MiEye8 retinal neurospheres 
 
MiEye8 retinal neurospheres transfected with various formulations of K2-NPs 
 
 
Control MiEye8 retinal neurospheres  
 
 
Z-stack of MiEye8 control (untreated) at 120 hours post treatment. 20 slices of images were captured across the 
observable thickness of the retinal neurosphere. MiEye8 retinal neurosphere were counterstained with 5M of 








MiEye8 retinal neurospheres transfected with F2 K2-NPs 
 
 
Z-stack of MiEye8 at 120 hours post treatment with K2-NP (2µL:1µg). 20 slices of images were captured across the 
observable thickness of the retinal neurosphere. MiEye8 retinal neurosphere were counterstained with 5M of 














MiEye8 retinal neurospheres transfected with F5 K2-NPs 
 
 
Z-Stack of MiEye8 retinal neurosphere at 120 hours post treatment with K2-NP (20µL:2.5µg). 20 slices of images 
were captured across the observable thickness of the retinal neurosphere. MiEye8 retinal neurosphere were 
















MiEye8 retinal neurospheres transfected with F6 K2-NPs 
 
 
Z-Stack of MiEye8 retinal neurosphere at 120 hours post treatment with K2-NP (30µL:5µg). 20 slices of images were 
captured across the observable thickness of the retinal neurosphere. MiEye8 retinal neurosphere were counterstained 
with 5M of Syto™62 nuclei stain (red). Successful transfection is indicated by GFP expression (green). The object 













MiEye8 retinal neurospheres transfected with F7 K2-NPs 
 
 
Z-Stack of MiEye8 retinal neurosphere at 120 hours post treatment with K2-NP (10µL:2µg). 20 slices of images 
were captured across the observable thickness of the retinal neurosphere. MiEye8 retinal neurosphere were 
counterstained with 5M of Syto™62 nuclei stain (red). Successful transfection is indicated by GFP expression 
(green). 
